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Abstract 
Fullerene C60 is a charming molecule, its beautiful symmetry and its unique properties are still 
intriguing scientific community after almost three decades from its discovery. Investigation of 
its properties and applications is still an active field. 
In our group we are interested especially in the biological aspect of fullerene sciences. In this 
field, polyfunctional derivatives are particularly attractive, for the increased solubility and for 
the possibility to attach different biologically active molecules on the same carbon cage. 
 
In the first project we studied different methods to control the site selectivity of the double 1,3-
dipolar cycloaddition of azomethine ylides. To this purpose, we synthesized several bis-reactive 
templates with very different design, and we could obtain unusual fullerene-macrocyclic and 
fullerene-cyclophanes structures. A good degree of control of the site selectivity was achieved 
in some cases. A supramolecular approach to the control of the second cycloaddition was also 
developed. 
 
In the second part we focused our efforts in finding a feasible and scalable method to produce 
bis- or poly-functional fullerene derivatives from the easily accessible monoadduct. Triazine 
chemistry in combination with oxyethylenic chains allowed us to easily synthesize a library of 
polyfunctional, versatile and highly soluble derivatives. Some toxicological results indicate that 
this kind of compounds can be very useful carriers for drug delivery and some application in this 
sense are currently under investigation. 
 
Finally in a third part of the work we synthesized several fullerene-bipyridyl ligands and their 
ruthenium complexes. In this way we want to combine in the same molecule both the 
antiproliferative properties of ruthenium complexes and the photosensitizing effect of fullerene 
in order to obtain a synergistic effect against tumor cells. 
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Riassunto 
Il fullerene C60 grazie alla sua unica simmetria e alle sue proprietà continua ancora ad 
affascinare la comunità scientifica, a quasi tre decenni dalla sua scoperta. Infatti lo studio delle 
sue proprietà e delle possibili applicazioni è ancora un campo di ricerca molto attivo. 
Nel nostro gruppo siamo interessati soprattutto agli aspetti biologici del fullerene, settore in cui 
i derivati polifunzionali sono particolarmente interessanti, grazie alla loro maggiore solubilità e 
alla possibilità che offrono di ancorare diverse molecole biologicamente attive sullo stesso core 
fullerenico. 
 
La prima parte del progetto è incentrata sullo studio di diversi metodi per controllare la 
selettività di sito della seconda cicloaddizione 1,3- dipolare di ilidi azometiniche. A tale scopo, 
abbiamo sintetizzato vari templates recanti due funzioni reattive, atte a dare la reazione di 
cicloaddizione, e variando di molto il design tra i diversi composti. Per reazione degli stessi con 
il fullerene sono state ottenute insolite strutture macrociclo- e ciclofano-fullereniche. In alcuni 
casi è stato possibile ottenere un buon grado di controllo sulla seconda cicloaddizione. Inoltre è 
stato sviluppato anche un approccio supramolecolare per modificare la distribuzione dei diversi 
isomeri. 
 
Nella seconda parte abbiamo concentrato i nostri sforzi nella ricerca di un metodo pratico e 
scalabile per la produzione di derivati fullerenici bis- e poli-funzionali a partire dal monoaddotto 
facilmente ottenibile in quantità apprezzabili. La chimica delle triazine, insieme all’impiego di 
catene ossietileniche, ci ha permesso di sintetizzare facilmente una libreria di derivati 
polifunzionali, versatili e altamente solubili. Alcuni risultati tossicologici indicano che questo 
tipo di composti potrebbe trovare impiego come vettori per farmaci e qualche applicazione in 
questa direzione è attualmente sotto studio. 
 
Infine, in una terza parte del lavoro abbiamo sintetizzato diversi ligandi fullerene-bipiridile, che 
sono stati poi complessati con derivati del rutenio. In questo modo si è pensato di combinare 
nella stessa molecola sia le proprietà antiproliferative dei complessi di rutenio e l'effetto 
fotosensibilizzante del fullerene, al fine di ottenere un effetto sinergico contro le cellule 
tumorali. 
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Chapter 1. Introduction 
 
1.1. From carbon soot to fullerene soot 
 
History was not generous in giving the name to Carbon. Many other elements can claim mystic 
or divine origins from the Alchemy: Helium means “Sun”, while Phosphorous is the “Light-
bearer”, Iron was the “Holy Metal” for the Germans and so on. Carbon has much more humble 
origins: it dues its name to the Latin word carbo, used to indicate the soot obtained by burning 
organic material. Indeed in ancient times Iron allowed to build swords and tools, while Carbon 
was only a residue of the kitchen. But the time gave to Carbon the right place in Sciences. 
Earth’s crust is composed mainly of Silicon, Oxygen, Aluminium and Iron, while Carbon 
represents only 0.03% in weight, but a whole discipline is dedicated to it: Organic Chemistry. 
Carbon is a special element, different from all the others: thanks to the combination of medium 
electronegativity and 4 valence shell electrons, it is able to form up to 4 covalent bonds 
practically with any other element and with itself. Thanks to this fact, Carbon is undoubtedly 
the most important element on the Earth. The infinite number of molecules that Carbon can 
form gives rise to the beautiful complexity of living systems. 
Until mid ‘80s of XX century the only known allotropes of Carbon were Diamond, Graphite and 
amorphous Carbon. In 1985 Kroto, Curl and Smalley announced the serendipitous discovery of 
a new allotrope: the C60 Fullerene.
[1] In the experiment during the vaporization of graphite rods 
they observed the mass distribution of carbon clusters in gas phase and, surprisingly, under 
certain conditions, it was completely dominated by 60 atoms cluster and by a certain amount of 
70 carbons cluster. The only possible structure that can satisfy all the valences is spheroidal and 
subsequent studies confirmed the hypothesis. The choice of the name this time was happier 
than in the case of the parent Carbon. The new allotrope was named in honor of the architect 
Richard Buckminster Fuller, designer of geodesic dome that resembles the structure of 
fullerene (Figure 1). 
In the following years many other fullerenes were discovered, but C60 remained the most 
studied and important member of the family, first of all thanks to the work of Krätschmer who 
find in 1990 the way to produce fullerene C60 on large scale.
[2] In this method graphite rods are 
vaporized in electric arc in inert atmosphere and fullerene is recovered by solvent extraction 
from the so produced soot. 
In recent years fullerene C60 was observed also out from laboratories,
[3,4] in interstellar nebulae, 
in some minerals and also in common candle soot, the same that the Latins called carbo. 
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Figure 1: Geodesic Dome by R. B. Fuller (EXPO 1967, Montreal) 
 
1.2. Structure and Reactivity 
 
C60 is not the only member of fullerenes family, in fact also in the original experiment C70 was 
observed, and later many other allotropes were discovered. According to Eulero’s rule there 
are necessary 12 pentagons to close a tridimensional structure made of hexagons,[5] all the 
fullerenes are described from the general formula C2(10+M), in which M is the number of 
hexagonal rings, while the number of pentagons is ever 12. Among all the possibilities some are 
favorite as C60, C70, C76, C78, C84 that are commercially available, but the family is expanding 
every day until the recent discovery of C90.
[6] 
C60 is the smallest stable fullerene and is formed by 20 hexagons (M=20) fused with 12 
pentagons, however this is not sufficient to describe it, indeed there exist 1812 possible 
structures responding to this rule[7]. However C60 is a pure molecule, present in a single isomer, 
the only one that responds to the “isolated pentagon rule”, that means that each pentagon is 
surrounded by 5 hexagons and does not share any border with other pentagons (the same is 
true for higher fullerenes, but some of them exist in different isomeric form). Thus, 
[60]fullerene is a truncated icosahedron, more familiarly recognizable as a soccer ball. In this 
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way the geometrical strain is equally distributed on all the 60 carbon atoms and the structure is 
perfectly symmetric. 
As it is composed only by sp2 carbon atoms and it does not have a dipolar moment, it is 
completely insoluble in water and in common organic solvents, only few solvents such as 
toluene, o-dichlorobenzene or carbon disulfide are able to appreciably dissolve it. The 
insolubility hampers the employ of C60 as it is in many fields and a functionalization becomes 
necessary. 
Thanks to the Ih-symmetry all the carbons are equivalent, but not the bond order. Two types of 
bond (Figure 2) have been distinguished by means of crystallography[8] and AFM:[9] [6,6] 
junctions of 1.38 Å (an intermediate length between an alkene and an aromatic) and [5,6] 
junctions of 1.45 Å (longer than a double bond and shorter than single bond). This means that 
the electrons are only partially delocalized and the molecule is not aromatic. 
 
 
Figure 2 
 
This is due to the spherical shape that does not allow a perfect overlapping of the p orbitals as 
in a normal alkene. The deviation from the ideal is called pyramidalization angle (Figure 2), in 
fullerene C60 it measures 11.6° and explains its reactivity, similar to an electron-deficient poly-
ene. The driving force of all the reaction on fullerene is the relief of the geometrical strain that 
occurs when the hybridization of the involved carbon atoms passes from sp2 to sp3. Many 
reactions (Figure 3) are possible: nucleophilic additions and cycloadditions are the most 
versatile and frequently employed reactions, but even radical reactions were reported.[10] Less 
commonly exploited reactions are arylations[11] and halogenation of the fullerene cage.[12,13] 
As already mentioned the electronic density is higher on [6,6] junctions, indeed all the 
cycloadditions take place at this position with only few exceptions.[14] The additions usually 
have a 1,2-addition pattern, but also 1,4 is possible for secondary amines, but in this case the 
mechanism probably implies radicals.[15] 
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 Figure 3 
 
Bingel-Hirsch cyclopropanation and cycloaddition reactions are the more conventional 
approaches toward fullerene derivatization. Among the cycloadditions, the 1,3-dipolar addition 
of azomethine ylides is preferred to Diels-Alder and others for the variety of the substrates that 
can be used and for the stability of the resulting adduct, indeed retro Diels-Alder is easily 
achieved, while defunctionalization of the fulleropyrrolidine usually takes places only in harsh 
conditions. 
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As a consequence of the extended π-system, fullerene has a particular and very intense UV-Vis 
absorption and its solutions are violet-colored. When a functionalization takes place on a [6,6] 
junction the systems changes form 60 e- to 58 e- and this is reflected especially in the visible 
light region of spectrum (Figure 11), and in fact the solution of fullerene mono-adducts are 
typically brown. Independently from the type of functionalization the absorption is the same. 
Something different happens when the reactions take place on [5,6] bonds: the 60 e- π-system 
is only partially disturbed and the changes in the UV-Vis are not so dramatic. 
 
1.2.1. Bingel-Hirsch cyclopropanation 
 
Nucleophilic cyclopropanation (Figure 4) is achieved by reacting fullerene with a 
bromomalonate in presence of a strong non-nucleophilic base such as NaH.[16] The base 
abstracts the acidic malonate proton, the so generated carbanion reacts with an electrophilic 
double bond of fullerene cage. The resulting fullerene-centered carbanion undergoes an 
intramolecular displacement of the bromine and the 3-member ring is so formed. 
 
 Figure 4: Bingel-Hirsch reaction 
 
The halomalonate can be generated directly in situ in a convenient procedure by using directly 
the malonate and I2 or CBr4 as halogenating agent and the sodium hydride is frequently 
substituted by more manageable DBU[17]. Many Bingel-like reactions were also reported in 
which one or both the esters were substituted by other electron withdrawing groups such as 
ketones, nitriles, nitro, etc. 
The retrocyclopropanation can be accomplished both chemically[18] and electrochemically.[19] 
Retrofunctionalization generally is an undesired reaction, but it can be an useful tool for the 
optical resolution of inherently chiral fullerenes such as C76 by using chiral auxiliary on the 
malonate[20] and for the synthesis of polyadducts with a particular geometry in a sort of a 
“protection”-“deprotection” chemistry[21]. 
 
1.2.2. [1+2] Cycloadditions 
 
Thanks to [1+2] cycloadditions, it is possible to functionalize the fullerene surface with different 
three-member rings, for example, spontaneous oxidation of fullerene with atmospheric oxygen 
will introduce epoxide groups. For synthetic purposes carbenes[22], nitrenes[23] and sylilenes[24] 
are all used in 1+2 cycloadditions on [6,6] fullerene junctions. Particularly valuable are PCBM 
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(Figure 5) methanofullerene and its derivatives as excellent electron-acceptors in solar cells, 
that are obtained by means of an intermediate carbene.[25,26] 
 
 
Figure 5 
 
1.2.3. [2+2] Cycloadditions 
 
[2+2] cycloaddition leads to the formation of strained 4 member rings. It is not a common 
procedure to functionalize fullerene but some examples were reported. Benzyne usually acts as 
a dienophile in [4+2] cycloadditions, but it reacted with C60 in a [2+2] reaction on [6,6] 
junction.[27,28] With C70 was reported also the [2+2] cycloadduct on [5,6] junction as an evidence 
of the presence of a partial electron density also on longer bonds.[29] 1,3-diones undergoes 
photochemical [2+2] cycloaddition with fullerene affording a mixture of cis/trans isomers.[30] 
 
1.2.4. [3+2] Cycloadditions  
 
Many 1,3-dipoles were used to functionalize fullerene: organic azides[31,32] and diazo-
compounds[33] form the [3+2] cycloadduct that decomposes, by N2 extrusion, in a mixture of 
[6,6] adducts and [5,6] (aza)fulleroid, however the nitrene intermediate was not excluded in the 
case of the azide (Figure 6). 
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 Figure 6 
 
Other commonly used 1,3-dipoles are nitrile oxides,[34] and nitrile imines[35-36] that will form 
isooxazoline- and pyrazoline-fused fullerene respectively (Figure 7). Both reactive species are 
generated in situ under basic condition from the corresponding chloro-oxime or chloro-
hydrazone. 
 
 Figure 7 
 
Among 1,3-dipolar cycloadditions, the azomethine ylides is undoubtedly the most popular tool 
in fullerene chemistry since the products are extremely stable and there are practically no 
limitations to the variety of substituents that can be introduced in the resulting 
fulleropyrrolidine (Figure 8). Azomethine ylide is extremely reactive and cannot be isolated, so 
is generated in situ from different precursors.[37] The first reported procedure on fullerene[38] 
employs an α-aminoacid (or aminoester) and a carbonyl compound, usually an aldehyde, but 
ketones can be also suitable. By refluxing them with the fullerene in toluene or o-DCB, the 
condensation between the amine and the carbonyl will yield the iminium ion that will 
decarboxylate to generate the reactive 1,3-dipole that smoothly undergoes the [3+2] 
cycloaddition with the fullerene. 
Thermal ring opening and decarboxylation of isoxazolidinones is a variation of the classic 
procedure. Also aziridines with electron-withdrawing groups can be thermally opened to form 
in situ the azomethine ylide. 
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Finally, acid-catalyzed desilylation of trimethylsilylamine hemiaminal ethers is commonly used 
to perform 1,3-dipolar cycloaddition of azomethine ylides on electron-poor alkenes,[39] but was 
successfully used also on fullerene.[40] 
 
 Figure 8 
 
In the classic procedure, when aldehydes are used there is the formation of a stereocenter, but 
using symmetrical ketones is possible to obtain a 2,2-disubstituted symmetrical product. When 
an amino acid with a substituent on α-carbon is used in the reaction with an aldehyde there is 
the formation of a 2,5-disubstituted fulleropyrrolidine (Figure 9). In this way different 
substituents can be introduced at the same time, but however there is the formation of 2 
stereocenters and the product is usually obtained in a cis/trans isomeric mixture and for this 
reason this approach is not commonly exploited. A metal-catalyzed 1,3-dipolar cycloaddition of 
azomethine ylides was developed to control the stereochemistry of some 2,5-disubstitued 
fulleropyrrolidines.[41] 
The use of an N-substituted glycine and formaldehyde is the most common approach since it 
allows to introduce a substituent in position 1 and the obtained fulleropyrrolidine is symmetric 
(R=R’=H). 
 
 
Figure 9 
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The 2,5-unsubstituted pyrrolidine is extremely stable and can be cleaved only under forcing 
conditions,[42-44] however the introduction of substituents at the pyrrolidinic carbon can 
stabilize the incipient ylide and favor the retro-functionalization. 
It was demonstrated that under microwave irradiation in o-DCB/ionic liquid an equilibrium 
between cycloaddition and retro-cycloaddition is present and this can be exploited to control 
the number of addends introduced on the fullerene.[45] 
 
1.2.5. [4+2] Cycloadditions 
 
Since it behaves as an electron-deficient alkene, fullerene is a good dienophile in Diels-Alder 
reaction. However the reaction is easily thermally reverted, thus Diels-Alder is not a common 
method for permanent derivatization but its reversibility is rather exploited for several 
applications. Cyclopentadiene readily reacts with fullerenes[46] and this reaction is usefully 
employed in the purification of certain fullerenes by immobilization of the 1,3-dienes such as 
cyclopentadiene or even furan on a solid matrix.[47-49] Reversible Diels-Alder reaction between 
anthracene or its derivatives and fullerene is used to orient subsequent reactions taking 
advantage of the modification of the fullerene molecular orbitals and of anthracene steric 
hindrance. [50] 
 
1.3. Multiple additions 
 
Since reactivity of fullerene was deeply investigated and well described, an intriguing challenge 
in fullerene derivatization is the multiple functionalization. Indeed when a single 
functionalization is performed the maximum yield that is generally achieved is around 40-50%.  
After the first addition on the fullerene other 29 reactive double bonds remain, so in the classic 
experiment together the monoadduct is obtained a statistic mixture of bis-, tris- and higher 
adducts. A double or multiple functionalization can enormously enhance the solubility of 
fullerene derivatives and allows the construction of complex three-dimensional molecular 
architectures. Despite the advantages of the bis-adducts in many fields, they still remain 
scarcely studied. This is due to the problem of site-isomerism, indeed in the case of the bis-
addition of two identical and non-chiral groups there is the formation of 8 isomers (Figure 
10),[51-53] in the case of tris-addition the possible isomers becomes 46 and for the tetra-addition 
the number increases up 262. Then, if the addends are different one to the other or chiral the 
situation becomes even more complex.[54-56] 
Even if in some case the mixture of bis-adducts were employed, it is recommendable to work 
with isomerically pure compounds, because their physico-chemical properties can significantly 
differ, depending on the geometry.[57,58] This is particularly important in biological applications 
since the interaction with biomolecule is strongly dependent from the molecular structure. 
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It is clear that such reaction mixtures present some problems: first of all the tedious, time-
consuming chromatographic separation since the isomers usually have very similar polarity. 
Second the yield of each isomer, in non-selective reactions, can be very poor. 
In the case of bis-addition, the isomers are denominate as cis or trans depending if they are in 
the same or in the opposite hemisphere, with an equatorial intermediate position. 
Once the first addend is fixed, it is possible to localize 4 equivalent cis-1 positions, 4 cis-2, 4 cis-
3 in one hemisphere, 2 equatorial-edge and 2 equatorial-face sites (equivalents when the 
addends are identical), while in the other hemisphere are present 4 trans-4, 4 trans-3, 4 trans-2 
and only 1 trans-1 position. 
 
 
 Figure 10: fullerene bis-adducts 
 
Another element of complexity is that the isomers with C2 rotational symmetry (cis-3, trans-2, 
trans-3) are inherently chiral and the two enantiomers are called respectively Clockwise (C) and 
Anticlockwise (A). For some applications optically pure isomers can be required and this implies 
a further step of resolution.[59,60] 
Helpfully, each isomeric bis-addition pattern displays a typical absorption feature in the visible 
light region (Figure 11), almost independent from the type of addends (pyrrolidine, 
cyclopropane, etc.) and from the substituents.[61,62] The difference are so evident that some 
isomers can be distinguished even by eye, for example equatorial is cherry-red and trans-4 is 
olive-green, while the others are of different gradations of brown.[63,64] Hence, UV-Vis is the 
best technique employed to assign the isomerism, that is then confirmed by 1H and 13C-NMR. 
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Figure 11: UV-Vis spectra of C60, mono- and bis-adducts. 
 
Also the tris-adducts present a typical visible feature for each geometry but only some[65-67] of 
the 46 possible isomers have been identified so far, thus a comparison with literature data is 
possible only in few cases. 
The ratio between the isomeric bis-adducts is controlled by frontier molecular orbitals of 
fullerene derivative[68] with some contribution from steric hindrance. 
In the case of double Bingel-Hirsch reaction there is a certain selectivity for the equatorial and 
trans-3 isomers (Figure 12)[68] and the selectivity increases further in the case of tris- and 
subsequent additions, and this allow to easily obtain the two biologically important tris-
malonates C3 and D3 (Figure 20, compounds 5 and 6).
[65] 
 
 
Figure 12 
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The same is not true in the case of fulleropyrrolidines: equatorial and trans-3 are preferred 
(Figure 13), but the difference in yield from the other isomers are not so pronounced as in 
Bingel reaction.[54,62] 
 
 
Figure 13 
 
Rather cis-1, cis-3 and trans-1 are the less favored isomer, cis-1 mainly for steric hindrance, 
while trans-1 for the small molecular orbital but also the statistics plays a role, since it exist only 
one trans-1 site, while all the other isomers have four possible sites of formation. This latter 
isomer is particularly attractive for many applications thanks to its geometry and symmetry, 
thus a method for its production would be very helpful. Since the difference in terms of energy 
between the fulleropyrrolidine bis-adducts are too small, it is not possible to control kinetically 
nor thermodynamically the selectivity of the second additions. Only the ratio between 
unreacted C60, mono-, bis- and higher adducts can be controlled by varying stoichiometry of 
reagents, and reaction conditions, but the ratio between the isomeric bis-adducts cannot be 
altered in this way. 
 
1.4. Strategies to control the site selectivity of multi-addition 
 
1.4.1. Orthogonal transposition 
 
The so-called orthogonal transposition[69] is a multi-step method that exploits reversibility of 
both Diels-Alder and Bingel reactions (Figure 14). By heating in solid state fullerene-anthracene 
Diels-Alder monoadduct trans-1, bis-anthracene derivative A is obtained. Saturation of the 
equatorial positions (in red) is obtained by exhaustive Bingel cyclopropanation and hexakis-
adduct B is formed. Thermal retro-Diels-Alder will leave two reactive trans-1 positions (in 
green) on the symmetrical tetra-adduct C that can be functionalized with the required addends. 
Finally the four malonates can be removed to obtain the desired bis-adduct.[70-72] 
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 Figure 14 
 
This approach is very useful for the synthesis of disfavored trans-1 or symmetrical hexa-adducts 
but is not a general method for the production of other isomers, and moreover it requires 
many synthetic steps. 
Similarly, if exhaustive Bingel cyclopropanation is performed in presence of an excess of 9,10-
dimethylanthracene, it is possible to obtain octahedral Bingel hexakis-adduct (all equatorial) in 
a single step with a simpler purification of the product.[73] 
 
1.4.2. Switch of electronic reactivity 
 
A very elegant strategy was developed for the synthesis of the uncommon trans-4, trans-4, 
trans-4 Bingel tris-adduct, not accessible in normal conditions. In this method, a reversible cis-1 
functionalization is exploited to electronically activate three trans-4 double bonds in the 
opposite hemisphere.[74] 
Also this case is very specific for this geometry and to the best of our knowledge there are no 
other examples that follow this route. 
 
1.4.3. Tether-directed remote functionalization 
 
This latter approach is undoubtedly the more versatile, since the previously described 
methodologies are suitable only for certain geometries. As the name suggests, in this method 
the two (or more) reactive moieties are linked together by a tether. So, varying the length and 
the rigidity of the linker, the site-selectivity and the stereochemistry can be controlled. This 
route was widely explored in the case of the bis- and tris- Bingel additions since the pioneering 
work of Diederich and co-workers,[75] in which two malonate moieties are connected through a 
xylylene bridge (Figure 15 A). Double Bingel reaction afforded tethered bis-adducts with good 
selectivity and yields higher than 30%. Ortho-, meta- and para-substituted xylylenes gave 
different results in terms of site selectivity of the bis-cyclopropanation, while the replacement 
of malonic diester with ketoesters or iminoester provided changes in selectivity. It appeared 
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clear that a new powerful tool for selective bis-functionalization of fullerene was discovered 
being a lot of geometries accessible through this method. 
A more complex example involving a porphyrin core allowed the synthesis of trans-2 and trans-
1 isomer in very good yield. When a dibenzo 18-crown-6 ether was used (Figure 15 B), trans-1 
isomer was obtained with an unprecedented 30% yield, that in presence of K+ increased up to 
50%, presumably because the complexation of potassium reduces the tether flexibility, 
rendering it even more selective.[76-77] 
 
 
Figure 15 
 
After achieving the control on the site-selectivity, the new issue was the stereochemical control 
of the inherently chiral bis-addition patterns such as the case of cis-3 by using chiral tethers 
(Figure 16 A).[78,79] Also Tröger base analogues were successfully employed in the site-selective 
synthesis of some trans-adducts, thanks to their peculiar tweezers-shape (Figure 16 B). When 
optically pure Tröger bis-malonate were used, it was possible, for the first time, to control also 
the stereochemistry of the inherently chiral trans-2 and trans-3.[80-82] 
 
 
Figure 16 
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In order to obtain an even better control on the double Bingel addition, macrocyclic bis- and 
tris- malonates were employed. In this way the orientation of the reactive moiety is controlled 
from the tethers by the strain minimization of the macrocycle (Figure 17 A). Thanks to this 
methodology, excellent results were obtained for bis- and tris-, but also tetra- and hexa-
adducts, despite the great flexibility of the templates. It is particularly interesting that 
symmetric macrocycles with the same spacers between the malonates afforded exclusively 
isomers with C2 rotational symmetry, while asymmetric macrocycles gave only CS addition 
pattern. A stereoselective variant was also investigated by using chiral spacers and e,e,e tris-
adduct could be obtained in excellent yield with a diasteromeric excess of 53% (Figure 17 B).[83]. 
Tripodal tris-malonates were also successfully adopted in the synthesis of the well know C3 (e, 
e, e) and D3 (t3, t3, t3) isomers using cycloveratrylenes,
[84] 1,3,5-trisubstituted benzenes (Figure 
17 C)[85] or phosphate ester;[86] cleavage of the templating agent allows a further derivatization 
in the so called “polar” region rather than in the “equatorial” region. 
 
 Figure 17 
 
The scope of this methodology was extended also to other reactions, for example a tethered 
double [3+2] cycloaddition led to the synthesis of the first fullerenic vector for gene delivery 
(derivative 22, Figure 30)[87.88] Multiple Diels-Alder or carbene reaction were also tethered in 
the same way with good results on both C60 and C70.
[89-91] In two specific cases a second 
reaction was obtained on 2-substituted fulleropyrrolidines and only cis-1 bis-addition pattern 
was obtained for both nucleophilic addition of an alcohol[92] and for a Pauson-Khand 
cyclization[93] since the bridge between the two addend was only a methylene. 
Although the excellent results obtained in tether-directed remote functionalization with Bingel 
reaction, examples of other tethered reactions on fullerene are very scarce in literature. To the 
best of our knowledge, in the case in 1,3-dipolar cycloaddition of azometine ylides, all the 
efforts are referred to the tethering at the pyrrolidinic carbon, by using bis-aldehydes (Figure 18 
A,B), with only one exception of tethering at the pyrrolidinic nitrogen in a mixed isoxazoline-
pyrrolidine system (Figure 18 C). In the first example several bis-aldehydes were employed in 
1,3-dipolar cycloaddition in combination with sarcosine, allowing to obtain all the bis-adducts 
of trans and equatorial series with yields up to 50%, depending on the template. However the 
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situation is complicated by the formation of 2 stereogenic centers in the pyrrolidine units, thus, 
more diasteroisomers were obtained for some site-isomer (Figure 18 A).[94] In another paper a 
4,4’-diformyl-triphenylamine rigid template was used and afforded equatorial isomer in 30% 
yield as the sole bis-addition product. Some photophysical measurement were conducted and 
suggested an electron-transfer process from the triphenylamine to the fullerene.[95] Another 
tethered bis-addition was conducted on fullerene by using an electron-donor, this time a β-
modified porphyrin (Figure 18 B), here again two aldehydes are present on the template and 
1,3-dipolar cycloaddition gave rise to a trans-4 and trans-3 doubly linked fullerene-porphyrin 
dyads.[96] 
 
 Figure 18 
 
 
The only example of tethering at the pyrrolidinic nitrogen is constituted by a mixed system. A 
first cycloaddition of a nitrile oxide gave the aminoacid-decorated fullero-isoxazoline, then, an 
intramolecular cycloaddition afforded the mixed bis-adducts of the cis series. Depending on the 
length of the linker, different isomers were obtained with variable selectivity (Figure 18 C).[97] 
 
1.5. Biological applications[98] 
 
1.5.1. Fullerene Cluster Formation 
 
Before considering all the possible application of fullerene in bio-medical field it is important to 
take in account its behaviour in water or in biological media. Indeed the hydrophobicity of the 
fullerene cage, independently from the kind of functionalization, will encourage the 
aggregation. This is extremely important in the biological systems, since the biodistribution is 
strictly dependent on the size of the aggregates. Moreover the interaction with enzymes is 
highly sensitive to the aggregation state. For example, the HIV protease is inhibited when its 
catalytic site is occupied by the fullerene sphere, thus preventing the natural substrate access 
and subsequent cleavage, however, aggregation of the fullerene inhibitor would hinder its 
ability to enter the enzyme cavity, thereby lowering its efficacy. In other cases the aggregation 
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of fullerene derivatives can be desirable, for example to exploit the EPR effect in drug delivery 
(see below). 
Unavoidably, the introduction of substituents on the fullerene cage modulates the aggregation 
kinetics and the degree of association, depending on the nature of the introduced appendages 
and also on the regiochemistry.[99,100]  
 
1.5.2. Fullerene Toxicity 
 
Concerning fullerene derivatives toxicity, it is practically impossible to discuss as a general issue. 
It is evident that changes in the functionalization will vary the pharmacokinetic and the 
interaction with living systems. A typical example is the study of the hemolytic properties of a 
fulleropyrrolidine series composed by monoadduct and different bis-adducts[101] brought to a 
correlation between this activity and the ratio of the hydrophobic surface area 
(ASA_H)/hydrophilic surface area (ASA_P). Derivatives with relatively high ASA_H/ASA_P ratio 
seem to be better tolerated by red cells. It was also observed that cationic chains induced 
toxicity while the presence of neutral or anionic groups did not produce response in the studied 
models.[102] On the other hand it is also possible to observe a cytoprotective effect as in the 
case of the so-called bucky amino acid (Baa, Figure 19, 1), investigated for its antioxidant 
properties and used as building block for Solid Phase Peptide Synthesis (SPPS) of more complex 
fulleropeptides,[103,104] does not influence cell viability of human epidermal keratinocytes at 
concentrations lower than 0.04 mg/mL. Carboxyfullerene derivatives, as compound 2 (Figure 
19), were found to induce photo-cytotoxicity in HeLa cells,[105] but the number of malonic acid 
on the fullerene core affected the cytotoxicity that decreases with the increase of malonate 
moieties. 
 Figure 19 
 
 
1.5.3. Cellular Uptake and Membrane Interactions 
 
Understanding the interactions of fullerene with biological membranes is fundamental for the 
comprehension of the biological activity, because these interactions will determine the 
capability of the molecule to enter or not into cells and its intracellular localization (nucleus, 
mitochondria, etc.). The first biodistribution study of intravenously injected pristine C60 
aqueous suspension revealed a rapid clearance after 2 h, mainly through the liver (90%), the 
spleen and the lungs (7%).[106] However, C60 was retained in the liver up to 5 days, which 
unfortunately could lead to a long-term accumulation, discouraging the use of fullerene as 
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delivery platform. On the other hand, the findings that the C60 can distribute quickly to the 
tissues indicate that it could be potentially used for polar drug delivery, helping the membrane 
crossing. The intravenous administration of compound 3 (Figure 19), studied as HIV-1 protease 
inhibitor, presented a pharmacokinetic that resembles the previously reported:[107] quick 
distribution and slow excretion. Moreover, binding studies showed that the compound was 
highly protein bound (>99%). The in vivo performance of fullerenols was also evaluated. A 
C60(OH)x aqueous solution was radiolabeled with 
99mTcO4
– and injected in mice through the tail 
vein.[108,109] The 99mTc-C60(OH)x was quickly delivered to all organs and was retained particularly 
in the liver, the spleen and the bones, because of the uptake by the reticulo-endothelial cells. In 
vitro studies showed that a C60 dispersion was taken up by human monocyte macrophages and 
localized in lysosomes and nuclei.[110] Localization in different cellular organelles was found for 
derivatives with different functionalization, for example, carboxyfullerenes 2 (Figure 19) 
concentrate into mitochondria.[111,112] 
 
1.5.4. C60 Derivatives as Neuroprotective Agents 
 
Free radicals are reckoned to be responsible of cellular aging and are directly involved in many 
neurodegenerative pathologies such as Parkinson and Alzheimer diseases. Thus, fullerenes are 
able to absorb and delocalize unpaired electrons, thanks to the extended π-system, so that they 
can quench free radicals and be used as radical scavengers to protect cells from oxidative 
stress. In this light, since good solubility and capability to enter into cells are required, the most 
studied derivatives in this field are fullerenols 4 and carboxyfullerenes 5 and 6 (Figure 20). 
 
Figure 20 
 
The latter two compounds are regioisomers, differing only in the relative positions of the 
addends on the sphere, and they are respectively equatorial, equatorial, equatorial (known as 
C3) and trans-3, trans-3, trans-3 (or D3). Although both C3 and D3 isomers show the same 
capability to scavenge hydroxyl radicals in solution at very low concentration, a higher activity 
of C3 in cell cultures and in vivo was observed, due to the higher amphiphilicity of the latter 
with respect to D3, which is a characteristic that favours cell membrane crossing. These 
examples clearly underline the key importance of site-isomerism in determining biological 
behaviour. Carboxyfullerene 5 was found to be active in several types of induced oxidative 
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stress, such as glutamatergic overstimulation, oxygen-glucose deprivation and exposure to β-
amyloid or UV-B.[113]  
In vivo studies on zebrafish showed that both dendrofullerne 7 and carboxyfullerene C3 are 
excellent cytoprotective agents in different drug-induced apoptosis.[114] Dendrofullerene 7 
(Figure 21) possesses the highest antioxidant activity, even higher than C3, and in general, 
anionic fullerenes are more antioxidant than cationic or neutral derivatives.[115] Some fullerene-
amino acid/peptide derivatives were studied as cytoprotective agents: α- and β-alanine or 
phenylalanine derivatives are also efficient radical scavengers, comparable and in some case 
better than reference compounds such as ascorbic acid and Trolox,[116-118] while a poly-glutamic 
fullerene derivative is really efficient in neutralizing superoxide, acting as SOD mimetic with an 
efficiency 8 times lower than SOD itself, while C3 is approximately 100-fold less efficient than 
the enzyme.[118]  
 
 
Figure 21: Dendrofullerene 
 
1.5.5. Endohedrals 
 
Functionalization of fullerene usually takes place on the outer surface, but the inner cavity can 
also be exploited. The so-called endohedral fullerenes can accommodate in their hollow core a 
number of atoms, ions or small molecules (Figure 22). Although it exists the possibility to open 
the fullerene cage, fill and re-close it, as in a “molecular surgery”,[119] this is not the common 
way to produce endohedrals. The fullerene guest, usually a lanthanide or transition metal, is 
added to the carbon source used for the fullerene production and the metal is entrapped inside 
the cage at the moment of its closure. Endohedrals metallofullerene can find application in 
biomedical fields, such as magnetic resonance imaging (MRI) and radioimmunotherapy. 
 
1.5.5.1. MRI 
 
Paramagnetic contrast agents are often administrated for nuclear magnetic resonance, these 
substances are able to increase the relaxation rate of water protons, enhancing the image 
resolution. Many lanthanide ions are paramagnetic due to their f orbitals, among the series 
Gd3+ (4f7) with seven unpaired electrons in its half-filled 4f orbital, has the highest relaxation-
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increasing-power on the nearby nuclei. For this reason, Gd3+ chelates (i.e., Gd-DTPA) are 
commonly employed in MRI.[120]  
 
Figure 22: general structure of endohedral metallofullerene and Gd-DTPA. 
 
Gd@C2n (Figure 22) could find application as new generation MRI contrast agents, but high 
water solubility is strictly required for this application. In addition to the increased safety, 
water-soluble endohedral gadofullerenes have shown higher relaxivities than clinically used 
gadolinium chelates. The first reported example of water-soluble and air-stable derivative 
belonging to the M@C60 class, usually very unstable and difficult to handle, is the polymalonate 
Gd@C60[C(COOH)2]10, which was well tolerated in vivo by rodents and behaved like clinically 
employed Gd-chelates.[121] In vivo studies have confirmed the real applicability in MRI of 
Gd@C82(OH)40 as a RES-specific MRI contrast agents using just 1/20 of the clinically employed 
dose of Gd-DTPA (Figure 22).  
 
1.5.5.2. Radionuclides 
 
Gadolinium is the most studied guest in endohedral fullerenes for biological application, but 
endohedrals metallofullerenes with different guests are also produced for other applications; in 
fact, radionuclides can be encapsulated in fullerenes for either diagnostic or therapeutic 
purposes. 166Hox@C82(OH)y (x = 1, 2) was produced as radiotracer and its biodistribution in mice 
was compared with Na2[
166Ho(DTPA)(H2O)]. The holmium-fullerenol showed a longer blood 
pool residence period, higher than 1 h, contrary to classic metal chelates, and up to 4 days in 
some organs as liver and bones, showing a slow but steady clearance. This property permits to 
consider this endohedral as a possible new non-toxic radiotracer, suitable also for prolonged 
time studies.[122] However this approach can be not completely safe in some case, since the 
radionuclide can escape form fullerene [123] due to the break of the cage provoked by the 
emission as in the case of 212Bi/212Pb.[124] 
 
1.5.6. Photodynamic Therapy 
 
A biologically interesting property of fullerene is related to its ability, upon irradiation with UV 
and visible light, to generate the excited singlet state, which decays to a long-lived triplet state. 
The excited state can be quenched by oxygen before a spontaneous relaxation. In other words, 
fullerene acts as a photosensitizer, meaning that it can use the light energy to produce reactive 
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oxygen species, with a very high efficiency. This phototoxic effect can be exploited for 
therapeutic uses: it is possible to administrate a harmless compound and locally trigger the 
toxicity by focused irradiation, as in photodynamic therapy. Hence it is possible to selectively 
destroy tumor cells, viruses or bacteria. Fullerene seems to be an ideal scaffold for the design of 
novel photosensitizers, thanks to its low toxicity in the dark and the high quantum yield 
(number of 1O2 produced per absorbed photon), near to unity. There are different pathways for 
quenching of the 3C60* (Figure 23): it can directly transfer the energy to the molecular oxygen 
yielding highly reactive 1O2 (energy transfer or Type II). Otherwise, because the triplet state of 
fullerene is an excellent electron acceptor, it can be easily reduced to radical anion (charge 
transfer or Type I). This pathway is favoured by more polar environments and in presence of 
reducing agent such as NADH. However, the two mechanisms can be present at the same time. 
Another possibility, although uncommon, is the direct reaction of 3C60* with biomolecules, 
destroying the photosensitizer and the biomolecules at the same time (Type III).[125,126] 
 
 Figure 23: PDT types 
 
1.5.6.1. Anticancer photodynamic therapy 
 
Production of radicals and direct DNA damage can be an excellent treatment against cancer. 
The first experiment of photodynamic cell inactivation using fullerene dates back to 1993.[127] 
Water-soluble monoadduct 8 (Figure 24), together with its triethylammonium salt, was found 
to be cytotoxic against HeLa S3 cell line under visible light, while in the dark it did not show any 
cytotoxicity. To further investigate its biological properties, DNA cleavage was assayed, showing 
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a good activity with specificity at G bases. These findings demonstrated for the first time the 
feasibility of PDT with fullerenes derivatives. 
 
 
Figure 24 
 
A good dispersibility of the C60 derivatives is an essential requirement for fullerene-based PDT 
because of the shortening of the excited triplet state lifetime within the aggregates, meaning a 
loss of photodynamic activity for sparingly soluble derivatives, and because of their tendency to 
aggregate, polyhydroxylated fullerenes are not suitable for PDT. A study compared the 
photodynamic activity of C60(OH)24 and γ-CD-C60 complex in HaCaT cells. Although fullerenol has 
a much higher cellular uptake than the cyclodextrin complex, it was found to be 60 times less 
cytotoxic under photoirradiation.[128] Other γ-cyclodextrin inclusion were recently reported, in 
an example the cyclodextrin was modified and made pH responsive, in this way it is able to 
release C60 on the acidic surface of HeLa cancer cells on which it exert an increased 
photodynamic effect respect γ-CD-C60. 
[129] Several fulleropyrrolidines were also complexed 
with γ-CD and exhibited a photodynamic effect higher than parent γ-CD-C60. Even if C60 has a 
higher quantum yield than the mono-adduct, this latter has greater molar extinction coefficient 
at longer wavelength (> 500 nm) and can positively counterbalance the lower quantum 
yield.[130] Liposomes were studied in PDT as a delivery agent for C60 and C70 in HeLa cells 
cultures, and almost all the cells underwent apoptosis after irradiation.[131,132] Dendrofullerene 
7 (Figure 21) and C3 derivative (compound 5, Figure 20) are probably the most studied water-
soluble fullerenes, and their photodynamic properties were evaluated as well. In Jurkat cell 
cultures, dendrofullerenes reversibly inhibit proliferation, while C3 has only little effect; after 
irradiation with UVA and UVB light, both fullerenes have a toxic action, but photocytotoxicity of 
C3 is more pronounced, in contrast with what expected from quantum yield calculations, being 
φΔ = 1 for dendrofullerene 7 and φΔ = 0.3 for C3 carboxyfullerene 5.
[133] This is probably due to 
different localization of the photosensitizers in the cells. C3 localizes within mitochondria,
[134] 
while the branches of dendrofullerene probably keep it far from membranes. Another 
carboxyfullerene, namely a dimalonic derivative (DMA C60), exerts its phototoxic effect by 
damaging mitochondrial membrane in HeLa cells, effect driven, also in this case, by its 
intracellular localization.[111,135] Water-soluble fullerenes unfortunately do not have a special 
tropism for tumors, as reported for pristine fullerene, but they accumulated mainly into the 
liver and hence some attempts to selectively target tumor cells were done. A PEG-C60 was 
synthesized obtaining good water solubility and a molecular weight of 26,000 Da. It is known 
that high-molecular-weight molecules accumulate preferentially into solid tumors. This 
derivative follows this behavior; in fact, it is retained in tumors for a long period, and after 
photoirradiation, all the tumor-bearing mice were cured.[136] Another way to enhance the 
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selectivity for tumors was accomplished with the conjugation of C60 to glucose, in reason of the 
fact that GLUT-1 transporters are over-expressed in tumor cells. Some glycoconjugates bearing 
a different number of glucose units were synthesized; among these, the derivative 9 presenting 
one glucose residue (Figure 25) was the most effective in vitro against several types of cancer, 
and it was assayed also in vivo. Melanoma (COLO679) was photodynamically suppressed in 
mice after repeated PDT in presence of 9.[137] Rapidly proliferating cells, such as cancer cells, 
have enhanced uptake rate of nutrients, such as glucose, amino acids and folate. It is known 
that folic acid receptor is very common tumor marker, overexpressed in several kinds of cancer. 
Recently, the synthesis and the photodynamic activity of amino acid fullerene compounds (10 
and 11, Figure 25) and folate fullerene derivative (12, Figure 25) were reported. All these 
molecules are more efficiently internalized in HeLa cells than in N2a cells, indicating selectivity 
for cancer, with the best targeting activity and internalization for 12, which results also the 
most cytotoxic upon photoirradiation. 
 
 Figure 25 
 
Moreover, an increase of caspase-3 activity was observed with subsequent apoptotic cell death. 
For these reasons, bioconjugates 10-12 are very promising photosensitizers in cancer 
therapy.[138] A very high number of fullerene porphyrin dyads were synthesized in the last years, 
mainly for technological applications in the attempt to mimicking natural photosynthesis, but 
this kind of dyads offers also the possibility to exploit their particular photochemical properties 
in PDT. Porphyrin-C60 dyads, when irradiated, give rise to a long-lived radical ion pair (P
•+−C60
•-) 
through an electron transfer reaction. A dyad containing three methoxy phenyl groups on the 
porphyrin was designed to stabilize the positive charge on the tetrapyrrole (Figure 26) and its 
photodynamic properties were investigated on Hep-2 cells. 
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 Figure 26 
 
Due to its insolubility, compound 13 was administrated as liposomial inclusion. After incubation 
in the dark, no cytotoxic effect was observed, while, after irradiation, up to the 80% of cells 
were inactivated. Interestingly, this compound is able to kill cells even in hypoxic environment 
that is very frequent in solid tumors.[139] 
 
1.5.7. Inhibition of Enzymes, Viruses and Bacteria  
 
The interaction of the spherical apolar structure of fullerene with huge hydrophobic portions of 
proteins can lead to very favourable interactions, with interesting and unexpected results. Even 
though the most abundant number of papers is related to the interaction of fullerene 
derivatives to HIV proteases, where the computational works are corroborated by experimental 
results,[140,141] many different targets have been analyzed, especially in silico,[142] such as the 
binding site of C60 in the ATP-binding domain of human topoisomerase II alpha.
[143] Other 
studies are related to enzymes of general importance as acetylcholinesterase (AChE). AChE 
modulates the functions of central and peripheral nervous systems and its inhibition can be an 
important therapeutic approach in the cure of Alzheimer’s disease symptomatology. A series of 
four N,N-dimethyl bis-fulleropyrrolidium regioisomers (compounds 14-17, Figure 27) was 
studied by molecular modeling and by enzymatic inhibition assay, resulting in a new class of 
non-competitive inhibitors of the acetylcholine hydrolysis. Even in this case, the regioisomers 
gave sensibly different results, meaning different interactions with the enzyme and so a specific 
activity.[144] 
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 Figure 27: N,N-dimethyl bis-fulleropyrrolidinium regioisomer 14-17, respectively, trans 2, trans 
3, trans 4 and cis 3. 
 
The same series of N,N-dimethyl bis-fulleropyrrolidium salts is able to inhibit reverse 
transcriptase (RT), another key enzyme in the replication on HIV.[145] Tris-malonic fullerenes are 
able to inhibit restrictive endonucleases and DNA polymerase.[146] 
Polycationic C60 and C70 derivatives are under investigation for photodynamic inactivation of 
both cancer cells and bacteria, indeed the high positive charge (10+) will provide strong 
interaction with negatively charged bacterial wall. Also the iodide counter ion seems to have a 
role in photodynamic killing of bacteria, since it is probably involved in the pathway of OH• 
radical formation.[147,148] 
 
1.5.7.1. Virus photoinactivation 
 
Viruses are the most common and dangerous blood contaminants, and HIV, cytomegalovirus 
(CMV) and Hepatitis B and C viruses are particularly harmful. An economic procedure to 
decontaminate the blood of the donors is desirable as an alternative to the current multistage 
controls before hemotransfusion. Enveloped viruses are the most dangerous pathogens, and 
fortunately they are also much more sensitive to photoinactivation than the non-enveloped 
ones. Nowadays, water-soluble photosensitizers are employed, but frequently they cannot be 
removed from the blood sample after the treatment, and therefore the risk of side effects on 
patients is not excluded. Fullerene seems to be a good candidate, thanks to its insolubility, since 
it can be removed by simple techniques such as filtration or centrifugation and C60 can be 
recycled after the treatment and this constitutes a further advantage.[149-151] Many viruses were 
photoinactivated in this way, such as influenza virus,[152] herpes simplex virus,[153] H1N1 
influenza virus[154] and others. [155,156] Moreover, recently a soluble fullerene-glucose derivative 
has been designed to selectively bind HIV protease and to photoinactivate it: this compound is 
active also in the inhibition of viral replication, upon UV and visible light irradiation.[157] 
1.5.7.2. Antibacterial activity 
 
The increasing number of multi-resistant strains of bacteria, with related health threat, 
demands new antibacterial agents, encouraging the research in this direction. Since the 
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observation that a simple water suspension of fullerene has an antibacterial activity,[158] some 
studies in this field were accomplished. The antibacterial activity was related to disruption of 
cell membranes,[159-161] but in some cases contradictory results were reported, confirming the 
membrane integrity.[162] A ROS-dependent toxicity was excluded in some cases[163] and the 
mechanism of nC60 antibacterial effect is still debated. This mean that more than one 
mechanism could be possible to explain the activity, depending on the bacteria and on the 
fullerene derivatives. nC60, fullerenols, C60Brx and C60BrxCly inhibit the growth of several 
bacteria, also pathogens, and algae[164] In vitro studies on the well-known C3 carboxyfullerene 
(5, Figure 20) reported its antibacterial activity on Gram-positive species. Transmission electron 
microscopy (TEM) analyses showed intercalation of 5 into the cell wall. The presence of 
fullerene into the membrane weakens the outer shell of the bacteria, damaging the cells.[165] C3 
is also active in vivo, in fact, it can protect mice from lethal infection of Streptococcus 
pyogenes.[166] 
Cationic fullerenes in general are more active than neutral or anionic derivatives since they can 
strongly interact with negatively charged bacterial wall.[167] N,N-dimethyl bis-fulleropyrrolidium 
salt series (Figure 27) and related compounds are active against Enterococcus faecalis (Gram 
positive), and E. coli (Gram negative)[168] and Mycobacteria.[169] In the latter report, the 
mechanism was not clarified but in some other cases, the cationic derivatives act without 
disrupting bacterial wall; in fact, respiratory chain inhibition was reported.[170] Even in this case 
the isomerism plays a crucial role, indeed in the series of N,N-dimethyl bis-fulleropyrrolidium 
salts, trans-2 and trans-4 isomers (14 and 16, Figure 27) are the most active compounds with an 
antibacterial activity on E. coli comparable to vancomycine. At low doses the uptake of oxygen 
is inhibited, while at high doses it is enhanced, with concomitant production of hydrogen 
peroxide: this effect seems to be related to the different redox potential of the isomeric bis-
adducts.[171] Moreover, the interaction with negatively charged bacterial membrane and 
cationic fullerenes would lead to high affinity and consequently higher activity with respect to 
anionic or neutral fullerene compounds.[172] The photodynamic approach can be also exploited 
in killing bacteria. Once the higher affinity of cationic fullerenes for bacterial cells was 
established, photodynamic studies were accomplished on this class of derivatives. Of course, 
the photosensitizing power decreases with the increasing of addends due to the diminishing of 
π-system; on the other hand, a major number of addends and positive charges assure a higher 
solubility and stronger interaction with bacteria. Mono-, bis- and tris-N,N-dimethyl 
fulleropyrrolidium salts are able to kill more than 99.99% of bacteria when photoirradiated.[173] 
Structural variations on cationic fullerenes gave similar results and confirmed once more the 
importance of multiple positive charges in addressing the compounds to bacteria.[174,175] The 
broad activity spectrum, including both Gram-positive and Gram-negative microorganisms, 
which present different membrane permeability, was explained by a self-promoted uptake of 
cationic molecules, counteracting the differences in permeability.[176] Finally, QSAR evaluation 
of cationic fullerenes as antibacterial photosensitizers underlined that the effectiveness was 
related not only to the number of the charges but also to their positions on the sphere. A wide 
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dispersion of the positive charges on sphere surface inhibits the photosensitizer aggregation 
with an associated increase of activity.[177] 
 
1.5.8. Drug and Gene Delivery 
 
The lipophilicity of fullerene, together with the versatility in the carbon cage functionalization, 
permits to envision C60 as drug delivery platform, to vary the pharmacokinetics of active 
molecules and/or to overcome obstacles as multidrug resistance mediated by extrusion pumps. 
Drug delivery is particularly attractive in cancer chemotherapy in which a high selectivity for 
tumor tissue is preferred to overcome the heavy side effects on the organism. A non-covalent 
approach involves an amphiphilic fullerene derivative 18 (Figure 28) to prepare the so-called 
paclitaxel-embedded buckysomes (PEBs).[178] The hydrophobic pockets of the spherical 
nanostructures (100–200 nm), obtained by self-assembly of 18, are embedded with the 
anticancer drug. 
 
 
Figure 28: Structures of amphiphilic derivative 18 and of paclitaxel fullerene conjugate 19 
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In vitro studies showed that the PEBs’ efficacy toward MCF-7 human breast cancer cells is 
comparable to Abraxane (paclitaxel bound to albumin). The possible advantages of this 
preparation are the passive targeting of tumor thanks to the nanoscale dimension, with 
preferential accumulation driven from the enhanced permeability and retention (EPR) effect. In 
fact, the endothelial cells of tumor tissues present a leaky vasculature though which 
nanoparticles can exude. So the drug can be protected from enzymatic degradation and 
encounters a decreased uptake by RES. A C60-paclitaxel conjugate obtained via an ester bond 
among the two units (derivative 18, Figure 28) has been designed to obtain a lipophilic slow 
release system with advantages over liposomal delivery.[179] Paclitaxel retained its 
pharmacological activity and is released by hydrolysis of the ester bond. Conjugation of 
PEGylated fullerene to 5-fluorouracil enhanced the antiproliferative effect of the drug on 
mammary cancer cells MCF-7 and gastric carcinoma BGC-823 without any evidence of toxicity 
from the vector.[180] Also, DOX has been conjugated to fullerene by an amidic bond (compound 
20, Figure 29) and the cellular distribution of the new derivative has been studied, finding that 
while the free drug localizes mainly into the nucleus, 20 is mostly in the cytoplasm, as happens 
also for not fullerene DOX derivatives,[181] implying the possibility for the conjugate to gradually 
release DOX at pH lower than physiological values, with a subsequent drug access into the 
nucleus. Analogue methanofullerenes have been prepared and gave interesting results in 
inhibiting cell growth, with its efficiency comparable to that of the free drug.[182] DOX has also 
been attached to fullerenols, which offer a very high loading efficiency.[183,184] Fullerenol-DOX 
conjugate was found to suppress, both in vitro and in vivo, the proliferation of cancer cell lines, 
showing comparable anticancer efficacy as the free drug, without the systemic toxicity of 
DOX.[185] An analogous approach was used to deliver cisplatin by means of fullerenols. In this 
case also carboxylic units were introduced by cyclopropanation to link the metal as a 
carboplatin derivative (compound 21, Figure 29).[183] 
 
 
Figure 29: fullerene-doxorubicin 20 and fullerene-cisplatin 21 conjugates. 
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Fluorescent labelling of a fulleropyrrolidine derivative allowed to follow the internalization in 
MCF-7 mammary cancer cells, thanks to the efficient uptake and absence of cytotoxicity also 
these derivatives were recently proposed as drug delivery vectors and was used to deliver 
doxorubicin in resistant cells. Despite the presence of the extrusion pump it was possible to 
observe the same intracellular concentration of DOX than in the wild-type.[186] 
The advancement in research of the cellular delivery of exogenous nucleic acids such as RNA, 
short-interfering RNA, DNA and plasmid DNA (pDNA) has resulted in new viral and non-viral 
vectors, among which we can mention gluco-nanoparticles,[187] dendrimers and polymers,[188] 
silica nanoparticles[189] and carbon nanotubes.[190] The first attempt to use fullerene in this field 
dates back to 2000, when Nakamura et al. proposed cationic fullerene bis-adduct as gene 
delivery platform.[88] The first reported tetra-ammonium fullerene derivative 22 (Figure 30) was 
able to bind and deliver double-stranded pDNA into cells with efficiency comparable to 
commercial cationic lipids. Starting from these important results, a library of aminofullerenes 
was developed for a SAR study.[191] It emerged that the DNA-binding ability of the mono- and 
dicationic fullerene derivatives was generally higher than the corresponding cationic lipids, 
although the increase of cationic charges did not lead to a further benefit. The authors also 
reported that preparation of fullerene/DNA complexes could be affected by particle size. This 
parameter holds an important role in the transfection, considering that the fullerene-mediated 
mechanism takes place by endocytosis. Then, the fullerene/DNA complex reaches the 
cytoplasm and the DNA must be released. This process can be achieved either by 
deprotonation of the ammonium residues or by chemical/enzymatic hydrolysis, depending on 
the chemical structure of the derivative. The tetra(piperazino)fullerene epoxide (TPFE 23, 
Figure 30) efficiently acts as transfection agent in vitro and was selected for in vivo studies.[192] 
Compound 23 showed no acute toxicity and lower organ toxicity than lipid-based vectors. 
Transfection experiments were conducted with green fluorescent protein gene (GFP) using 
TPFE as a vector. While lipid vector delivers the gene only to lungs, the fullerene carrier is able 
to transfect also liver and spleen. The same vector was able to carry insulin-2 gene and 
reduction of hematic level of glucose was observed in mice. 
 
 
Figure 30: Tetraammonium fullerene derivatives 22 and 23 used as transfection agents. 
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Also multifunctionalized fulleropyrrolidines were proposed as possible vectors.[193] Poly-N,N-
dimethyl fulleropyrrolidinium salts consisted of a regioisomer mixture, with an average of 6.05 
charges per fullerene. Nakamura’s vector requires a certain percentage of DMSO for a 
complete solubilizations (with potential negative consequences), while poly-N,N-dimethyl 
fulleropyrrolidinium salts are completely water soluble, do not aggregate and, thanks to the 
positive charge, can establish strong interactions with nucleic material. Different water-soluble 
fullerene polyadducts were also tested for the transfection of cells with the GFP sequence.[194] 
Recently, C60 polycationic hexakis-adducts have showed that are efficient and non-toxic gene 
transfection platforms.[195] Despite the hydrophobic–hydrophilic balance shown by Nakamura 
et al., the dendritic fullerene hexakis-adducts displayed gene delivery capability even with low-
generation dendrons, contrary to classical dendritic vectors that usually require high generation 
numbers.[196] 
A study on a series of water-soluble fulleropyrrolidines, decorated with PAMAM dendrons, 
showed that bis-adducts are able to bind DNA at a concentration 21 times lower than the 
corresponding monoadducts, and also in this case was observed a different behaviour for each 
isomer.[197] 
 
1.5.9. Miscellaneous Applications of Fullerene 
 
New aspects of fullerene interactions with biomolecules are under investigation, and recently a 
computational study analyzed the possible targets of fullerene, pointing out hypoxanthine 
phosphoribosyltransferase and β-secretase as the most favorable objects of interaction with 
C60.
[198] Experimental work has also been focused on the direct inhibition of receptors or 
modulation of receptor expression. As already cited, fullerenols are known to be 
neuroprotective, acting as free radical scavenger but in some cases, this protection seems to be 
related to other pathway. They have been reported to reduce glutamate-induced neurotoxicity 
by 80% at 50 μM, but surprisingly, when the toxicity was induced by Fenton reaction, no 
protection was reported. Further investigations demonstrated a direct inhibition of the 
receptors, in a dose-dependent manner. Also, potassium channel can be modulated or 
inhibited by fullerene derivatives,[199] and moreover, it has been recently reported that the 
exposure of cell cultures to a trans-3 bis-fulleropyrrolidine leads to a modulation in genetic 
expression of some receptors.[200] Adenosine receptors (A1 and A2) up-regulation in 
neuroepithelioma, a neurodegenerative model, was achieved by treatment with trans-3 bis-
fulleropyrrolidine, this is particularly interesting since adenosine receptor is involved in a 
neuroprotective process since it inhibits glutamate release. 
Also, allergic response is modulated by fullerene. C60 preincubation of human mast cells and 
peripheral blood basophils led to a decrease in IgE-dependent mediators by reducing the 
activation of signaling molecules. Also in vivo important variations in histamine release were 
reported.[201] Fullerenols show specific immunomodulatory effects to the immune cells, i.e., T 
cells and macrophages, both in vitro and in vivo, increasing the production of T helper cell type 
1 cytokines and stimulating the immune cells to release more cytokines.[202] Inflammatory 
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response, induced by 12-myristate 13-acetate, is also abolished when the cells are pre-treated 
by fullerene derivatives.[203,204] A thalidomide fullerene derivative present interesting anti-
inflammatory activities, exerted by suppressing inducible nitric oxide synthase expression, 
inhibiting ERK phosphorylation and reducing NO and TNF-α release into the cell medium by 
scavenging ROS.[205,206] 
A adipose tissue inflammatory model, with macrophage infiltrations, was treated with a 
squalane-dissolved fullerene, the presence of which significantly inhibits macrophage 
migrations and intracellular oil droplet accumulations.[207] Administration of C60 derivatives in 
rats with arthritis significantly inhibits the osteoclastic precursor cell response and also the 
chondrocyte catabolic activity by neutralizing ROS that have an important role in osteoclast 
differentiation, encouraging further studies on rheumatic pathologies.[208,209] 
Very recently the toxicological behaviour of two fulleropyrrolidines was investigated. Neutral 
derivative seems to be well tolerated and, since it is able to penetrate in the cell, could be used 
as a novel scaffold for drug-delivery.[210] On the other hand, the cationic analogue exert a 
certain toxic effect on MCF-7 breast cancer cells and is able to influence the expression of 
several genes involved in cell adhesion and other processes.[211]  
 
1.5.10. Conclusions 
 
The research about the possible applications in medicine of pristine fullerene and its derivatives 
started about 25 years ago. In medicinal chemistry, this temporal interval is considered 
standard for the development of new drugs, so it is not surprising that this field is still under 
investigation, although at the present there are no fullerene compounds approaching clinical 
use. The peculiarities of this form of carbon can give unexpected interaction with many targets, 
so there is still a lot of work to be done with this nanomaterial. The more promising 
applications, among the ones so far explored, are the use fullerene as a new platform for drug 
delivery, as a neuroprotector and as a contrast agent in MRI. The use of fullerene in drug 
delivery has not been fully investigated and still holds considerable potential, especially taking 
into account the most recent in vivo experiments of nucleic acid transfection. 
Moreover, bis and polyfunctional fullerenes seems to be particularly attractive in biological 
field, but isomerism has to be take in account since the difference between isomers can be very 
different both in terms of biodistribution and interaction with target biomolecules. 
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Chapter 2: Objective 
The goal of the present work is the synthesis of new polyfunctional fullerene derivatives for 
biological applications. This kind of derivatives will be obtained by double functionalization of 
fullerene carbon cage, and by branching monofunctional fullerenes. 
 
In the case of the double functionalization the problem of isomerism will occur, so we will apply 
the tether-directed remote functionalization to 1,3-dipolar cycloaddition of azomethine ylides. 
By varying the shape and the flexibility of the template we will try to control the site selectivity 
of the double cycloaddition. In this way, reducing the number of the possible isomers, the idea 
is to increase their yield and to simplify the purification. 
Since we want to conjugate biologically active molecules to the bifunctional fullerenes we will 
use removable templates, obtaining, after the removal, functional groups available for further 
functionalizations. To do this the templates will contain ester groups that can be easily 
hydrolyzed, in order to leave on the functionalized fullerene hydroxyl or carboxylic groups, 
suitable for the subsequent derivatization. 
We will also try to modify the distribution of the isomer productions, thanks to an approach 
based on supramolecular interactions in a fullerene-based rotaxane. 
 
For the branching of the fullerene monoadduct chain we will develop a simple and versatile 
method. In order to increase the water solubility we will interpose oxyethylenic spacers 
between the branching point and the fullerene. The use of trichlorotriazine as trivalent 
ramification point seem to be suitable to the purpose, since its well known reactivity should 
allow easy “one pot” synthesis of poly-functional molecules. 
Moreover, some fullerene-drug conjugate will be synthesized and their biological behavior will 
be tested. 
 
Eventually we want to synthesize a series of fullerene-ruthenium complexes with potential 
biological applications as both antiproliferative compounds, thanks to the ruthenium activity, 
and photosensitizers, due to the presence of the fullerene itself. To do this a series of different 
fullerene-bipyridine ligands it will be synthesized and coordinated to ruthenium precursor 
bearing solubilizing ligands. 
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Chapter 3: Discussion 
3.1 Control on the bis-addition  
 
Fullerene bis-adducts are very charming molecules, the increased solubility and the possibility 
of multiple functionalization make them particularly attractive in biological field. Moreover they 
present very nice three-dimensional shapes to build complex molecular architectures. Despite 
their possible advantages, the bis-adducts remain scarcely employed, mainly for synthesis and 
purification issues. Indeed, the 8 isomers cannot be obtained selectively, but a mixture of them 
is usually produced. The tedious and repeated chromatographic separation and the low yield (in 
the range of 5%) discourage their use and the monoadduct is usually preferred. 
Bingel reaction and 1,3-dipolar cycloaddition of azomethine ylides are undoubtedly the more 
important tools to functionalize the fullerene, especially the latter that allows a greater 
variability and tolerance of functional groups. 
Concerning the double, or even triple, Bingel additions excellent results were obtained in terms 
of selectivity and yield, while the same is not true for the 1,3-dipolar cycloaddition. Only few 
examples of controlled double cycloaddition are reported in literature, most of them presenting 
some problems, such as the introduction of chiral centers, while in the remaining example 
there is the formation of a mixed pyrrolidine-isooxazolidine system. 
In the first part of this thesis we propose some methodologies to control the site selectivity of 
the double cycloaddition. 
 
3.1.1 Initial work 
 
In a previous work[212] we tried to control the site selectivity of the second 1,3-dipolar 
cycloaddition by means of tether directed remote functionalization. Differently from the 
previously reported examples, we decided to tether the two pyrrolidines through the nitrogen 
instead of the pyrrolidine carbon, in order to avoid the formation of stereocenters. To do this a 
series of bis-aminoacids (A, Figure 31) were synthesized and employed to obtain tethered bis-
adducts (B, Figure 31). A second important element was the introduction of hydrolysable ester 
bonds in the template, so after the isolation of the bis-adduct it would be possible to remove 
the core and to obtain fullerene derivatives with two reactive moieties, such as alcohols (C, 
Figure 31), for a subsequent derivatization. 
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Figure 31: general scheme of removable tethers 
 
The cores employed in the work were small diacids while the spacers between the nitrogen and 
the oxygen atoms were respectively ethyl, propyl and pentyl chains. Cycloaddition reaction 
mixtures were analyzed by HPLC, integration of the peak areas at 330 nm allowed to estimate 
the yield, while the UV-Vis feature of each peak permitted to determine the geometry of each 
product. Chromatograms (Figure 32 and 34) of the tethered cycloaddition clearly showed a 
decrease in the number of isomers, simplifying the separation on preparative scale. 
In general, for this kind of templates we observed that the best length of the spacer is of 3 
carbon atoms. The derivative with longer chains (pentyl) loses selectivity, while the shorter 
(ethyl) are more selective, but the excessive strain makes them less reactive and efficient. This 
kind of templates seems to be good for the low-mid distance isomers (cis and equatorial), while 
failed for the trans isomer that were detected only in few cases with the longer spacer with 
practically no selectivity. 
In this way it was possible for the first time to achieve a certain degree of control in the bis-
addition without introducing stereocenters or other kind of functionalization. 
 
In the present work we scaled-up the two best cycloadditions reported in the previous work.  
An equimolar mixture of bis-aminoacid and fullerene in o-DCB / DMF 3:1 with an excess of 
paraformaldehyde was heated at 150°C under MW irradiation for 15 minutes. 
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Figure 32: bis-aminoacid 3.1 and chromatogram of tethered cycloadditon. 
 
From the HPLC analysis of reaction performed using aminoacid 3.1, cis-2 isomer is the most 
favored isomer (31%), followed by equatorial (10%) and traces of cis-1 (2.7%). Equatorial 
isomer was isolated by chromatography in 2.8% yield (7.1% on reacted C60), while cis-2 was 
always contaminated by cis-1 and other by-products, even after repeated purifications. 
 
 
Figure 33: equatorial 3.2, 1H-NMR 500 MHz, CDCl3 
 
Equatorial isomer (Cs symmetry) has a plane of symmetry that passes through the plane of 
pyrrolidine 1 and it is orthogonal to pyrrolidine 2, thus the protons of the pyrrolidine ring 1 
gives two singlets (a and a’), while the ones attributed to pyrrolidine 2 are two geminal 
doublets (b and b’). In non-tethered equatorials the difference on the chain are not so 
appreciable and usually an unique set of signal is observed, instead in this case the two chains, 
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are magnetically different. A splitting of the signal is observed for all the protons c, d and e, and 
especially for the protons of the succinic core (f and f’) giving two multiplets at 2.60 and 2.35 
ppm. This is due to the strong current generated from the fullerene that can shield some 
protons. 
 
The other tethered cycloaddition that was scaled-up employed bis-aminoacid 3.3, containing a 
more rigid terephthalic core and, also in this case, the propyl spacer. 
 
 
 
 
Figure 34: bis-aminoacid 3.3 and chromatogram of tethered cycloadditon. 
 
From the chromatogram in figure 34, it is evident that the selectivity is completely changed; the 
size of the two tethers (1 and 3) are comparable, but while succinic acid is flexible and can 
adapt to a cis bis-addition pattern, the aromatic terephthalic core forces the two addends in 
more distant positions. Trans-4 3.4a (13%) and equatorial 3.4b (5.3%) are observed in this 
cycloaddition. Both the products were easily isolated by chromatography respectively in 5.9% 
(12.9% on reacted C60) and 2.8% (6.0% on reacted C60) and were characterized. 
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Figure 35: equatorial 3.4b, 1H-NMR 500 MHz, CDCl3 
 
Here again the typical pattern of equatorial is present: two singlets (a and a’) and two doublets 
(b and b’) for the pyrrolidines, and, also in this case, the two spacers (c, d, e) are non-equivalent 
and give two set of signals, while the core gives two doublet typical of para-disubstituted 
benzenes. In this example is visible not only the effect of the current generated from the 
fullerene, but also the anisotropic effect of the terephthalic benzene ring is evident, indeed 
pyrrolidine signals a’ and b’ (endo) are shifted upfield from their characteristic region, while the 
effect on the others (a and b) is less pronounced since they are exo with respect to the 
cyclophane and so are less influenced by the ring current (Figure 36). 
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Figure 36: equatorials 3.2 and 3.4b, 1H-NMR 500 MHz, CDCl3 
 
In this way we reported for the first time a double 1,3-dipolar cycloaddition tethered at the 
nitrogen.  
However, even if from HPLC the yield seems to be good, the real yield is much lower and is not 
increased respect to the classic condition. HPLC takes in account only the soluble part of the 
reaction, while the not soluble part is filtered off before the injection In fact an insoluble black 
material was observed, that explains the differences in yield from HPLC to weighted products. 
In light of these observations we designed and synthesized new templates with particular 
geometry with the aim at achieving better selectivity and yield. 
 
First of all, observing the geometry of bis-Bingel adducts and bis-pyrrolidine (Figure 37) it is 
clear that our first approach is heavily disadvantaged, indeed while the two Bingel addends are 
convergent, the substituents on the pyrrolidine nitrogen are divergent, this implies that the 
tether has to bend in a disfavored high-energy conformation. 
 
Figure 37: double Bingel VS double cycloaddition 
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To satisfy the geometrical requirement, we attempted other strategies in order to force the 
reaction in cis or trans positions by using more complex and suitable cores. 
 
3.1.2 Tethering at Pyrrolidine Carbon: Fulleroprolines 
 
The easiest approach is to tether the two pyrrolidines through the carbon (as in some examples 
reported in literature), however a modification of the pyrrolidine carbon will introduce a 
stereocenter in the molecule and there is the risk to obtain not only the usual bis-addition 
isomers, but also different diasteroisomer of each one. We decided to try also this way but 
using a template that could be removed in a subsequent step. According to the scheme (Figure 
38) we synthesized some bis-aminoesters in order to obtain bis-fulleroproline esters. After 
hydrolysis of the ester, the remaining acids should be decarboxylated to restore the symmetry 
of the pyrrolidine. 
 
 Figure 38: general scheme for tethered fulleroprolines. 
 
Ethylene glycol or 1,3-propanediol were reacted with bromoacetyl bromide in dry THF with 
pyridine as base and catalyst. Then the two bromines were substituted with an excess of 
butylamine. To properly purify the mixture, it was necessary to protect with Boc group all the 
amines. After chromatography, the protecting groups were removed and the aminoesters were 
obtained as stable TFA salts. 
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Figure 39: synthesis of bis-aminoesters. 
 
Cycloaddition of 3.9 and 3.10 on fullerene was carried out in refluxing toluene in presence of 
paraformaldehyde.  
Reaction of 3.9 afforded only cis-3 as a single peak in HPLC (42%), and the product was isolated 
in 19% yield by chromatography. There are three possible way to arrange the ethylene glycol 
bridge between the two cis-3 prolines (Figure 40): two of these preserve the Cs symmetry of cis-
3 isomer (A and B), while the third one (C) is completely non-symmetric. 1H and 13C spectra 
revealed that the product is present as diasteromeric mixture, that cannot be separated neither 
by HPLC. 
 
 
Figure 40: diasteromeric cis-3. 
 
The superior analogue 3.10 lead to the formation of cis-3 (23%) and cis-2 (10%) by HPLC (Figure 
41). Considering the problem due to the presence of the diasteromeric mixture, as obtained in 
the previous example, we decided to not scale-up the reaction. 
 
 
Figure 41: chromatogram of the cycloaddition of bis-aminoester 3.10 
 
Another bis-aminoester (3.13, Figure 42) was synthesized starting from 1,3-
phenylenedimethanol. In order to introduce 2 amino groups in the final compound we 
substituted butylamine with a monoprotected ethylenediammine. We used Cbz group that is 
removed in the same conditions of the benzyl ester and is orthogonal to the Boc groups, 
necessary for the efficient purification of the compound. 
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Figure 42: synthesis of 3.13 
 
Cycloaddition of 3.13 was attempted on C60 in refluxing toluene and in presence of an excess of 
paraformaldehyde, but the bis-aminoester was degraded in these conditions and no product 
was formed. 
Another problem encountered using this approach was the decarboxylation of the 
fulleroprolines, necessary to restore the symmetry of the compound. All the decarboxylation 
attempts performed on a model fulleroproline monoadduct failed, and in most of the cases a 
certain degree of retrocycloaddition was observed. For these reasons, this synthetic pathway 
was eventually discharged. 
 
3.1.3 Tethering at Pyrrolidine Nitrogen: cis bis-adducts 
 
Concerning the original approach (Paragraph 3.1.1) we consider that increasing the spacer 
flexibility to decrease the geometrical strain could be a solution, but, as we demonstrated in 
the initial experiments, too flexible templates are more reactive (in terms of consumed C60) but 
very scarcely selective. However if the flexibility is complete, a very short template could be 
effective for the selective double cycloaddition on the cis hemisphere. So we developed a 
highly flexible template 3.17 (Figure 43). Moreover this template carries the advantage that the 
ester introduced in the fullerene bis-adduct can be hydrolyzed and will leave on the fullerene 
two different groups, a carboxylic acid and an alcohol that could be selectively modified. 
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Figure 43 
 
The β-alanine tert-butyl ester hydrochloride was alkylated with benzyl 2-bromoacetate (BBA), 
the mixture of mono and di-alkylated products was protected with benzyl chloroformate, then 
tert-butyl ester was deprotected by treatment with TFA, yielding acid 3.14. Alcohol 3.15 was 
synthesized starting from 3-aminopropanol, that was alkylated and protected in the same way. 
Acid 3.14 and alcohol 3.15 were condensed by reaction with EDC and catalytic DMAP, 
compound 3.16 was deprotected by hydrogenation on palladium and asymmetric bis-
aminoacid 3.17 was obtained.  
Cycloaddition of the latter and fullerene was carried out in o-DCB at 130°C in presence of an 
excess of paraformaldehyde. Cis-3 (3.18a) isomer was obtained in remarkably 18.0% yield 
(38.5% on reacted C60) after purification, and cis-1 (3.18b) was also formed in traces (2.4%, 
5.2% on reacted C60). Due to the presence of the ester group, in NMR spectrum there is the 
overlapping of the signals of the chain with the pyrrolidine protons, thus in order to better 
analyze the compound we synthesized an analogue with a completely alkyl chain of the same 
length (Figure 44). 1,7-diamminoheptane was alkylated with benzyl 2-bromoacetate. The 
mixture of amines was protected with Cbz group to allow the purification of the compound. 
Hydrogenation of the four benzylic groups afforded the bis-aminoacid 3.20. 
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 Figure 44 
 
Cycloaddition of 3.20 was performed in the same condition, as expected the selectivity for cis-3 
isomer is preserved, but the replacement of the carbonyl with an sp3 carbon is enough to 
increase the flexibility of the tether, able to reach also cis-2 position. Indeed the cycloaddition 
produced a 12% of cis-3 (23% on reacted C60, 3.21a), 4.8% of cis-2 (9.2% on reacted C60, 21b) 
and 2.4% of cis-1 (4.6% on reacted C60, 3.21c). 
 
Figure 45: 3.18a (cis-3), 3.21a (cis-3) and 3.21b (cis-2). 
 
As shown in the cis-3 (compound 3.21a) 1H-NMR (Figure 46, top), the four protons of each 
pyrrolidine are magnetically non-equivalent due to the C2 symmetry, and indeed they appear as 
four geminal doublets in the region from 4.70 to 3.50 ppm. The two protons of the methylene 
linked to the pyrrolidinic nitrogen should be equivalent, but in the spectra are visible two 
multiplets integrating 2H each one, splitted of 0.65 ppm (3.49 and 2.84 ppm). This is explained 
by the fact that the geometrical strain of the tether hampers the rotation of that methylene 
and the two protons a and a’ are forced in one conformation, becoming diastereotopic. 
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In cis-2 isomer (3.21b) the situation is similar (Figure 46, bottom): four doublets for the 
pyrrolidines (Cs symmetry) from 5.00 to 3.60 ppm and again two multiplets (3.88 and 2.87 
ppm). 
 
Figure 46: 1H-NMR 200 MHz, CDCl3, Cis-3 3.21a (top); bottom: Cis-2 3.21b (bottom). 
 
3.1.4 Tethering at Pyrrolidine Nitrogen: Tröger base analogues 
 
This latter approach seems to work properly for cis isomers, however trans isomers are much 
more attractive for many application since, being less amphiphilic, they have a lower tendency 
to aggregate in polar media. To reach a trans position it is necessary a bigger tether but an 
excessive flexibility is not compatible with a good selectivity, thus the template has to be not 
only bigger, but also rigid and bent, so it can act as a molecular tweezers.  
The ideal scaffold to this purpose seems to be Tröger base (TB). This particular and charming 
molecule named after Julius Tröger, who synthesized it first in 1887,[213-214] is a bicyclic aromatic 
compound obtained by acidic condensation of an aniline (p-toluidine in Tröger’s work) with 
formaldehyde (Figure 47). 
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Figure 47: 3D model of TB and enantiomers 
 
The presence of the bridging methylene makes the molecule bent, with an angle between of 
the aromatic rings of roughly 90°, depending on the substituents. Another characteristic of this 
molecule is its chirality and is one of the few examples of molecules containing a stereogenic 
nitrogen, indeed due to the bicyclic structure the inversion of the nitrogen atoms is disabled. 
Thanks to its particular geometry and its size, comparable to the fullerene diameter, Tröger 
base analogues were successfully employed to tether the double Bingel addition.[80-82] In light of 
the excellent results obtained we decided to apply the same methodology to the 1,3-dipolar 
cycloaddition. Following the method of paragraph 3.1.1 we synthesized a 2,8-dicarboxylic TB 
derivative in order to obtain hydrolysable diester templates. 
 
 
Figure 48: Synthesis of bis-amino acid TB derivatives 
 
The 4-aminobenzoate ester was condensed with paraformaldehyde in TFA to obtain diester TB 
derivative 3.23. The pentyl ester was employed instead of conventional methyl or ethyl, since it 
is reported that the low solubility of the resulting TB analogue makes more difficult the 
chromatographic purification of the product.[215] The pentyl diester 3.23 can be crystallized 
directly from crude in 57% yield avoiding the chromatographic separation. Hydrolysis of the 
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ester gave diacid 3.24, that was condensed with the alcohol of the protected amino acid 3.15 
and 3.25. Finally hydrogenation of the four protecting groups left on the TB derivatives 3.28 
and 3.29 two amino acid moieties available for the cycloaddition. 
The attempts to allow the bis-amino acid TBs to react with fullerene failed, probably for 
solubility reason. After 2 hours of reaction no product was detected, but only degradation of 
the starting materials took place.  
For this reason we decided to replace α-amino acids with another functional group able to 
generate the azomethine ylide. 
 
1,3-dipolar cycloaddition on fullerene was reported by acid-catalyzed desilylation of 
trimethylsilylmethylamines hemiaminal ethers (Figure 49, A).[40] However, these functional 
groups are extremely acid- and moisture-sensitive and all the derivatives encountered in 
literature were purified by distillation. In our case the molecules will be too heavy to be 
distilled. Thus, we tried to perform the cycloaddition using directly trimethylsilylmethylamines 
(Figure 49 B-E) in presence of formaldehyde in order to generate in situ the corresponding 
hemiaminal and the related azomethine ylide. 
 
 
Figure 49: “one pot” cycloaddition of trimethylsilylmethylamines trials, condition non-
optimized. 
 
Trimethylsilylmethylamines B, C and D are able to generate the ylide and the corresponding 
fullerene were obtained, while compound E did not gave cycloaddition under these conditions. 
To understand the reason we performed a blank experiment without the fullerene and cyclized 
product F was isolated. We tried to react F with fullerene under acid catalysis condition but no 
reaction occurred. 
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Once demonstrated that trimethysilylamines give cycloaddition on fullerene in presence of 
paraformaldehyde we synthesized the bis-trimethylsilylmethylamino TB derivatives. 
 
 
Figure 50: synthesis of bis-trimethylsilylmethylamino TB derivative 
 
 
Chloromethyl)trimethylsylane was reacted in neat ethanolamine, in presence of catalytic 
potassium iodide. The monoalkylated amine was Boc protected and the alcohol 3.30 was 
condensed with 2,8-TB-dicarboxylate 3.24 using EDC and DMAP, then acidic deprotection of 
3.31 yielded the bis-trimethylsilylamino TB derivative 3.32 as trifluoroacetate salt. 
Since the template was obtained as TFA salt, the addition of catalytic acid in the cycloaddition 
was not necessary, C60 and an excess of paraformaldehyde were dissolved in o-DCB, and to this 
solution was added one equivalent of 3.32 dissolved in DMSO. The reaction was stirred at room 
temperature for three days. 
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Figure 51: TB-tethered double cycloaddition and its chromatogram 
 
In the HPLC of the crude unreacted C60 (42.3%) and monoadduct are detected (3.2%). 
Concerning the bis-adducts, as expected, only mid-long distance isomers are formed: trans-4 
(6.4%), equatorial (13.8%), trans-3 I (6.5%), trans-3 II (11.1%) and trans-2 (13.5%). 
Some observations are necessary: both Tröger base and trans-3 bis-addition pattern are chiral 
and C2 symmetric, this means that two pairs of enantiomeric trans-3 can be formed (R,R-A; S,S-
C and R,R-C; S,S-A), for this reason two peaks of diasteromeric trans-3 are observed. The same 
should happen for trans-2 isomer, but only one peak is visible, however we cannot exclude also 
in this case a diasteromeric mixture. Moreover, while usually bis-adducts elutes in silica 
according the order t1, t2, t3, t4, c1, e, c2, c3 (decreasing the angle between the addends 
increases the dipolar moment), in this case the order of elution is not the usual, or neither 
reverse, but is totally shuffled. We speculate that TB changes the angle between the two rings 
to adapt to the different geometry, in this way the TB contribution to the polarity of the system 
is not the same for all the isomers. 
This mixture of isomer is particularly hard to separate, indeed repeated preparative TLC were 
necessary for some of them. Chromatographic separation gave in the order: 19.6% of 
unreacted C60, 0.4% of monoadduct dimer 3.33a (0.5% on reacted fullerene), traces (0.4%, 0.5% 
on reacted fullerene) of cis-2 3.33b, 3.1% (3.8%) of trans-4 3.33c, 4.7% (5.9%) of equatorial 
3.33d, 5.8% (7.2%) of trans-3 3.33e (after a second chromatography: 4.3%, 5.3% on reacted 
fullerene), traces (1.4%, 1.7% on reacted fullerene) of trans-2 3.33f and finally 5.6% (7.1%) of 
another isomer (or mixture) 3.33g, whose structure is still unclear. 
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Since the molecule is symmetric, NMR spectrum of 
3.33a (Figure 52) shows a single pyrrolidine peak (a) 
at 4.50 ppm integrating 8H. With a better resolution 
it is possible to determine that it is not a perfect 
singlet, but a minimal splitting is present, since the 
protons are diasterotopic. The other signals are a 
triplet for protons b and a multiplet (instead of a 
triplet) for diasterotopic protons c. The symmetry of 
TB is preserved and indeed the aromatic protons (d, 
e and f) do not present any particular behavior, 
benzylic protons g (4.24 ppm, endo) and g’ (7.74 
ppm, exo) gives two doublets with a big coupling 
constant (16.6 Hz).typical of TB’s geminal protons, 
while the bridging methylene (h) gives a singlet at 
4.28 ppm. 
 
The situation is much more complex in the case of the tetherd bis-adducts 3.33c (trans-4) and 
3.33d (equatorial). Indeed the combination of the Cs symmetry of these bis-addition patterns 
with the C2 symmetry of the Tröger base produces completely asymmetric compounds in which 
neither a plane nor an axis of symmetry is present. This is reflected in the NMR in which there 
are none equivalent protons, so each signal represents 1 H.  
Figure 52: monoadduct dimer 
3.33a, 1H-NMR 500 MHz, 
CDCl3/CS2 (top), UV (bottom). 
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The lack of molecular symmetry of tethered trans-4 
(3.33c, Figure 53) is evident for all the signals, for 
example the six aromatic protons are non-
equivalent and for each ring a set of signal can be 
distinguished (d, e, f and D, E, F), the same is true 
for the ethylene spacer, but in this case the 
situation is even more complex due also to the 
geminal coupling between each of the four pair of 
diastereotopic protons (b/b’, B/B’, c/c’, and C/C’). 
Also TB benzyl protons are split. Indeed at 4.21 and 
4.12 ppm we can observe the two different endo 
protons (g and G), while their exo counterpart (g 
and G’) are overlapped to signals “c” at ~4.7 ppm. 
All the other eight unlabeled doublets represent the 
protons of pyrrolidines “a” and “A”: a classic trans-4 
isomer gives four doublets, but here also these 
signals are split due to the absence of symmetry. The only nuclei that seem to be not affected 
are the bridging methylene protons (h), probably because they are too far from fullerene 
asymmetric center. Assignations of the signals were possible thanks to COSY bidimensional 
spectroscopy and to the measurement of coupling constant (around 16.5 Hz for TB benzyl 
protons, and ~10.0 Hz for pyrrolidines). 
Figure 53: trans-4 3.33c, 1H-NMR 500 
MHz, CDCl3 (top), UV (bottom) 
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Assignation of the right geometry was possible by comparing Uv-Vis feature, that is the typical 
for trans-4 bis-addition pattern. 
 
 
 
Equatorial isomer (3.33d) presents a similar 
situation: here again the splitting of the signals is 
present for all aromatics, ethylene chain and TB 
benzylic protons that are visible as four doublets 
(exo: 4.74 and 4.69 ppm; endo: 4.21 and 4.15 ppm). 
In equatorial bis-addition pattern usually are 
present two singlets (2H each) for the pyrrolidine 
“a” and two doublets (2H each) for the pyrrolidine 
“A” (see also compounds 3.2 Figure 33 and 3.4b 
Figure 35), but in this case all the eight protons are 
magnetically non-equivalent, so eight doublets 
(some of them overlapped) are present in the 
region from 4.25 to 3.80 ppm. Here again bridging 
methylene (h) is the only non-split peak. Also in this 
case, COSY-NMR was essential to understand the 
structure. 
Figure 54: equatorial 3.33e, 1H-NMR 
500 MHz, CDCl3 (top), UV (bottom) 
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Also here there is an almost perfect matching between the UV-Vis spectrum of 3.33d and the 
spectrum of another equatorial fullerene derivative, used as reference. 
 
 
 
Even at a first look the NMR of trans-3 (3.33e, 
Figure 55) is definitely simpler than the previous 
two cases. As already mentioned, the trans-3 C2 
symmetry and the same C2 symmetry of TB element 
will produce a C2 symmetric compound, even if two 
couples of diastereoisomer are possible from this 
combination (R,R-Anticlockwise isomer here 
represented). Indeed all the TB’s signals (aromatics 
d, e, f, benzylic g, g’ and bridge h) present their 
typical pattern without any splitting, the same is 
true for pyrrolidine protons “a” that give four 
doublets as in non-tethered trans-3. The only 
splitted signals are the ethylene spacer protons 
(b/b’ and c/c’) since they are diastereotopics due to 
the disabled rotation of the bonds. 
UV-Vis spectrum of 3.33e (Figure 55) is in good 
agreement with other trans-3 reported in literature. 
 
Figure 55: trans-3 3.33d, 1H-NMR 
500 MHz, CDCl3 (top), UV (bottom) 
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The last major fraction obtained from the purification was still not completely defined. UV-Vis-
spectrum does not match with any bis-addition pattern and could be the sum of the trans-3 and 
trans-2 spectra. NMR presents three sets of signals whose integrations are roughly 1 : 0.8 : 0.2. 
However after a second chromatographic purification the ratio between the three sets 
remained exactly the same. The other hypothesis was that the compound is present as a 
mixture of rotamers due to a high geometrical strain, but NMR at 25° and 40°C does not 
present any appreciable difference. Thus the structure of the last compound is still not clarified. 
 
3.1.5 Tethering at Pyrrolidine Nitrogen: Anchoring 
 
Since Bingel adduct presents a favorable orientation of the groups for a second reaction we 
decided to exploit this kind of functionalization as an anchoring point, to orient two 1,3-dipolar 
cycloadditions. We synthesized three malonates decorated with protected amino acid moieties 
at the periphery. 
 
 
Figure 56: synthesis of bis-amino acid fullerenes 
 
In the general procedure, an excess of aminoalcohol was alkylated with tert-butyl 2-
bromoacetate, after Boc protection of the monoalkylated amine, The free hydroxyl group was 
allowed to react with malonyl chloride and the symmetric malonate (3.40, 3.41 and 3.42) was 
obtained. This latter was reacted in Bingel-Hirsch reaction in toluene using iodine and DBU, 
then the deprotection of two Boc and two tert-butyl esters gave the bis-amino acid fullerene 
derivatives (3.46, 3.47 and 3.48). 
These compounds are insoluble in almost any solvent, thus the intramolecular cycloadditions 
were carried out in DMF (the only solvent able to partially dissolve them) at 130°C in presence 
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of an excess of paraformaldehyde. The reactions of 3.47 and 3.48 gave very complex mixtures, 
without any apparent selectivity for one product. The attempts to isolate some of them 
produced very small amount of inseparable mixtures of products even after repeated 
chromatography. Only the derivative with the shortest spacer (3.46) gave a mixture containing 
a major product. 
 
 
Figure 57: intramolecular double cycloaddition 
 
The major product 3.49, a tris-adduct, was obtained in 12% yield after repeated 
chromatography. NMR analysis revealed the presence of an element of symmetry (a plane or 
an axis), indeed only four doublets for the pyrrolidine protons are present indicating that the 
two pyrrolidines are equivalent. Also the number of aflkylic carbon signal is consistent with a 
symmetric pattern. This means that the spatial relation between the pyrrolidine and the 
cyclopropane is the same for both the pyrrolidines. However many tris-addition symmetric 
pattern are possible. Since the UV-Vis spectrum does not match with any known tris-adduct, 
the correct assignation of the geometry was not possible. 
In conclusion, we observed that also in this case that to achieve a certain degree of selectivity 
for an isomer is extremely important to use a template with the minimal flexibility as possible, 
and ethylene chain is the shortest that can be used in this approach. The propyl or pentyl chain 
dramatically decreases the selectivity, discouraging us in following this way. 
 
3.1.6 Non-covalent approach: Rotaxane 
 
A completely different strategy was developed to control the pattern of bis-addition. In all the 
previous examples the two anchoring points were covalently linked while in this new strategy 
we tried to exploit supramolecular interaction in a fullerene-based rotaxane. 
Rotaxanes are charming supramolecular systems in which the two elements (thread and 
macrocycle) are irreversibly interlocked. Although the two elements interact one with the other 
through non-covalent interactions, it is impossible to dissociate the system. A fullerene-based 
rotaxane 3.54 (Figure 58) was reported and its behavior was deeply investigated.[216] The 
system is constituted by a thread (3.53, Figure 58) with two different stoppers - a 
fulleropyrrolidine on one side and a (diphenylacetyl)glycine amide on the other - and a tetra-
amidic macrocycle. The system was designed in order to have multiple H-bonds between the 
macrocycle and the diamide station.  
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Figure 58: synthesis of fullerene-stoppered rotaxane. 
 
Rotaxane 3.54 was synthesized according to literature procedures: Boc-protected fullerene-
amine was synthesized by means of 1,3-dipolar cycloaddition with aminoacid 3.50 and 
paraformaldehyde, then quantitative deprotection of Boc group afforded fullerene-ammonium 
3.52. Thread 3.53 was obtained by amidation of 3.52 with diphenylacetyl glycine, using the EDC 
/ HOBt procedure. Finally a p-xylylendiamine solution and an isophthaloyl chloride solution 
were added simultaneously to an highly diluted solution of thread 3.53. Since the reaction is 
carried out in chloroform the H-bonds strength is maximized, thus the thread diamide moiety 
itself templates the formation of the macrocycle by pre-orientatation of the reagents through 
H-bonds. In this way the macrocycle enclosure is favored around the thread and the rotaxane 
3.54 is formed. 
The latter exists in two possible conformations: in non-polar solvents such as chloroform the 
strength on H-bonds is high and the macrocycle preferentially stays on position 0 (diamide 
station), in polar solvents, such as DMSO or DMF, the amides are solvated and the H-bonds 
broken, thus the macrocycle is stacked, for a solvophobic effect, on fullerene station (position 
1), on which it can establish π-interactions. Hence, by changing the polarity of the environment 
it is possible to drive the macrocycle preferentially to one station of the thread. 
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Since in polar media the macrocycle stays preferentially in position 1, a portion of the cis 
hemisphere is covered and the macrocycle can be envisioned as a sort of “protecting group”. 
Thus, a second cycloaddition should give preferentially trans isomers, since the cis hemisphere 
is partially hindered. However 1,3 dipolar cycloaddition of azomethine ylides requires high 
temperatures (>100°C) in the conventional procedure (α-amino acid + aldehyde or ketone), and 
under these condition the weak interactions between the fullerene and the macrocycle will be 
weakened even more, so that method does not seem to be suitable for our purpose. Here again 
we exploited the acid-catalyzed desilylation of trimethylsilylmethylamine hemiaminal ether, 
that, contrary to “amino acid” procedure, proceeds at room temperature or even at lower 
temperatures.  
A commercial trimethylsilylmethylamine hemiaminal ether (Figura 59) was employed for 
simplicity and to avoid any other contribution to the equilibrium from the amine and the 
aldehyde. To have comparable data, the second cycloaddition was performed on fullerene 3.51, 
thread 3.53 and rotaxane 3.54 in the same condition by the “silane” procedure in three 
anhydrous solvents (to exclude any water contribution): chloroform, DMSO and DMF. 
Moreover, as the heating will weaken the supramolecular interaction between the fullerene 
and the macrocycle, a cooling should enhance the strength of these interactions. So we tried to 
determine the minimal temperature at which the reaction proceeds on C60. We observed that 
at -50° or -40°C apparently the reaction does not take place (TLC), while at -30°C traces of 
product start to appear even though very slowly. Being difficult to maintain such a low 
temperature for a long time (days), we opted for -20°C. 
 
  
 
Figure 59: cycloaddition on rotaxane (top), example of chromatogram (bottom). 
 
The cycloadditions were performed on the three fullerenes under the following conditions: 
chloroform, DMSO or DMF at room temperature for 24 hours, and chloroform or DMF at -20°C 
for 14 days (Figure 59).  
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In the latter cases the reactions were performed in a freezer, to keep the temperature 
constant. Then, to remove DMSO or DMF, the crudes were extracted and precipitated with 
Et2O to clean them from any non-fullerenic by-product. The crudes were analyzed by HPLC, the 
integration of peak areas at 322 nm gave us an estimation of the relative yield of the products, 
while the UV-Vis spectrum of each peak allowed us to distinguish every isomer. For each 
sample three runs were carried out and the averages were compared. 
The reactivity fullerene derivative is very variable depending on the solubility of the fullerene 
derivative in the three solvents. Indeed, rotaxane 3.54 is soluble in chloroform at room 
temperature, but when cooled it partially precipitates, thus only the soluble part reacted, while 
monoadduct 3.51 is completely soluble in chloroform and DMF, but only sparingly soluble in 
DMSO. Thus, to compare the yield of the isomer the ratio between the bis-adducts was 
calculated, excluding the unreacted starting material and the tris- and higher adducts, formed 
in variable amount. The data here reported represent only the distribution of the bis-adducts 
and cannot be considered as an indication of the real yields. 
 
 
 
Figure 60: cycloaddition on fullerene monoadduct 3.51 (top) and on thread 3.53 (bottom) 
 
In both cases the distribution of the isomer is the usual that is encountered in literature:[54,62] 
dominated by equatorial and trans-3, followed by trans-4, trans-2 and cis-2, the remaining 
trans-1 and cis-3 are formed only in limited amount, while cis-1 was not detected in any 
chromatogram of all the series. As expected the different solvents did not produced 
appreciable variations in the distribution of the isomer in both monoadduct 3.51 and thread 
3.53, thus any change in the case of the rotaxane cannot be ascribed to a non-specific solvent 
effect. 
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Figure 61: cycloaddition on rotaxane 3.54. 
 
When the cycloaddition on rotaxane 3.54 is carried out in chloroform (position 0, Figure 58) the 
distribution is the usual: equatorial and trans-3 are the major products, then trans-2, trans-4 
and cis-2, and trans-1 and cis-3 are the less favored. Moving from chloroform to DMSO or DMF 
some changes are evident: the selectivity for trans-3 increased from 20% in chloroform to 25-
27% in DMSO or DMF, while the opposite effect was observed for equatorial (that decreases 
from 23% in chloroform to 20% in DMF) and for cis-2, the yield of which drops from 12% in 
chloroform to 7-5% in DMSO or DMF. The ratio of the other isomer is practically unaffected by 
the change of solvent. 
The decrease of cis-2 is in perfect agreement to what expected. Analogously for equatorial a 
decrease is observed, even though not so pronounced as in the case of cis-2. This is explained 
by the fact that equatorial position is more distant than cis-2 position from the first pyrrolidine, 
so there is only a partial steric hindrance due to the presence of the macrocycle. On the other 
side we expected an increase in the yield of all the trans isomer, but this was observed only for 
the trans-3 and, with a much lower intensity, for the trans-2. However, considering that the 
suppression of cis isomers is only partial, the slight increase of the trans is probably 
proportionally distributed among the series: since trans-3 and trans-2 are more abundant even 
in normal conditions the increase becomes more appreciable than in the cases of trans-1 and 
trans-4. Moreover for this latter isomer we cannot completely exclude a minimum of steric 
hindrance by the macrocycle that could negatively counterbalance the expected general effect 
on the trans series. 
As last consideration we notice that the lower temperature (-20°C) has only a little or null 
additional effect on the distribution. 
 
3.1.7 Summary 
 
In conclusion, in this first part of the work we developed different strategies to control the 
pattern of bis-addition of the 1,3-dipolar cycloaddition of azomethine ylides. We can conclude 
that small and highly flexible tethers are suitable for the selective synthesis of cis type isomer, 
while, for the trans type rigid and tweezers-shaped tethers are required.  
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A non-covalent control was also attempted by exploiting intra-rotaxane interactions and an 
increased selectivity for trans isomers was observed. 
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3.2 Fullerene derivatives for Biological Applications 
 
The second part of the thesis is focused on the synthesis of soluble multifunctional fullerene 
derivatives. Here we present some drug-fullerene conjugates and some new soluble, 
multifunctional and versatile fullerene scaffold that can be suitable for several biological 
applications. 
Different triethyleneglycol fulleropyrrolidines derivatives were previously synthesized by our 
group and were tested on cell cultures in order to assess their toxicity and to understand their 
uptake for a possible use as drug delivery vectors.[210]  
To increase the water solubility of these compounds, quaternary ammonium derivatives were 
synthesized, however their biological behavior dramatically changed. In general we observed 
that fulleropyrrolidine 3.52 has a negligible cellular toxicity (<10% cell viability inhibition) on 
different cell lines, while the corresponding N-methylfulleropyrrolidinium salt seems to be toxic 
(up to 40-50% on cellular inhibition).  
Since fullerene 3.56 interferes with the expression of several proteins involved in cell-cell 
adherence junctions[211] a possible anti-metastatic employ is proposed. Indeed we recently 
reported that fullerene 56 is able to reduce invasion and migration of HT-29 cell (human 
colorectal adenocarcinoma) even in non-toxic dose.[217] 
 
 
Figure 62: synthesis of fulleropyrrolidine 3.52 and fulleropyrrolidinium 3.56.[210] 
 
 
So far fullerene 3.52 it seems to be an ideal scaffold for drug delivery, thanks to the negligible 
toxicity and to its ability to enter into cells, as it was demonstrated with fluorescent labeling 
with FITC. 
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3.2.1 Fullerene-Doxorubicin 
 
Doxorubicin (DOX), a milestone in cancer chemotherapy, was chosen as active molecule to be 
delivered by means of a fullerene carrier. The expression of a transported able to rapidly 
extrude the drug – in this case DOX - from the cell leads to drug-resistant tumors so the drug 
will never reach the therapeutic level. However the conjugation to the bulky fullerene carrier 
does not allow the transporter action, in this way a higher intracellular concentration of DOX 
can be achieved. Moreover DOX is fluorescent and thus the cellular uptake can be easily 
followed by cytofluorimetry or confocal microscopy.  
In our group were previously synthesized two fullerene-doxorubicin conjugate.[186] In the first 
the drug was linked to the carrier by a simple amide bond (Figure 63, A). The cellular uptake of 
the conjugate was effective, but the compound does not exert the cytotoxic effect, probably 
because the drug was not released from the carrier. Thus a second system (Figure 63, B) was 
developed in which the drug was linked through the GFLG tetrapeptide, known to be cleaved by 
lysosomal cathepsin. Also in this case a high intracellular concentration of drug was obtained, 
but without any pharmacologic effect. 
 
 
Figure 63: fullerene-doxorubicin conjugates 
 
In this work we replaced the amidic bond with the more labile urethane, in order to obtain the 
release of the drug. According the scheme (Figure 64), γ-butyrolactone was opened by 
fullerene-amine 3.52, the resulting hydroxyamide 53.7 was converted in the asymmetric 
carbonate 3.58 by reaction with an excess or p-nitrophenylchloroformate. The good p-
nitrophenol leaving group was finally displaced by the amino group of doxorubicin and the 
carbamate-linked fullerene-doxorubicin conjugate 3.59 was obtained. 
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Figure 64: synthesis of carbamate-linked fullerene-doxorubicin conjugate 3.59. 
 
The 1H-NMR of 3.59 shows all the doxorubicin and fullerene’s proton signals and, thanks to 
COSY and HSQC, the full assignment was possible (Figure 65, top). 
UV-Vis spectrum of the conjugate (Figure 65, bottom left) shows the typical absorbance of DOX 
at 482 nm and the characteristic fullerene-monoadduct peak at 430 nm, while in the emission 
spectrum (Figure 65, bottom right) a strong quenching of doxorubicin fluorescence is observed, 
due to an intramolecular interaction with the fullerene. Intermolecular quenching has to be 
excluded since the emission spectrum of the physical mixture 1:1 of DOX and 3.57 does not 
present any quenching and is perfectly superimposable to the spectrum of DOX alone. However 
the residual fluorescent is still enough to be detected in cells and to follow the internalization of 
the compound. 
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Figure 65: 1H-NMR (500 MHz, DMSO-d6), UV-Vis (10
-5 DMSO) and Fluorescence (5x10-6 DMSO, 
excitation at 482 nm) spectra of 59 
 
However, as in the previous two cases, also this conjugate is able to maintain a high 
concentration of doxorubicin even in resistant cells, but without the desired cytotoxic effect. 
Thus other enzymatically cleavable or pH sensitive hydrolysable linkers have to be developed to 
achieve this goal. 
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3.2.2 Fullerene-Tacrine 
 
Tacrine and its derivatives are anticholinesterase drugs, employed to 
improve cognition in Alzheimer affected patients. Since C60 is able to act 
as radical scavenger, its cytoprotective effect can be coupled with tacrine 
to obtain a synergistic effect. Thus a tacrine-fullerene derivative 3.61 was 
synthesized according the following scheme (Figure 66). 
Amino-functionalized fullerene 3.52 was converted into the 
correspondent succinate 3.60 by reaction with succinic anhydride. The 
resulting acid was condensed with amino-functionalized 6-chlorotacrine 
using EDC and HOBt and the final conjugate 3.61 was obtained.  
 
 
Figure 66: conjugation of chlorotacrine to fullerene 
 
Despite the presence of the triethylene glycol chain and two amides moiety, the solubility of 
the compound in biocompatible media (as water or water/DMSO) is negligible. Thus a second 
derivative 3.62 was synthesized following the same procedure but replacing the butyl spacer 
with a second triethylene glycol chain: the solubility of 3.62 was sufficient to allow the 
enzymatic inhibition assay. 
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Figure 67: fullerene-chlorotacrine conjugate 3.62 with two TEG chains. 
 
Even if the enzymatic inhibition activity is reduced of three orders of magnitude with respect to 
the parent compound, a residual activity is still present. In fact chlorotacrine has a nanomolar 
IC50, while conjugate 3.62 presents an IC50 = 2.08 ± 0.16 μM.. Thus the compound could still be 
effective, due to a different bioavailabilty and due to the proposed synergistic effect. Other 
biological studies will be performed to describe also these effects. 
 
3.2.3 Fullerene-triazine 
 
As previously mentioned, bi- or poly-functional fullerene derivatives are really attractive, for 
the possibility to attach on the same carrier both a drug and a targeting moiety (such as a 
peptide, folic acid or antibodies), or more than one drug molecule in order to obtain a very high 
local drug concentration.  
However, since isomerically pure bis-adducts are hardly obtainable in large quantity, and only 
after laborious separation, here we developed a simple and efficient method to obtain bi- and 
poly-functional derivatives starting from the readily accessible fullerene monoadduct 3.52. It 
seemed convenient to exploit triazine chemistry to introduce a branching point in the molecule, 
indeed the three chlorine atoms of Cyanuric Chloride (CC, 2,4,6-trichloro-1,3,5-triazine) can be 
substituted by nucleophiles in a thermally controlled way. The first chlorine is substituted at 0°C 
or below, the second one at room temperature, while the third substitution requires 
temperatures higher than 60°C. In this way some notably one-one pot syntheses were 
accomplished.[218] 
 
 
Figure 68: subsequent chlorine displacement on CC. 
 
To our purpose we easily synthesized a set of monochlorotriazines (MCTs) in one-pot reactions 
by using different monoprotected diamines and/or aminoalcohols. By adding at 0°C the first 
amine, only the monosubstitution occurred, then the second amine was added and the 
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reaction was allowed to warm to room temperature, to substitute the second chlorine atom. 
MCT 3.63 was synthesized in a modified procedure (see experimental part), since mono-Fmoc 
protected diamine (B) is unstable, thus the Fmoc protection was performed after the 
introduction of the amine on the triazine. 
 
 
Figure 69: synthesis of MCTs. 
 
The last chlorine was substituted by the amino group present on fullerene 3.52 and the 
fullerene-triazine compound were obtained from moderate to good yield (Figure 70). An 
accurate control of the reaction conditions is very important at this point, since below 70°C the 
reaction proceeds too slowly, while over 90°C an extensive degradation is observed (for model 
reaction with MCT 3.64), probably because the basic environment (amine and DIEA) is scarcely 
tolerated by the fullerene at high temperature. Moreover also the concentration seems to play 
a role, in fact in too diluted the reactions are very slow, while in highly concentrated solution 
some degradation is reported (probably because of the higher base concentration). Thus the 
ideal conditions seem to be a concentration of 3.52 of 5 mg/ml in o-DCB at 80° C.  
The so obtained compounds are very versatile since they contain orthogonally protected 
amines, or protected amines and alcohols. The conjugation with biomolecules can be 
performed introducing thiourea and/or amide bonds from amines or esters from alcohols. 
 
 
75 
 
 
Figure 70: synthesis of fullerene-triazines 
 
Once obtained these new derivatives as potential scaffold for drug delivery we investigated also 
their biological behavior on the derivatives of fullerene-triazine 3.69.  
 
 
Figure 71: synthesis of water-soluble 3.73 and 3.75. 
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To extend the toxicological studies with synthesized also the triazine analoque of 3.52 and 3.56 
(Figure 62) we synthesized also compounds 3.73 and 3.75 (Figure 71).  
Methylation of 3.69 has to be carefully controlled in order to avoid the methylation also of the 
triazine core, thus the reaction was performed at 60°C (the minimum temperature at which the 
reaction proceeds) for 5 hours. Even in this case some traces of dimethylated compound were 
detected by mass spectrometry. Deprotection of Boc group of both 3.69 and 3.74 gave 
respectively 3.73 and 3.75, water-soluble fullerene-triazine derivatives. 
 
The cytotoxic effect of both the compounds was studied by MTT test on MCF-7 cell line (human 
breast cancer) as the parent fullerenes, and the same trend was observed: neutral 
fulleropyrrolidines are well tolerated, while quaternary ammonium derivatives exert a cytotoxic 
effect. Quite surprisingly the fullerene-triazine 3.73 is completely free of toxicity at least up to 
25 μM, while the parent fulleropyrrolidine 3.52 present a 10% of cell viability inhibition. On the 
quaternary ammonium counterparts the situation is the opposite, indeed the presence of the 
triazine in compound 3.75 decreases the toxicity at low concentration (20-30% with respect to 
40% of derivative 3.56) while increases the cell viability inhibition up to 90% at higher 
concentrations. 
In light of these considerations, 
compound 3.75 cannot be used as 
platform for drug delivery, but its 
toxicity could be exploited by making it 
selective for cancerous cells by means 
of conjugation with a targeting agent. 
Neutral fullerene-triazine 3.73, instead, 
seems to be a very promising carrier, 
even better than parent 3.52 thanks to 
the absence of toxicity, the much better 
solubility and the presence of two 
groups (-NH2 and -OH) that can allow 
further conjugations with drugs and/or 
targeting agents. 
To confirm the cellular internalization of 
this compound, a fluorescent derivative 3.76 was synthesized by reacting 3.73 with fluorescein 
isothiocyanate (FITC).  
As in the case of fullerene-doxorubicin conjugate, the UV-Vis spectrum presents the features of 
both fullerene and fluorescein, while in the emission spectrum a partial quenching of the 
fluorescence. 
 
Figure 72: compared toxicity of fullerene 
derivatives 3.52, 3.56, 3.73 and 3.75 on MCF-7 
cells. 
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Figure 73: top - synthesis of fullerene-triazine-fluoresceine 3.76; bottom left - its UV-Vis spectra 
(2x10-5 DMSO/TEA 0.1M); bottom right - Fluorescence spectra (10-6 DMSO/TEA 0.1M, excitation 
at 488 nm). 
 
Also in this case the quenching is due to an intramolecular interaction since the spectrum of the 
physical mixture 1:1 of FITC and 3.73 does not present any quenching. Notably the quenching is 
less dramatic than in the case of 3.52-FITC conjugate previously synthesized in our group.[102] 
This fact is consistent with the increased length of the spacer between fullerene and the 
fluorophore (one TEG chain in derivative 3.52, two TEG chains in derivative 3.76). 
The residue fluorescence is still enough to be detected in cells. Cytofluorimetry revealed an 
efficient internalization in HT-29 cells (human colorectal adenocarcinoma) after 24 hours 
incubation, however, due to the formation of aggregates, it was not possible to assess the 
intracellular localization by fluorescence microscopy. To solve this issue we replaced fluorescein 
with another more soluble fluorophore of xanthenes family: sulforhodamine B. 
Reaction of 3.73 with sulforhodamine B acid chloride afforded derivative 3.77. This compound 
is found to be unstable in solution, even if protected from light and the attempts to observe its 
internalization gave non-reproducible results. 
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Figure 74: synthesis of fullerene-triazine-sulforhodamine B 3.77. 
 
 
G-quadruplexes are structures encountered in guanine-rich DNA regions, especially telomers, in 
which four guanines forms a supramolecular tetramer by Hoogsteen base-pairing, usually 
templated by cationic center. Formation of G-quadruplexes in telomers inhibits the activity of 
telomerase, an enzyme involved in most of the cancers. Thus, the use of molecules such as the 
naphthalene bis-imide A (NBI, Figure 75) that can induce the formation or the stabilization of 
the G-quadruplex alredy present is a new approach to cancer therapy. The combination of a 
fullerene moiety with a G-quadruplex ligand can open new possibilities, for example, not only 
the bioavailability of the ligand will change but we could exploit the photosensitizing property 
of fullerene once the conjugate is bound to DNA. In this way by photoirradiation it could be 
possible to irreversibly damage cancer cells’ DNA. 
A first attempt to link NBI A to fullerene 3.52 gave a completely insoluble product, thus we 
decide to perform the reaction using the new carrier 3.73. The reaction afforded the desired 
thiourea, but due to the presence of the basic tertiary amine the conjugate is unstable, even if 
stored at -18°C in solid state. Thus the product was converted in the stable chlorohydrate salt, 
that presents also a better solubility in water/DMSO (about 10-5 M in H2O/DMSO 99.9:0.1). 
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Figure 75: synthesis of fullerene - G quadruplex ligand 3.78. 
 
Very preliminary biological results have shown that compound 3.78 is a powerful proapoptotic 
agent (with a minimal necrotic effect), even at the lower concentration assayed up to now (4 
μM), while the carrier 3.73 itself has no effect up to the highest concentration (32 μM), thus the 
pharmacological profile seems to be very promising and further studies are under development 
to understand the mechanism of action. 
3.2.3.1 Folic Acid 
 
Since these fullerene-triazine derivatives are bi- or poly-functional we sought the possibility to 
use one of the branches to conjugate a tumor targeting unit in order to achieve selectivity for 
cancer cells. Among all the possible markers we chose Folic Acid (FA), since it is a good 
candidate for many cancer types, it has a very high selectivity for tumor tissues and its 
chemistry does not requires special equipment as it could be for antibodies. However FA has 
two carboxylic groups, so the conjugation usually yields a mixture of γ/α from 70:30, but only γ-
conjugates are properly active in vivo.[219] So we decided to conjugate Pteroic Acid to a 
protected glutamic functionalized fullerene-triazine. Pteroic Acid è very expensive, but it can be 
obtained by hydrolysis of the cheap FA. Since direct acidic hydrolysis of FA leads to the 
formation of a complex mixture of degraded products the procedure involves a multistep 
sequence, with many and laborious purification steps, giving Pteroic Acid in 10% overall 
yield.[220] 
Considering the ease conversion of FA in Pteroyl-hydrazide (Figure 76) we decided to follow this 
route.[221] Then, IBX oxidation of the hydrazide[222] afforded Pteroic Acid that was purified by 
simple precipitation. With this modified procedure we were able to obtain Pteroic Acid in three 
steps with a 57% overall yield. 
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Figure 76: modified degradation of Folic Acid to Pteroic Acid 
 
The obtained derivative was conjugate to fullerene derivatives both with and without the 
glutamic residue, giving respectively the Folic- or the Pteroic-fullerene-triazines. However the 
final constructs were almost insoluble and aggregate in every solvent, so their proper 
characterization was not possible. 
 
3.2.4 Summary 
 
In conclusion in this second part of the thesis we developed a simple and efficient method to 
obtain bi- and poly-functional fulleropyrrolidines by introducing s-triazine as branching unit. 
Moreover, from some preliminary studies of cellular toxicity it emerged that the model 
fullerene-triazine 3.73 is completely non-toxic and is able to enter in the cells. Thus we propose 
this new family of fullerene derivatives as carrier for drug delivery. 
A fullerene – naphthalene bis-imide was synthesized as G-quadruplex ligand and preliminary 
biological assays are very promising, since the compound possesses a strong proapoptotic 
activity even at low concentration. 
Finally some attempts to conjugate FA to fullerene were conducted, but the insolubility of the 
obtained derivatives vanified the efforts. Thus other markers (such as peptides) would be more 
recommendable for the conjugation to fullerene. 
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3.3 Fullerene-Ruthenium complexes 
 
The last part of the thesis was focused on the synthesis of fullerene-bipyridyl ligands and their 
complexation with Ruthenium (II) center. 
Since the discovery of antiproliferative properties of cisplatin (Figure 77) in ‘60s, there was an 
increasing interest in metal-based antitumor drugs, however, only few platinum-based drugs 
are currently employed in therapy after some decades of investigation.  
In recent years, ruthenium complexes gained a central role in this field. Thanks to a better 
solubility and to a lower in vivo toxicity, probably due to a slower hydrolysis kinetic, it seem to 
be the ideal candidate for metal-based chemotherapy. The discovery of Ru(III) complex NAMI-A 
(New Anti-tumor Methastasis Inhibitor)[223-224] and the Ru(II) RAPTA-C (Ruthenium Arene 
PTA)[225] antimethastatic properties opened the way to a new challenge in cancer 
chemotherapy (Figure 77), considering that, in particular, the latter exhibited a low toxicity in 
vitro but good selectivity for tumors in vivo. 
 
 
Figure 77: chemical structure of cisplatin, NAMI-A and RAPTA-C (containing a PTA ligand: 
PhosphaTriazaAdamantane) and general structure of fullerene-Ru-bpy complexes synthesized 
in the present work. 
 
Thus, new RuCl2(PTA)(Fullerne-bpy) were developed in this work. 
We believe that the conjugation of the ruthenium active center to a fullerene carrier can lead 
to interesting results, first of all by changing the pharmacokinetic profile of Ruthenium 
complexes, on the other hand the presence of suitable ligands on the metal will enhance the 
solubility of the whole fullerene-ruthenium complex. Finally these complexes will be able to 
deliver into cells both the antiproliferative properties of ruthenium and the photosensitizing 
activity of fullerene, and this combination could have a synergistic effect for the suppression of 
cancerous cells. 
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3.3.1 Synthesis of fullerene-bpyridyl ligands 
 
We chose bipyridyl ligand (bpy) for the complexation of the ruthenium precursor, since the 
reaction of bpy with ruthenium is well described and gives stable complexes. Different 
fullerene-bpy ligands were synthesized by varying the position of bpy with respect to the 
fullerene and the solubilizing chain. Derivatized bpy are asymmetric and the resulting 
complexes will be formed in diastereomeric ratio, whose NMR interpretation can be very tricky. 
Thus we synthesized also two symmetric diazafluorene- spiro ligands 3.94 and 3.95 (see later 
Figure 82) and an TEG-free asymmetric fullerene-bpy 3.85 to be used as comparison, since also 
the superimposition of 1H-NMR signals TEG signals with PTA ligand signals will complicate NMR 
analysis. 
A bipyridyl aldehyde 3.79 was synthesized according to literature by mild oxidation of 4,4’-
dimethyl-2,2’-bipyridine (Figure 78). Alkylation of 2-(2-aminoethoxy)ethanol with tert-butyl-2-
bromoacetate gave aminoester 3.80, whose amine was orthogonally protected as benzylic 
carbamate 3.81. Methylation of the alcohol with iodomethane in presence on sodium hydride 
as base gave compound 3.82. Selective deprotection of the Cbz group yielded the aminoester 
3.84, while sequential deprotection of both tert-butyl ester and Cbz gave the aminoacid 3.83. 
 
  
Figure 78: synthesis of organic synthons. 
 
1,3-dipolar cycloaddition on fullerene using bpy-aldehyde 3.79 with commercially available 
sarcosine (N-methylglycine) or amino acids 3.50 and 3.83 produces respectively the racemic 
ligands 3.85, 3.86 and 3.87 (Figure 79). Ligand 3.85 does not possess TEG chain and will be used 
as reference for the interpretation of the NMRs. The presence of a Boc-protected amine in 
ligand 3.86 will allow the construction of more complex systems, for example a tumor targeting 
agent could be further attached in this position. 
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Figure 79: synthesis of ligand 3.85, 3.86 and 3.87. 
 
In order to increase the distance from fullerene and ruthenium complex, other two ligands 
were synthesized. 3.88 was obtained directly from amidation of fullerene 3.52 with bipyridine 
monoacid in presence of EDC and HOBt (Figure 80). Moreover this derivative does not present 
any stereogenic center. 
 
Figure 80: synthesis of ligand 88. 
 
In order to increase even more the solubility of the derivative we synthesized also a ligand 
containing oxyethylenic chains by the following multistep procedure (Figure 81). Cycloaddition 
of bpy-aldehyde 3.79 and aminoester 3.84 gave the tert-butyl ester fulleroproline 3.89, the 
ester of which was quantitatively deprotected by acid treatment with TFA. The resulting acid 
3.90 was condensed in the usual way with mono-Boc protected TEG-diamine and the amide 
3.91 was obtained in nearly quantitative yield. By deprotection of the Boc group and coupling 
with bpy monoacid, finally we obtained the desired ligand 3.93. 
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Figure 81: synthesis of ligand 93 
 
Eventually, to overcome the problem related to the chirality of most of the ligands and to the 
general asymmetry of the bipyridyl moieties we synthesized the two diazafluorene spiro ligand. 
Aminoacid 3.50 was used in the 1,3-dipolar cycloaddition with the symmetrical 4,5-diaza-9H-
fluoren-9-one and spiro ligand 3.94 was obtained (Figure 82). Even if the compound is perfectly 
symmetric there is still the TEG chain that will cover PTA signals, thus a N-methyl 
fulleropyrrolydine analogue 3.95 was synthesized by using sarcosine in the 1,3-dipolar 
cycloaddition (Figure 82). 
 
 
Figure 82: synthesis of symmetrical ligands 3.94 and 3.95. 
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3.3.2 Ruthenium complexation 
 
Ligands 3.85- 3.88, 3.94 and 3.95 were reacted with RuCl2(PTA)2(dmso)2 to form the all-cis 
corresponding fullerene-Ru-bpy complexes (Figure 83). The complexations were carried out in 
o-DCB at 80°C under Argon atmosphere during 18-24 hours and the products were obtained 
after chromatographic separation over silica or alumina in moderate yield. 
 
 
Figure 83: complexation of with fullerene-bpy ligands. 
 
From complexation with ligand 3.88 it was not possible to isolate the desired product, since 
every attempt of purification resulted in the decomposition of the mixture. Traces of the 
expected product can be detected only in the crude mixture by mass spectrometry. These 
observation are consistent with the fact that this ligand is the only one presenting an amide 
group on the bipyridyl system, thus the complexation with the structurally related ligand 3.93 
was not performed yet. 
In the ligands, one pyridine is linked to the fulleropyrrolidine (Py-Full), while the other has only 
a methyl substituent (Py-Me), so we expect a diasteromeric mixture for the ruthenium 
complex, indeed Py-Full can be trans to PTA or to Cl, and reversely Py-Me can be trans to Cl or 
to PTA. 
As expected, the complexes from asymmetric fullerene-bpy ligands (3.96, 3.97 and 3.98) were 
obtained as 50:50 diasteromeric mixtures as can be calculated from 1H-NMR integrations. 
Since in complexes 3.97, 3.97 and 3.99 the oxyethylenic hydrogen signals overlap PTA signals in 
the region between 3.5 and 4.5 ppm, in the following part we present only the NMR spectra of 
the model complexes 3.96 and 3.100 bearing only a methyl group on pyrrolidine’s nitrogen. In 
this way the PTA ligands protons can be clearly appreciated without any interference from the 
solubilizing chain. 
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Figure 84: 1H-NMR (top) and aromatic region COSY (bottom) spectra of complex 96 (500 MHz, 
CDCl3) 
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In 1H-NMR spectrum it is possible to observe an almost equimolar mixture of diastereoisomers, 
the splitting of the signals is particularly evident for the bpy-methyl group A and for the N-
methyl B (Figure 84). The situation in the aromatic region is much more complex, since in the 
diastereomeric mixture are present four isolate pyridine rings, thus were arbitrarily labeled as 
1, 2, 3 and 4. Since the mixture is approximately equimolar, it was not possible to 
unambiguously correlate system 1 to 2 and 3 to 4 by peak integral comparison. From COSY 
spectrum it was possible to visualize the four systems (1: 8.63, 7.86 ppm; 2: 9.69, 7.90, 7.39 
ppm; 3: 9.69, 8.07, 7.42 ppm; 4: 8.55, 7.48 ppm), only two signals (8.58 and 8.22 ppm) cannot 
be certainly assigned to ring 1 or 4 since they appear as isolate protons, and no correlations 
with other nuclei are observed in the COSY spectrum. Similarly, the related complexes 3.97 and 
3.98 were obtained as a 50:50 diastereomeric mixtures. 
 
A simpler situation is constituted by the diazafluorene-derived ligand. Indeed, the chirality of 
the ruthenium center is still present, but there are no other asymmetry centers. However the 
bpy ligands 3.94 and 3.95 possess only one plane of symmetry, while the bipyridine itself 
possesses two orthogonal planes (Figure 85): one sectioning the 2,2’ bond while the other is 
constituted by the bipyridine plane itself, so the two faces are identical. 
 
 
Figure 85: symmetry planes of bpy and ligand 95. 
 
In these ligands, the presence of the fulleropyrrolidine breaks this symmetry and the two faces 
become different: one will be cis to the pyrrolidine (trans to the fullerene) and the other will be 
trans to the pyrrolidine (cis to the fullerene). Thus the complexation with a ruthenium 
derivative bearing two different axial groups (a PTA and a Cl) can give a diastereomeric mixture. 
 
As expected in the 1H-NMR spectrum there are two sets of signals, with a 77:23 ratio, 
corresponding to the two possible all-cis ruthenium configuration, but the splitting can be 
observed only for the axial PTA signals (H’/h’, I/i and I’/i’) and for the N-methyl group (J/j).  
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Figure 86: 1H-NMR (top), COSY (bottom left), HSQC (bottom right) (500 MHz, CDCl3), spectra of 
complex 3.100. 
 
Indeed the only difference between the two isomers is the axial PTA that can stay above the 
plane of the bipyridine (isomer 1, magenta labeled) or below (isomer 2, green labeled) and so it 
will be influenced or not by the fullerene current. Integrating the data from 1H-NMR, COSY and 
HSQC it was possible to unambiguously assign each signal to the corresponding nucleus. 
Remembering the chirality of this molecule (only one enantiomer shown for each possibility) 
we can note that the asymmetry of ruthenium center is reflected in the whole molecule. Not 
only the two pyridine rings give two set of signals (one is trans respect to PTA, the other is trans 
89 
 
to the chlorine), but also the two PTA are non-equivalent. Notably the asymmetry is observed 
even in the far pyrrolidinic protons G/G’ that, instead of being a 2H singlet as in 3.95 before the 
coordination, resembles two collapsed doublets, even though the system is more complex since 
it represents the sum of both isomers 1 and 2. 
However with these techniques it was still not possible to determine unambiguously which is 
the majoritarian isomer. We postulated that the 
methyl group on the pyrrolidinic nitrogen in isomer 1 is 
close enough to axial PTA, while in isomer 2 no, thus a 
NOE has to be present between the methyl (J) and the 
PTA protons (I/I’). NOESY experiment showed the cross 
peak corresponding to the NOE between these nuclei 
(Figure 87) for the J-I/I’ instead that for j-i/i’, thus it is 
possible to conclude that in the majoritarian isomer 
(77%) the axial PTA is cis with respect to the 
pyrrolidine (trans respect to the fullerene), namely 
isomer 1. 
 
 
Figure 87: NOESY spectrum of diasteromeric mixture 100 (500 MHz, CDCl3), NOE cross peaks 
between PTA protons and between aromatic protons are not indicated. 
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3.3.3 Summary 
In conclusion in the last part of the thesis we synthesized a set of seven different fullerene-
bipyridyl ligands, and five ruthenium complexes were obtained. Biological studies will be 
conducted to assay the antiproliferative activity of these complexes both in the dark and upon 
irradiation. Thanks to NOESY technique we were able to unambiguously define the three-
dimensional disposition of the ligands around ruthenium center in the two diasteroisomer of 
complex 3.100. 
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Chapter 4: Conclusions 
In the first part of the work we explored different strategies to modify the ratio between 
isomeric bis-adducts. Tether-directed remote functionalization methodology was successfully 
applied to 1,3-dipolar cycloadditon of azomethine ylides. We have synthesized several 
molecules, and we analyzed how different geometries can influence the bis-addition pattern. 
We were able to isolate and characterize some interesting and unusual macrocyclic tethered 
fullerene bis-adducts. We concluded that tethering at the pyrrolidine carbon can give an almost 
perfect selectivity for some bis-addition patterns, however the introduction of two 
stereocenters complicates the situation.  
For the selective synthesis of cis bis-adducts, the best choice is a very short and completely 
flexible tether. In the case of trans isomer, instead, the structural requirements for a good 
selectivity are much more strict, indeed bigger and suitably shaped templates are required, and 
flexibility as low as possible has to be preferred. 
We also analyzed by HPLC the bis-addition ratio on a fullerene-based rotaxane, by exploiting an 
intra-rotaxane solvophobic effect. In polar solvents we observed an increase of the ratio in 
favor of trans type isomers, while in less polar medium we did not observe any difference from 
the blank experiments. 
 
A fullerene-doxorubicin and two fullerene-tacrine conjugates were synthesized, but their 
biological behavior does not seem to be promising. 
We synthesized also a series of monochlorotriazines and we found how to react them with a 
fullerene-amine derivative in a simple and efficient way. The so obtained fullerene-triazine 
derivatives are highly soluble and the presence on their periphery of orthogonally protected 
amines, or protected amines and alcohols makes these molecules very attractive and versatile. 
One of these derivatives was tested on cell cultures and surprisingly we noticed that it was 
completely non-toxic at least up to 25 µM concentration. This, its water-solubility and its 
capability to cross cellular membranes makes it a promising candidate for drug delivery.  
A G-quadruplex ligand conjugate of this fullerene-triazine was synthesized and preliminary 
cellular studies revealed that the conjugate is very active in inducing apoptosis, thus further 
tests in this direction are currently ongoing. 
 
In the last part of the thesis we synthesized a set of fullerene-bipyridine ligands and five 
corresponding ruthenium-fullerene-bpy complexes were isolated as diastereomeric mixtures. 
Moreover in the model compound we were able to unambiguously determine which was the 
majoritarian isomer by means of NOESY-NMR technique. 
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Chapter 5: Experimental Part 
 
5.1 Materials and Methods 
 
Reagents and solvents 
All reagents have been purchased from Sigma-Aldrich, Fluka, Acros and TCI. Solvents were used 
as received without further purification, unless specified. Deuterated solvents were purchased 
from Cambridge Isotope Laboratories. Fullerene C60 has been acquired from Bucky-USA. 
 
 
NMR experiment 
Nuclear magnetic resonance (NMR) 500 MHz 1H-NMR and 125 MHz 13C-NMR spectra were 
obtained on a Varian Gemini 500 spectrometer. 270 MHz 1H-NMR and 67.5 MHz 13C- NMR 
spectra were obtained on a Jeol JNM-EX270. 200 MHz 1H-NMR and 50 MHz 13C-NM were 
obtained on a Varian Gemini-200 
Chemical shifts are reported in ppm using the solvent residual signal or tetramethyl silane as an 
internal reference. Coupling constants are given in Hz. The resonance multiplicity is described 
as s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), m (multiplet), br 
(broad signal). 
 
 
Mass spectroscopy 
Electrospray (ES-MS) experiments were recorded on a Perkin-Elmer API1 at 5600 eV. 
 
 
HPLC analyses 
HPLC analyses were conduncted on Waters PDA996 and on a Waters PDA2998 equipements. 
Solvents and samples were previously filered on 0.45 μm MILLEX filters 
 
UV Measurements 
UV-Vis measurements were recorded on a Varian 5000 UV-Vis-NIR spectrometer. 
 
 
IR Spectroscopy 
FT-IR and ATR spectra have been recordered on a FT-IR Varian 670 
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Thin Layer chromatography (TLC) 
Reactions have been followed by silica gel thin layer chromatography 60 F254 purchased 
fromMerck. Non-colored compounds were detected by UV lamp or by oxidation with a solution 
of KMnO4. 
 
 
Chromatographic separation 
Chromatographic separations have been performed with silica gel 40-63 μm from Merck, unless 
differently specified. 
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5.2 Synthetic procedures 
 
SYNTHESIS OF 3.2 
 
86.50 mg of C60 (0.120 mmol) and 901.02 mg of paraformaldehyde (30.034 mmol) were 
dissolved in 45 ml of o-DCB and 69.16 mg of bis-aminoacid 3.1 (0.120 mmol) were added in 15 
ml of DMF. The mixture was heated under MW irradiation in open vessel at 150°C for 15 min. 
The reaction was repeated 7 times (tot: 605.50 mg C60, 0.841 mmol). 
The solvent was evaporated, the residue dissolved in Tol and separated by flash 
chromatography (Tol up to Tol / EtOAc 90:10). Two main fractions were obtained and each of 
them was was further purified. Unreacted C60 was precipitated from CS2/MeOH, the products 
were precipitated from CHCl3/MeOH. 
 
C60: 
361 mg, 60% 
 
Equatorial: 
24 mg, 0.024 mmol, 2.8% (7.1% on reacted C60) 
 
 
 
C74H24N2O4 (MW 1004.99) 
1H-NMR (500 MHz, CDCl3, 25°C): = 4.47 (t, J = 5.5 Hz, 2H), 4.44 (t, J = 6.0 Hz, 2H), 4.27 (d, J = 
9.8 Hz, 2H), 4.16 (s, 2H), 4.10 (s, 2H), 3.86 (d, J = 9.8 Hz, 2H), 3.17 (t, J = 6.0 Hz, 2H), 3.12 (s, J = 
6.4 Hz, 2H), 2.61 (m, 2H), 2.35 (m, 2H), 2.14 (m, 2H), 2.06 (m, 2H). 
The low solubility of product did not allow to record 13C-NMR spectrum. 
IR (ATR): 2950, 2780, 1731, 1456, 1342, 1276, 1182, 1159, 765, 748. 
ES-MS (THF / MeOH) m/z = 1005.1 (MH+). 
 
 
SYNTHESIS OF 3.3 
 
86.50 mg of C60 (0.120 mmol) and 901.02 mg of paraformaldehyde (30.034 mmol) were 
dissolved in 45 ml of o-DCB and 75.00 mg of bis-aminoacid 3.4 (0.120 mmol) were added in 15 
ml of DMF. The mixture was heated under MW irradiation in open vessel at 150°C for 15 min. 
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The reaction was repeated 4 times (tot: 346 mg C60, 0.481 mmol). 
The solvent was evaporated, the residue was dissolved in Tol and separated by flash 
chromatography (Tol to Tol / EtOAc 90:10). Two main fractions were obtained and each of 
them was further purified. 
Unreacted C60 was precipitated from CS2/MeOH, the products were precipitated from 
CHCl3/MeOH. 
 
C60: 
187 mg, 54% 
 
3.4a. Trans-4: 
30 mg, 0.028 mmol, 5.9% (12.9% on reacted C60) 
 
 
 
C78H24N2O4 (MW 1053.04) 
1H-NMR (500 MHz, CDCl3 /CS2, 25°C): = 7.98 (s, 4H), 4.83 (t, J = 8.1 Hz, 2H), 4.68 (d, J = 9.3 Hz, 
2H), 4.62 – 4.56 (m, 2H), 4.54 (d, J = 9.3 Hz, 2H), 3.82 (d, J = 9.6 Hz, 2H), 3.58 (d, J = 9.4 Hz, 2H), 
3.34 (t, J = 9.6 Hz, 2H), 3.17 (m, 2H), 2.29 (m, 2H), 2.20 (m, 2H). 
The low solubility of product did not allow to record 13C-NMR spectrum. 
IR (ATR): 2947, 2904, 2776, 1713, 1454, 1405, 1343, 1260, 1113, 1099, 756, 722. 
ES-MS (THF / MeOH) m/z = 1053.1 (MH+). 
 
3.4b Equatorial: 
14 mg, 0.013 mmol, 2.8% (6.0% on reacted C60) 
 
 
 
C78H24N2O4 (MW 1053.04) 
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1H-NMR (500 MHz, CDCl3, 25°C): = 8.00 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 8.5 Hz, 2H), 4.72 (t, J = 
6.0 Hz, 2H), 4.60 (m, 2H), 4.52 (d, J = 10.1 Hz, 2H), 4.00 (s, 2H), 3.66 (d, J = 10.0 Hz, 2H), 3.56 (s, 
2H), 3.15 (t, J = 6.2 Hz, 2H), 3.08 (m, 2H), 2.30 (m, 2H), 2.23 (m, 2H). 
The low solubility of product did not allow to record 13C-NMR spectrum. 
IR (ATR): 2948, 2783, 1720, 1459, 1341, 1268, 1119, 1101, 728. 
ES-MS (THF / MeOH) m/z = 1053.1 (MH+). 
 
 
SYNTHESIS OF 3.5 
 
 
 
To a solution of 588 μl of bromoacetyl bromide (1.36 g, 6.8 mmol) in 10 ml of dry THF under 
Argon, was added dropwise at 0°C a solution of 179 μl of ethylene glycol (200 mg, 3.2 mmol) 
and 547 μl of dry Pyridine (535 mg, 6.8 mmol) in 5 ml of dry THF. After 2 hours, the precipitate 
was filtered over celite and the solution was evaporated, the residue was dissolved in DCM and 
washed with water with HCl (pH = 3-4). 
Were obtained 780 mg (2.57 mmol) of a yellow oil in 80% that was used without any further 
purification. 
 
C6H8Br2O4 (MW 303.93) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.42 (s, 4H), 3.87 (s, 4H). 
ES-MS (MeOH) m/z = 325.5 (M+Na+). 
Characterization are in accordance with literature.[226] 
 
 
SYNTHESIS OF 3.6 
 
To a solution of 588 μl of bromoacetyl bromide (1.36 g, 6.8 mmol) in 10 ml of dry THF under 
Argon, was added dropwise at 0°C a solution of 233 μl of 1,3-propanediol (245 mg, 3.2 mmol) 
and 547 μl of dry Pyridine (535 mg, 6.8 mmol) in 5 ml of dry THF. After 2 hours, the precipitate 
was filtered over celite and the solution was evaporated, the residue was dissolved in DCM and 
washed with water with HCl (pH = 3-4). 
Were obtained 708 mg (2.23 mmol) of a yellow oil in 69% that was used without any further 
purification. 
 
C7H10Br2O4 (MW 317.96) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.29 (t, J = 6.2 Hz, 4H), 3.85 (s, 4H), 2.08 (q, J = 6.2 Hz, 2H). 
98 
 
ES-MS (MeOH) m/z = 338.8 (50%), 340.8 (100%), 342.8 (50%) (M+Na+). 
Characterizations are in accordance with literature.[227] 
 
 
SYNTHESIS OF 3.7 
 
  
To a solution of 2.58 ml of butylamine (1.90 g, 26.0 mmol) in 10 ml of DCM was added dropwise 
a solution of 780 mg of 3.5 (2.6 mmol) in 20 ml of DCM. When all the starting material was 
reacted 5.68 g of Boc2O (26.0 mmol) and 2.60 g of KHCO3 (26.0 mmol) in 5 ml of water were 
added. The mixture was extracted with water / EtOAc and separated by flash chromatography 
in gradient up to petroleum ether / EtOAc 80:20 to obtain 318 mg (0.65 mmol) of a colorless oil, 
in 25% yield. 
 
C24H44N2O8 (MW 488.61) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.33 (s, 1H), 3.95 and 3.87 (s, 4H), 3.26 (m, 4H), 1.46 and 
1.41 (s, 18H), 1.27 (m, 8H), 0.92 (t, J = 7.1 Hz, 6H). 
ES-MS (MeOH) m/z = 511.2 (M+Na+), 527.2 (M+K+). 
 
 
SYNTHSIS OF 3.8 
 
  
To a solution of 1.33 ml of butylamine (977 mg, 13.4 mmol) in 5 ml of DCM was added dropwise 
a solution of 708 mg of 3.6 (2.2 mmol) in 20 ml of DCM. When all the staring material was 
reacted 2.92 g of Boc2O (13.4 mmol) and 1.34 g of KHCO3 (13.4 mmol) in 5 ml of water were 
added. The mixture was extracted with water / EtOAc and separated by flash chromatography 
in gradient up to petroleum ether / EtOAc 80:20 to obtain 663 mg (1.31 mmol) of a colorless oil 
in 60% yield 
 
C25H46N2O8 (MW 502.64) 
1H-NMR (500 MHz, CDCl3, 25°C): = 4.20 (t, J = 5.8 Hz, 1H), 3.93 and 3.85 (s, 4H), 3.26 (m, 1H), 
1.97 (m, 4H), 1.49 (m, 4H), 1.46 and1.42 (s, 18H), 1.30 (m, 4H), 0.92 (t, J = 7.3 Hz, 6H). 
13C-NMR (126 MHz, CDCl3, 25°C): = 170.30, 170.21, 156.00, 80.17, 61.56, 61.45, 49.36, 48.81, 
48.29, 48.23, 30.69, 30.41, 28.50, 28.43, 28.17, 20.15, 19.99, 13.97. 
ES-MS (MeOH) m/z = 525.2 (M+Na+), 541.2 (M+K+). 
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SYNTHESIS OF 3.9 
 
  
318 mg of compound 3.7 were dissolved in 3 ml DCM and 3 ml TFA, the mixture was stirred at 
room temperature for 2 hours, then the solvents were evaporated and the product was 
triturated with Et2O. 
284 mg (0.55 mmol) of a white powder were obtained in 85% yield. 
 
C18H30F6N2O8 (MW 516.43) 
1H-NMR (200 MHz, CDCl3, 25°C): = 10.28 (br s, 4H, 2xNH2
+), 4.38 (s, 4H), 3.75 (s, 4H), 3.00 (br 
m, 4H), 1.80 (m, 4H), 1.40 (m, 4H), 0.96 (t, J = 7.3 Hz, 6H). 
13C-NMR (68 MHz, CDCl3, 25°C): = 163.74, 63.01, 48.29, 30.98, 27.62, 19.85, 13.45. 
IR (ATR): 2967, 2874, 2787, 1756, 1680, 1426, 1201, 1108, 720. 
ES-MS (MeOH) m/z = 289.0 (MH+), 311.0 (M+Na+). 
 
 
CYCLOADDITION WITH 3.9 
 
 
 
300 mg of fullerene (0.417 mmol), and 125 mg of paraformaldehyde (4.167 mmol) were 
dissolved in 600 ml of Tol, 215 mg of 3.9 were added in 2-3 ml of DCM and the mixture was 
heated at reflux for 30 min. The mixture was separated by chromatography with Tol / EtOAc 
95:5. The product was precipitated from DCM/MeOH, and 81 mg (0.068 mmol) of a brown 
powder were obtained in 19% yield as an inseparable mixture of diasteroisomers. 
 
C76H28N2O4 (MW 1033.05) 
1H-NMR and 13C-NMR presents a lot overlapped signals for the diasteromeric mixture, 
attribution and integration cannot be done properly. 
IR (ATR): 2951, 2928, 2856, 1735, 1458, 1217, 1156, 760. 
ES-MS (THF / MeOH) m/z = 1033.1 (MH+). 
HPLC (Phenomenex LUNA 250x10 mm, 5 μm silica, 1ml/min, Tol/AcOEt 98:2, 60 min) 31.8 min 
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SYNTHESIS OF 3.10 
 
  
663 mg of compound 3.8 were dissolved in 3 ml DCM and 3 ml TFA, the mixture was stirred at 
room temperature for 2 hours, then the solvents were evaporated and the product was 
triturated with Et2O. 
645 mg (1.12 mmol) of a white powder were obtained in 92% yield. 
 
C19H32F6N2O8 (MW 530.46) 
1H-NMR (200 MHz, CDCl3, 25°C): = 9.78 (br s, 4H, 2xNH2
+), 4.27 (t, J = 5.1 Hz, 4H), 3.87 (s, 4H), 
3.03 (m, 4H), 2.03 (br m, 2H), 1.72 (m, 1H), 1.40 (m, 1H), 0.94 (t, J = 7.2 Hz, 2H). 
13C-NMR (68 MHz, CDCl3, 25°C): = 166.46, 62.11, 47.96, 47.42, 27.69, 27.05, 19.74, 13.41. 
IR (ATR): 2966, 2877, 1753, 1679, 1404, 1201, 1178, 1126, 835, 796, 721. 
ES-MS (MeOH) m/z = 303.0 (MH+), 325.0 (M+Na+). 
 
 
CYCLOADDITION WITH 3.10 
 
10.00 mg of fullerene (0.0139 mmol), and 4.17 mg of paraformaldehyde (0.139 mmol) were 
dissolved in 20 ml of Tol, 7.37 mg of 3.10 were added in 1 ml of DCM and the mixture was 
heated at reflux for 20 min. HPLC (Phenomenex LUNA, 5 μm silica, 250x10 mm) 
TIME (min) FLOW (ml/min) % Toluene % i-PrOH 
0 0.00 95 5 
1 1.00 95 5 
45 1.00 90 10 
50 1.00 95 5 
55 1.00 95 5 
69 1.00 95 5 
70 0.00 95 5 
 
 
SYNTHESIS OF 3.11 
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To a solution of 614 μl of bromoacetyl bromide (1.427 g, 7.1 mmol) in 10 ml of dry THF under 
Argon, was added dropwise at 0°C a solution of 465 mg of 1,3-phenylenedimethanol (3.4 mmol) 
and 572 μl of dry Pyridine (559 mg, 7.1 mmol) in 5 ml of dry THF. After 2h30’ the precipitate 
was filtered over celite and the solution was evaporated, the residue was dissolved in DCM and 
washed with water with HCl (pH = 3-4). 
917 mg (2.4 mmol) of a pale yellow oil were obtained in 71%yield. 
 
C12H12Br2O4 (MW 380.03) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.37 (br m, 4H), 5.21 (s, 4H), 3.88 (s, 4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 167.07, 135.67, 129.17, 128.59, 128.20, 67.67, 25.88. 
ES-MS (MeOH) m/z = 401.3 (50%), 403.2 (100%), 405.2 (50%) (M+Na+). 
 
 
SYNTHESIS OF 3.12 
 
 
To a solution of 2.812 of ethylenediammine mono-Cbz (14.5 mmol) in 5 ml of DCM was added 
dropwise a solution of 917 mg of 3.11 (2.4 mmol) in 20 ml of DCM. When all the starting 
material was reacted 3.160 g of Boc2O (14.5 mmol) and 1.450 g of KHCO3 (14.5 mmol) in 5 ml of 
water were added. The reaction was extracted with water / EtOAc and separated by flash 
chromatography in gradient up to DCM / EtOAc 80:20 to obtain 451 mg (0.56 mmol) of a white 
foam in 23% yield. 
 
C42H54N4O12 (MW 806.90) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.33 (br m, 14H), 5.55 (br s, 2H, NH), 5.14 (s, 4H), 5.09 (s, 
4H), 3.96 and 3.90 (s, 4H), 3.41 (br m, 4H), 3.32 (br m, 4H), 1.43 and 1.33 (s, 18H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 170.69, 170.41, 156.67, 155.63, 136.66, 135.92, 129.10, 
128.57, 28.18, 128.07, 81.00, 80.90, 66.80, 50.62, 49.99, 49.10, 39.98, 28.43, 28.30. 
ES-MS (MeOH) m/z = 829.6 (M+Na+), 845.5 (M+K+). 
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SYNTHESIS OF 3.13 
 
 
 
451 mg of compound 3.12 were dissolved in 3 ml DCM and 3 ml TFA, the mixture was stirred at 
room temperature for 2 hours, then the solvents were evaporated and the 463 mg of product 
were obtained as a sticky solid in quantitative yield. 
 
C36H40F6N4O12 (MW 834.71) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.30 (br m, 14H), 6.63 – 6.29 (br s, 2H, NH), 5.12 (s, 4H), 
5.03 (s, 4H), 3.86 (s, 4H), 3.46 (br m, 4H), 3.20 (br m, 4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 165.94, 157.08, 136.27, 135.07, 129.05, 128.58, 128.17, 
67.90, 67.27, 48.25, 47.90, 37.70. 
ES-MS (MeOH) m/z = 607.5 (MH+), 473.5 (M-Cbz+H+). 
 
 
CYCLOADDITION WITH 3.13 
 
5.00 mg of fullerene (0.00694 mmol), and 2.10 mg of paraformaldehyde (0.0694 mmol) were 
dissolved in 10 ml of Tol, 5.56 mg of 3.13 were added in 0.5 ml of DCM and the mixture was 
heated at reflux and followed by TLC for 21 hours. No reaction took place, and the degradation 
of the starting materials occurred. 
 
 
SYNTHESIS OF 3.14 
 
 
A: To a solution of 1.50 g of β-alanine tert-butyl ester (8.25 mml) and 2.30 ml of TEA (1.67 g, 
16.5 mmol) in 75 ml of dioxane, was added dropwise a solution of benzyl-2-bromoacetate in 50 
ml of dioxane. The solution was stirread at room temperature overnight. The solvent was 
evaporated and the residue was redissolved in water and extracted with EtOAc, organic phase 
was evaporated. The mixture containing mono and bis-alkylated product was dissolved in 10 ml 
of DCM and 1.15 ml of TEA were added (0.836 g, 8.25 mmol), the solution was cooled at 0°C 
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and 1.18 ml of benzyl chloroformate (1.41 g, 8.25 mmol) were added. The reaction was stirred 
overnight at room temperature, was diluted with 100 ml of DCM and washed with 50 ml of 
water and 50 ml of BRINE. Product was chromatographed in gradient up petroleum ether / 
EtOAC 80:20. 
1.688 g of an impure colorless oil were obtained in 48% yield and was directly deprotected. 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.30 (m, 10H), 5.18 and 5.16 (s, 2H), 5.09 and 5.07 (s, 2H), 
4.16 and 4.11 (s, 2H), 3.59 (m, 2H), 2.55 (m, 2H), 1.42 (s, 9H). 
 
B: The compound was dissolved 5 ml of DCM and 5 ml of TFA and was stirred at room 
temperature for 1 hour, solvents were evaporated and the residue was redissolved in saturated 
NaHCO3, washed with Et2O. acqueous solution was acidificated with 2N HCl and the product 
was extracted with EtOAc. 
733 mg (2.08 mmol) of a colorless oil were obtained in 53% yield. 
 
C20H21NO6 (MW 371.88) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.30 (m, 10H), 5.30 and 5.16 (s, 2H), 5.07 and 5.07 (s, 2H), 
4.16 and 4.11 (s, 2H), 3.62 (br t, 2H), 2.74 and 2.66 (t, J = 6.4 Hz, 2H). 
13C-NMR (50 MHz, CDCl3, 25°C): =176.61, 176.25, 169.94, 156.32, 155.91, 136.26, 135.39, 
128.71, 128.56, 128.40, 128.28, 128.17, 128.02, 127.92, 126.05, 67.99, 67.75, 67.26, 67.14, 
50.90, 45.49, 44.59, 33.88, 33.32. 
IR (NaCl) = 3441, 3064, 3033, 2955, 1739, 1708, 1477, 1456, 1426, 1406, 1188, 1125, 978, 738, 
697. 
ES-MS (MeOH) m/z = 394.0 (M+Na+), 369.8 (M-1-). 
 
 
SYNTHESIS OF 3.15 
 
 
 
A: 3-amino-propan-1-ol (2.95 g, 39.3 mmol) was dissolved in DCM (150 ml). A solution of 
benzyl-2-bromoacetate (3.00 g, 2.07 ml, 13.1 mmol) in DCM (100 ml) was added dropwise at 
0°C over a period of 4 hours. The solution was stirred overnight at r.t. The solvent was 
concentrated to 50 ml ca. and washed with water, the DCM was removed under reduced 
pressure and the residue was redissolved in water (50 ml) and MeOH (< 5 ml) and extracted 
with petroleum ether until all the bis-alkylated product was removed from the aqueous phase. 
Finally the product was exctracted with AcOEt. The organic solution was dried over anhydrous 
Na2SO4 and the solvent was removed under reduced pressure giving pure product as a colorless 
oil in a 44% yield (1.30 g, 5.8 mmol) 
C12H17NO3 (MW 223.27) 
104 
 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.36 (s 5H), 5.17 (s 2H), 3.80 (t J = 5.5 Hz), 3.47 (s 2H), 2.87 
(t J = 5.8 2H), 1.71 (m 2H) 
Characterization are in agreement with literature.[228] 
 
B: Compound 3.15A (1.30 g, 5.8 mmol) was dissolved in DCM (10 ml) and triethylamine (0. 59 g, 
0.81 ml, 5.8 mmol) was added. Benzyl chloroformate (0.99 g, 0.83 ml, 5.8 mmol) was added 
slowly. The mixture was stirred at r.t overnight and washed once with water (10 ml) with some 
drops of HCl (pH = 2-3) and once with brine (10 ml), the solvent was removed under reduced 
pressure and the product was purified by flash chromatography on silica gel with petroleum 
ether / AcOEt 7:3 giving the desired product in a 74% yield (1.53 g, 4.3 mmol) 
C20H23NO5 (MW 357.40) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.31 (m 10H), 5.17 (s 2H), 5.10 (s 2H), 4.08-3.99 (s 2H), 3.62 
(m 2H), 3.52 (m 2H), 1.69 (m 2H). 
IR (NaCl) = 3453, 3064, 3033, 2947, 2884, 1749, 1700, 1474, 1454, 1240, 1173, 1130, 739, 697. 
Characterizations are in agreement with literature. 
 
 
SYNTHESIS OF 3.16 
 
 
350 mg of 3.14 (0.94 mmol) were dissolved in 3 ml of dry DCM under Argon, 271 mg of 
EDC•HCl (1.41 mmol) were added, after 15 minutes was added a solution of 505 mg of 3.15 
(1.41 mmol) and 115 mg of DMAP (0.94 mmol) in 2 ml of dry DCM. The reaction was stirred at 
room temperature overnight, then was diluted with DCM and washed with BRINE, dried over 
anhydrous Na2SO4 and the product was purified by flash chromatography in gradient up to 
petroleum ether / EtOAc 70:30. 399 mg (0.56 mmol, 60% yield) of a colorless sticky oil were 
obtained. 
 
C40H42N2O10 (MW 710.77) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.32 (m, 20H), 5.18 and 5.17 and 5.15 and 5.14 (s, 4H), 5.09 
and 5.08 and 5.07 and 5.06 (s, 4H), 4.21 and 3.92 (m, 6H), 3.59 (m, 2H), 3.41 (m, 2H), 2.70 and 
2.45 (m, 2H), 1.85 (m, 2H). 
13C-NMR (126 MHz, CDCl3, 25°C): = 172.35, 172.28, 172.02, 171.91, 169.98, 169.94, 169.91, 
169.88, 169.67, 156.56, 156.53, 156.39, 156.35, 155.94, 155.86, 155.84, 136.45, 136.44, 136.41, 
136.38, 135.55, 135.54, 135.48, 135.42, 135.39, 128.75, 128.72, 128.69, 128.58, 128.52, 128.45, 
128.32, 128.25, 128.16, 128.14, 128.01, 127.93, 127.90, 67.82, 67.58, 67.16, 67.08, 67.06, 
66.97, 62.28, 62.25, 62.20, 62.09, 50.71, 49.72, 49.66, 49.59, 46.40, 46.30, 45.64, 45.61, 45.54, 
45.50, 44.66, 44.59, 34.14, 34.01, 33.59, 33.47, 27.76, 27.73, 27.36, 27.34. 
ES-MS (MeOH) m/z = 733.5 (M+Na+), 749.4 (M+K+). 
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SYNTHESIS OF 3.17 
 
 
384 mg of 3.16 (0.54 mmol) were dissolved in 25 ml of MeOH, the solution was degassed by 
bubbling Argon, catalytic Pd/C was added and the Argon atmosphere was replaced with H2 by 
means of 3 vacuum / H2 cycles. The reaction was stirred overnight at room temperature, 
filtered over celite. The solvent was concentrated and the product was precipitated with Et2O, a 
sticky precipitate was obtained and was washed with 4-5 ml of cold MeOH (-18°C). 107 mg 
(0.15 mmol) of a white powder were obtained in 70% yield. 
 
C40H42N2O10 (MW 710.77) 
1H-NMR (200 MHz, D2O, 25°C): = 4.28 (br m, 2H), 3.65 (s, 2H), 3.63 (s, 2H) 3.37 (t, J = 5.0 Hz, 
1H), 3.20 (t, J = 7.0 Hz, 2H), 2.92 (d, J = 6.2 Hz, 2H), 2.12 (m, 2H). 
13C-NMR (126 MHz, D2O, 25°C): = 172.74, 171.79, 171.63, 63.80, 50.16, 50.08, 45.67, 43.57, 
31.01, 25.46. 
IR (ATR): 3442, 3064, 2878, 1734, 1594, 1391, 1330, 1183, 565. 
ES-MS (MeOH) m/z = 263.6 (MH+), 285.6 (M+Na+). 
 
 
SYNTHESIS OF 3.18 
 
100 mg of fullerene (0.139 mmol), and 42 mg of paraformaldehyde (1.389 mmol) were 
dissolved in 200 ml of o-DCB, the mixture was heated at 130°C and 36 mg of bis-aminoacid 3.17 
were added in solution of MeOH (~ 1 ml). The reaction was stirred at 130°C for 1 hour. Solvent 
was evaporated and the mixture was separated by flash chromatography in gradient up to Tol / 
EtOAc 90:10. The products were precipitated from DCM or CS2/MeOH, washed with EtOAc and 
Hexane. 
HPLC (Phenomenex LUNA, 5 μm silica,  250x10 mm) 
TIME (min) FLOW (ml/min) % Toluene % EtOAc 
0 0.00 100 0 
1 1.00 100 0 
20 1.00 100 0 
60 1.00 90 10 
85 1.00 90 10 
90 1.00 100 0 
99 1.00 100 0 
100 0.00 100 0 
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Unreacted C60: 
53 mg, 53%. 
 
Monoadduct (traces): 
3.1 mg, 3.65 µmol, yield 2.4% (5.2% on reacted C60) 
 
 
 
C66H11NO2 (MW 849.80) 
1H-NMR (200 MHz, CDCl3 / CS2, 25°C): = 4.46 (s, 4H), 3.82 (s, 3H), 3.47 (t, J = 7.2 Hz, 2H), 2.97 
(t, J = 7.2 Hz, 2H). 
ES-MS (THF / MeOH) m/z = 850.3 (MH+), 872.2 (M+Na+). 
 
3.18b Cis-1: 
3.1 mg, 3.37 µmol, yield 2.4% (5.2% on reacted C60) 
 
 
 
C70H18N2O2 (MW 918.90) 
1H-NMR (200 MHz, CDCl3 / CS2, 25°C): = 4.77 (d, J = 9.0 Hz, 1H), 4.71 – 4.33 (m, 5H), 4.06 (d, J 
= 8.7 Hz, 1H), 3.81 (d, J = 8.8 Hz, 1H), 3.75 – 3.65 (m, 2H), 3.61 (d, J = 8.9 Hz, 1H), 3.35 (d, J = 
10.2 Hz, 1H), 3.31 – 3.14 (m, 2H), 2.99 – 2.70 (m, 2H), 2.28 (m, 2H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
ES-MS (THF / MeOH) m/z = 919.3 (MH+). 
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3.18a Cis-3: 
23 mg, 25 µmol, yield 18.0% (38.5% on reacted C60) 
 
 
 
C70H18N2O2 (MW 918.90) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.99 – 4.52 (m, 4H), 4.45 (m, 2H), 4.37 – 4.15 (m, 2H), 4.15 
– 4.00 (m, 1H), 4.00 – 3.66 (m, 2H), 3.47 (m, 1H), 3.19 – 2.63 (m, 4H), 2.24 (m, 2H). 
The low solubility of product did not allow to record 13C-NMR spectrum. 
IR (ATR): 2953, 2803, 2781, 1730, 1455, 1341, 1195, 759, 747, 703. 
ES-MS (THF / MeOH) m/z = 919.3 (MH+), 941.2 (M+Na+). 
 
 
SYNTHESIS OF 3.19 
 
 
1.825 ml of benzyl-2-bromoacetate (11.516 mmol) in 50 ml of THF were added at 0°C during 2 h 
to a solution 500 mg of 1,7-diaminoheptane (3.839 mmol) and 5.350 ml of TEA (3.884 g, 38.387 
mmol) in 25 ml of THF. The solution mixture was stirred at room temperature for additional 2 h, 
then 832 μl of Z-Cl (982 mg, 5.758 mmol) were added and the mixture was stirred overnight. 
Solvent was evaporated and the residue was dissolved in 50 ml of DCM, washed with 50 ml of 
BRINE, 50 ml of 2N HCl, 50 ml of BRINE and dried over anhydrous Na2SO4. The product was 
purified by flash chromatography in DCM / EtOAc 98:2. 544 mg (0.84 mmol) of a colorless oil 
were obtained in 20% yield. 
 
C41H46N2O8 (MW 694.81) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7. 35 (m, 20H), 5.18 and 5-16 (s, 4H), 5.10 and 5.08 (s, 4H), 
4.05 and 3.99 (s, 4H), 3.31 (br m, 4H), 1.47 (br m, 4H), 1.23 (br m, 6H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.69, 156.59, 155.87, 136.61, 135.41, 128.67, 128.49, 
128.35, 128.05, 128.01, 127.85, 67.56, 67.42, 67.04, 66.98, 49.29, 49.12, 49.07, 48.37, 29.20, 
28.44, 28.06, 26.76. 
ES-MS (MeOH) m/z = 717.3 (M+Na+) 
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SYNTHESIS OF 3.20 
 
 
 
529 mg of 3.19 (0.761 mmol) were dissolved in 30 ml of MeOH, the solution was degassed by 
bubbling Argon, catalytic Pd/C was added and the Argon atmosphere was replaced with H2 by 
means of 2 vacuum / H2 cycles. The reaction was stirred overnight at room temperature, 
filtered over CELITE. The solvent was concentrated and the product was precipitated with Et2O. 
58 mg (0.23 mmol) of a white powder were obtained in 31% yield. 
 
C11H22N2O4 (MW 246.30) 
1H-NMR (200 MHz, D2O, 25°C): = 3.55 (s, 4H), 3.00 (t, J = 7.6 Hz, 4H), 1.65 (m, 4H), 1.34 (br m, 
6H). 
13C-NMR (50 MHz, D2O, 25°C): = 172.81, 50.73, 49.03, 29.24, 26.99, 26.97. 
IR (ATR): 3407, 3057, 2943, 2851, 1623, 1579, 1395, 1378, 1320. 
ES-MS (MeOH) m/z = 269.1 (M+Na+). 
 
 
SYNTHESIS OF 3.21 
 
100 mg of fullerene (0.139 mmol), and 42 mg of paraformaldehyde (1.389 mmol) were 
dissolved in 200 ml of o-DCB, the mixture was heated at 130°C and 36 mg of bis-aminoacid 3.20 
were added in solution of MeOH (~ 1 ml). The reaction was stirred at 130°C for 1 hour. Solvent 
was evaporated and the mixture was separated by flash chromatography in gradient up to Tol / 
EtOAc 90:10. The products were precipitated from DCM or CS2/MeOH, washed with EtOAc and 
Hexane. 
 
Unreacted C60: 
48 mg, 48%. 
 
Traces of Cis-1 + Monoadduct: 
3 mg, 3.3 µmol, yield 2.4% (4.6% on reacted C60) 
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ES-MS (THF / MeOH) m/z = 903.1 (MH+). 
 
3.21a Cis-3: 
15 mg, 16.6 µmol, yield 12% (23% on reacted C60) 
 
 
 
C71H22N2 (MW 902.95) 
1H-NMR (200 MHz, CDCl3 / CS2, 25°C): = 4.61 (d, J = 11.0 Hz, 2H), 4.51 (d, J = 10.7 Hz, 2H), 4.33 
(d, J = 10.6 Hz, 2H), 3.59 (d, J = 11.1 Hz, 2H), 3.47 (m, 2H), 2.83 (m, 2H), 1.73 (m, 10H). 
The low solubility of product did not allow to record 13C-NMR spectrum. 
ES-MS (THF / MeOH) m/z = 903.1 (MH+). 
 
3.21b Cis-2: 
6 mg, 6.64 µmol, yield 4.8% (9.2% on reacted C60) 
 
 
 
C71H22N2 (MW 902.95) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.94 (d, J = 11.3 Hz, 2H), 4.40 (dd, J = 10.9, 2H), 4.00 (d, J = 
11.0 Hz, 2H), 3.87 (dd, J = 12.5, 8.0 Hz, 2H), 3.60 (d, J = 11.3 Hz, 2H), 2.96 – 2.78 (m, 2H), 2.34 – 
1.34 (m, 10H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
ES-MS (THF / MeOH) m/z = 903.1 (MH+). 
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SYNTHESIS OF 3.22 
 
 
5.00 g of p-aminobenzoic acid (36.4 mmol) and 8.32 g of p-toluenesulfonic acid were 
suspended in 75 ml of 1-pentanol and refluxed for 2h30’. The solvent was concentrated until 
the product starts to precipitate, petroleum ether was added and the precipitate was collected 
by filtration. The product was washed with 3 x 100 ml petroleum ether and finally 50 ml of 
pentane. 
12.63 g (33.28 mmol) of a white powder were obtained in 91% yield. 
 
C19H25NO5S (MW 379.47) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.88 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 7.9 Hz, 2H), 7.44 (d, J = 
8.4 Hz, 2H), 6.98 (d, J = 7.8 Hz, 2H), 4.31 (t, J = 6.5 Hz, 2H), 2.27 (s, 3H), 1.74 (br, 2H), 1.41 (br, 
2H), 0.95 (br, 3H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 165.47, 141.22, 140.06, 134.68, 130.97, 130.83, 129.06, 
125.81, 123.76, 65.66, 28.54, 28.34, 22.53, 21.43, 14.18. 
IR (ATR) = 2915, 2873, 1716, 1613, 1277, 1186, 1124, 1035, 1011, 762, 680, 567. 
ES-MS (MeOH) m/z = 208.0 (MH+), 170.7 (TsO-). 
 
SYNTHESIS OF 3.23 
 
 
8.00 g of 3.22 (21.08 mmol) were dissolved in 50 ml of ice-cold TFA, the solution was degassed 
by bubbling nitrogen for 10 min, then 1.01 g of paraformaldehyde (33.73 mmol) were added to 
the solution. The mixture was allowed to warm to room temperature and stirred under 
nitrogen for 5 days. The solution was poured in 200 ml of ice-cold concentrated 
ammonia/water 1:1 and extracted with 3 x 150 ml of EtOAc, the combined organic phases were 
washed with 100 ml of saturated NaHCO3 and with 100 ml of BRINE and dried over anhydrous 
Na2SO4, then the solvent was evaporated. 
The product was crystallized from hot EtOAc/MeOH. 2.730 g (6.06 mmol) of pure product were 
obtained as white needles in 57% yield. 
In alternative the product can be purified by flash chromatography in gradient of c.Hex/EtOAc 
and recovered in 78% yield. 
 
C27H34N2O4 (MW 450.57) 
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1H-NMR (200 MHz, CDCl3, 25°C): = 7.83 (dd, J = 7.6, 3.8 Hz, 2H), 7.63 (d, J = 0.7 Hz, 2H), 7.25 
(d, J = 3.2 Hz 2H), 4.74 (d J = 13.6 Hz, 2H), 4.33 (s, 2H), 4.28 (d J = 13.6 Hz, 2H) 4.24 (t, J = 6.7 Hz 
4H), 1.73 (m= 4H), 1.36 (m, 8H), 0.90 (m, J = 7.1 Hz, 6H) 
13C-NMR (50 MHz, CDCl3, 25°C): = 166.16, 152.25, 128.89, 128.84, 127.45, 126.28, 124.94, 
66.78, 66.14, 58.83, 28.60, 28.32, 22.51, 14.15 
IR (NaCl): 3052, 2916, 2850, 1712, 1609, 1330, 1277, 1183, 736. 
ES-MS (MeOH) m/z = 451.2 (MH+), 473.2 (M+Na+), 489.1 (M+K+). 
 
SYNTHESIS OF 3.24 
 
 
2.00 g of compound 769 (4.439 mmol) were dissolved in 15 ml THF and 10 ml MeOH, a solution 
of 1.00 g of LiOH•H2O (23.832 mmol) in 10 ml of water was added, the mixture was stirred at 
room temperature for 4 hours. The white lithium salt that precipitated during the reaction was 
filtered and washed with THF. The solution was evaporated and the residue was suspended in 
THF/Et2O, filtered and washed with Et2O. The two precipitates were dissolved in 5 ml of water 
and 2N HCl was added dropwise until pH = 3. The white precipitate was filtered and washed 
with 3 x 5 ml of aqueous HCl solution (pH = 3) and with 2 x 5 ml Et2O. 
1.29 g (4.16 mmol) of pure product were collected in 94% yield. 
 
C17H14N2O4 (MW 310.30) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 12.65 (br, 2H), 7.69 (dd, J = 8.4, 1.3 Hz, 2H), 7.57 (d, J = 
1.3 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 4.71 (d, J = 17.0 Hz, 2H), 4.26 (d+s, 4H) 
Characterization are in agreement with literature.[229] 
 
 
SYNTHESIS OF 3.25 
 
 
 
Ethanolamine (2.67 g, 0.0436 mol) was dissolved in DCM (150 ml) and a solution of benzyl 
bromoacetate (5.00 g, 3.46 ml, 0.0218 mol) in DCM (100 ml) was added at 0°C during 4 hours, 
the solution was checked by TLC (AcOEt / MeOH 9:1) and stirred at 0°C until benzyl alcohol 
became visible in TLC (petroleum ether / AcOEt 1:1 to distinguish benzyl alcohol from benzyl 
bromoacetate), then the solution was concentrated (100 ml) under reduce pressure and 
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washed with water (50 ml) to remove the excess o ethanolamine, the organic phase was cooled 
again at 0°C and benzyl chloroformate (4.65 g, 3.89 ml, 0.0273 mol) and TEA (3.31 g, 4.56 ml, 
0.0327 mol) were added. The solution was stirred for additional 15 minutes, concentrated 
under reduced pressure (50 ml) and washed with HCl 6N (50 ml), brine (50 ml), dried over 
anhydrous Na2SO4 and the solvent was removed under reduced pressure. The crude was 
chromatographed on silica gel using petroleum ether / AcOEt 1:1. The pure product was 
collected as a colorless oil in a 29% yield (2.180 g, 0.00635 mol) 
C19H21NO5 (MW 343.37) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.36-7.29 (m 10H), 5.21-5.18 (s 2H), 5.11-5.10 (s 2H), 4.11-
4.07 (s 2H), 3.82-3.67 (m 2H), 3.54 (m 2H), 3.17 (m 1H OH) 
13C-NMR (50 MHz, CDCl3, 25°C): = 171.79-171.40, 156.29, 136.38-136.30, 135.18-135.14, 
128.82, 128.75, 128.72, 128.65, 128.55, 128.33, 128.27, 128.09, 127.99, 68.02-67.91, 67.75, 
67.62, 61.19-61.06, 53.03-52.38, 51.23-51.04 
IR (NaCl) = 3455, 3064, 3032, 2950, 2888, 1748, 1703, 1455, 1410, 1235, 1189, 1135, 1000, 738, 
698. 
ES-MS (MeOH) m/z = 366.4 (M+Na+) 
 
 
SYNTHESIS OF 3.26 AND 3.27 (GENERAL PROCEDURE) 
 
250 mg of diacid 3.24 (0.806 mmol), alcohol 3.15 or 3.25 (2.014 mmol), 49 mg of DMAP (0.403 
mmol) and 386 mg of EDC•HCl (2.014 mmol) were suspended in 20 ml of dry THF under Argon 
and the mixture was stirred overnight. The solvent was evaporated and the residue was 
dissolved in 50 ml DCM, washed with 2 x 25 ml BRINE and dried over anhydrous Na2SO4, then 1 
ml of Pyridine and 3 ml of Ac2O were added to the mixture (to acetylate the excess of alcohol). 
After 1h30’ the reaction mixture was washed with 2 x 25 ml 2N HCl, 25 ml of saturated NaHCO3, 
and 25 ml of BRINE. The organic phase was dried over anhydrous Na2SO4 and purified by flash 
chromatography in DCM/EtOAc gradient up to 50:50. 
 
3.26 
White foam: 281 mg (0.29 mmol), 36% 
 
 
 
C55H52N4O12 (MW 961.02) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.76 and 7.72 (d, J = 8.4 Hz, 2H), 7.58 and 7.54 (s, 2H), 7.35 
– 7.17 (m, 20H), 7.12 and 7.10 (d, J = 8.5 Hz, 2H), 5.11 and 5.10 (s, 4H), 5.07 and 4.99 (s, 4H), 
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4.70 and 4.67 (d, J = 17.0 Hz, 2H), 4.38 (m, 4H), 4.28 (s, 2H), 4.21 and 4.19 (d, J = 17.4 Hz, 2H), 
4.15 and 4.07 (s, 4H), 3.72 and 3.69 (t, J = 5.4 Hz, 4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.49, 165.87, 156.36, 155.96, 152.84, 136.32, 136.25, 
135.41, 135.33, 129.10, 129.07, 128.98, 128.76, 128.68, 128.60, 128.38, 128.26, 128.21, 127.93, 
127.67, 125.57, 125.43, 125.14, 68.04, 67.83, 67.26, 67.16, 66.80, 63.33, 63.19, 58.86, 50.34, 
48.22, 47.51. 
IR (NaCl) = 3057, 2955, 1916, 184, 1717, 1456, 1265, 1182, 1124, 737. 
ES-MS (MeOH) m/z = 983.6 (M+Na+), 999.4 (M+K+) 
 
3.27 
White foam: 273 mg (0.28 mmol), 34% 
 
 
C57H56N4O12 (MW 989.07) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.82 and 7.74 (d, J = 8.1 Hz, 2H), 7.62 and 7.56 (s, 2H), 7.28 
(m, 20H), 7.15 and 7.12 (d, J = 8.3 Hz, 2H), 5.16 and 5.13 (s, 4H), 5.08 and 5.07 (s, 4H), 4.73 and 
4.69 (d, J = 18.9 Hz, 2H), 4.28 (m, 8H), 4.08 and 4.01 (s, 2H), 3.48 (m, 4H), 1.97 (m, 4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.63, 165.98, 156.54, 155.94, 152.66, 136.43, 135.47, 
135.41, 129.00, 128.76, 128.61, 128.42, 128.15, 127.89, 127.62, 125.93, 125.82, 125.09, 67.86, 
67.67, 67.17, 66.84, 62.56, 62.38, 58.89, 49.79, 46.60, 45.80, 28.12, 27.71. 
IR (NaCl) = 3057, 3036, 2954, 2917, 2850, 1746, 1707, 1609, 1467, 1278, 1249, 1182, 1126, 735, 
698. 
ES-MS (MeOH) m/z = 1011.6 (M+Na+), 1027.5 (M+K+) 
 
 
SYNTHESIS OF 3.28 AND 3.29 (GENERAL PROCEDURE) 
 
275 mg of 3.26 (0.286 mmol) or 268 mg of 3.27 (0.271 mmol) were dissolved in 5 ml of CHCl3 
and 25 ml of MeOH, the solution was degassed by bubbling Argon, catalytic Pd/C was added 
and the Argon atmosphere was replaced with H2 by means of 2 vacuum / H2 cycles. The 
reaction was stirred for 3 days, more Pd/C and H2 were added when necessary. Once the 
reaction was complete it was filtered over celite. The solvent was concentrated and the product 
was precipitated by Et2O, a sticky precipitate was obtained and was washed with THF, EtOAc, 
DCM and Pentane until a white powder was obtained. 
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3.28 
153 mg (0.30 mmol), quantitative yield 
 
 
 
C25H28N4O8 (MW 512.51) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 9.42 (br, 4H, 2xNH2
+), 7.84 (d, J = 8.5 Hz, 2H), 7.74 (s, 
2H), 7.27 (d, J = 8.4 Hz, 2H), 4.76 (d, J = 16.8 Hz, 2H), 4.46 (br, 4H), 4.35 (s, 2H), 4.31 (d, J = 16.9 
Hz, 2H), 3.93 (br, 4H), 3.34 (br, 2H). 
13C-NMR (50 MHz, DMSO-d6, 25°C): = 167.90, 164.94, 152.58, 128.94, 128.49, 127.98, 124.67, 
124.16, 65.73, 60.10, 58.14, 47.02, 45.61. 
IR (ATR): 2977, 2785, 1720, 1614, 1431, 1283, 1194, 1115, 858, 767. 
ES-MS (MeOH) m/z = 510.9 (M-1-). 
 
 
3.29 
136 mg (0.25 mmol), 93% 
 
 
 
C27H32N4O8 (MW 540.56) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 9.18 (br, 4H, 2xNH2
+), 7.74 (d, J = 8.4 Hz, 2H), 7.62 (s, 
2H), 7.25 (d, J = 8.5 Hz, 2H), 4.74 (d, J = 17.1 Hz, 2H), 4.29 (m, 8H), 3.89 (br, 4H), 3.04 (br 4H), 
2.06 (br, 4H). 
13C-NMR (50 MHz, DMSO-d6, 25°C): = 167.83, 164.99, 152.54, 128.37, 128.04, 127.98, 124.74, 
124.40, 65.69, 61.64, 58.03, 46.87, 44.06, 24.89. 
IR (ATR): 1713, 1611, 1412, 1285, 1196, 1117, 848, 770. 
ES-MS (MeOH) m/z = 539.0 (M-1-). 
 
 
SYNTHESIS OF 3.30 
 
 
115 
 
A solution of 568 μl of (chloromethyl)trimethylsilane (500 mg, 4.07 mmol) in 2.5 ml of THF was 
added to 5 ml of ethanolamine in a PYREX tube, and some KI crystals were added. The tube was 
sealed and stirred at 80°C overnight. The mixture was poured in 25 ml of water and extracted 
with 4 x 25 ml of Et2O, and the combined organic phases were washed with BRINE 10 ml. The 
solvent was evaporated and the residue was dissolved in 5 ml of DCM and 888 mg of Boc2O 
(4.07 mmol) were added. After 2 hours the reaction was diluted with 25 ml of Et2O and washed 
with 2 x 25 ml of saturated NaHCO3 and 15 ml of BRINE. The organic layer was dried over 
anhydrous Na2SO4 and evaporated, giving 702 mg (2.84 mmol) of pure product as a colorless oil 
in 70% yield. 
 
C11H23NO3Si (MW 247.41) 
1H-NMR (270 MHz, CDCl3, 25°C): = 3.76 (br 2H), 3.37 (br 2H), 2.80 (s 2H), 2.30 (br 1H OH), 1.47 
(s 9H), 0.08 (s 9H). 
ES-MS (MeOH) m/z = 270.5 (M+Na+). 
Characterization are in agreement with literature.[230] 
 
 
SYNTHESIS OF 3.31 
 
 
250 mg of compound 3.24 (0.806 mmol), 498 mg of 3.30 (2.014 mmol) and 49 mg (0.401 mmol) 
of DMAP were vacuum dried for 3 hours and then suspended in 10 ml of dry DCM under Argon 
atmosphere. The mixture was cooled at 0°C and 463 mg of EDC•HCl (2.417 mmol) were added. 
The mixture was allow to warm to room temperature and was stirred overnight. 700 μl of 
Pyridine and 2.500 ml of Ac2O were added to the mixture (to acetylate the excess of alcohol). 
After 1h30’ the reaction was diluted with 20 ml Et2O and washed with 25 ml of saturated 
NaHCO3, 25 ml of 0.2N HCl and 25 ml of BRINE. The organic phase was dried over anhydrous 
Na2SO4 and purified by flash chromatography in DCM/EtOAc gradient up to 80:20. 
529 mg (0.688 mmol) of product were obtained as a colorless sticky dense oil in 85% yield. 
 
C39H60N4O8Si2 (MW 769.09) 
1H-NMR (270 MHz, CDCl3, 40°C): = 7.81 (d, J = 7.6 Hz, 2H), 7.62 (s, 2H), 7.15 (d, J = 8.3 Hz, 2H), 
4.72 (d, J = 16.6 Hz, 2H), 4.43 – 4.10 (m, 8H), 3.50 (br, 4H), 2.78 (s, 4H), 1.37 (s, 18H), 0.05 (s, 
18H) 
13C-NMR (50 MHz, CDCl3, 40°C): = 165.92, 152.65, 129.03, 127.55, 125.82, 124.95, 79.55, 
66.87, 62.36, 59.40, 58.90, 48.21, 39.15, 28.56, -1.33 
IR (NaCl) = 2954, 2825, 1717, 1689, 1610, 1454, 1391, 1279, 1248, 1167, 1121, 850, 770. 
ES-MS (MeOH) m/z = 791.3 (M+Na+), 807.3 (M+K+) 
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SYNTHESIS OF 3.32 
 
 
480 mg of compound 3.31 (0.624 mmol) were dissolved in 5 ml DCM and 5 ml TFA. The mixture 
was stirred at room temperature for 2h45’, then the solvents were evaporated and co-
evaporated with Et2O, Tol and Et2O. The product was triturated with Et2O and 465 mg (0.583 
mmol) of a white powder were obtained in 94% yield. 
 
C33H46F6N4O8Si2 (MW 796.90) 
1H-NMR (270 MHz, DMSO-d6, 25°C): = 8.54 (br, 4H, NH2
+), 7.81 (d, J = 8.3 Hz, 2H), 7.67 (s, 2H), 
7.27 (d, J = 8.4 Hz, 2H), 4.75 (d, J = 16.7 Hz, 2H), 4.28 (m, 8H), 3.36 (br, 4H), 0.13 (s, 9H). (N-CH2-
Si is covered by DMSO). 
13C-NMR (68 MHz, DMSO-d6, 25°C): = 164.96, 152.86, 128.73, 128.33, 128.06, 124.68, 124.02, 
66.68, 59.72, 58.12, 49.10, 37.02, -2.15 
IR (ATR): 3011, 2960, 2820, 1715, 1667, 1698, 1487, 1280, 1199, 1173, 1134, 848, 796, 721. 
ES-MS (MeOH) m/z = 569.3 (MH+) 
 
SYNTHESIS OF 3.33 
 
100 mg of fullerene (0.139 mmol) and 83 mg of paraformaldehyde (2.778 mmol) were dissolved 
in 20 ml of o-DCB. A solution of 110 mg of compound 3.32 (0.139 mmol) in 7 ml of DMSO was 
added. The reaction was stirred for 69 hours and monitored by TLC (Tol/MeOH 90:10). The 
mixture was diluted with 50 ml of Tol and washed with 2 x 50 ml of water and 1 x 50 ml BRINE. 
The organic layer was dried over anhydrous Na2SO4 and loaded on a silica gel column, 
unreacted C60 was eluted first with 100% Tol, then the mixture of tethered bis-adduct was 
eluted with Tol/MeOH 99:1 and 97:3. 
Bis-adducts were separated on preparative TLC in 100% chloroform (containing 1% of EtOH as 
stabilizer) by running the same plate 4 times; a second preparative TLC was necessary for 
fractions 5 and 7. 
Unreacted C60 was precipitated from CS2/Acetone and washed with MeOH: 19.65 mg were 
recovered. 
Each product was finally precipitated from DCM or CS2/MeOH and washed once with MeOH. 
HPLC (Waters SPHERISORB 10μ silica 250x10 mm, 2 ml/min CHCl3/MeOH 99:1) 
 
Unreacted C60: 
19.65 mg, 0.027 mmol, 19.7%. 
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3.33a Monoadduct: 
2.05 mg, 1.08 µmol, 0.39% (0.48% on reacted fullerene). 
 
 
C145H28N4O4 (MW 1889.80) 
1H-NMR (500 MHz, CDCl3 / CS2, 25°C): = 7.91 (dd, J = 8.4, 1.9 Hz, 2H), 7.72 (d, J = 1.7 Hz, 2H), 
7.14 (d, J = 8.4 Hz, 2H), 4.82 (m, 4H), 4.74 (d, J = 16.6 Hz, 2H), 4.50 (s, 8H), 4.28 (s, 2H), 4.24 (d, J 
= 16.7 Hz, 2H), 3.48 (t, J = 5.5 Hz, 4H). 
The small quantity of product did not allow to record 13C-NMR spectrum and its very low 
solubility in solvents that can be used to perform ES-MS analysis (as THF/MeOH) did not allow 
to record the mass spectrum. 
 
3.33b Cis-2: 
0.62 mg, 0.53 μmol, 0.38% (0.47% on reacted fullerene)  
 
C85H28N4O4 (MW 1169.16) 
ES-MS (THF / MeOH) m/z = 1170.2 (MH+), 1191.1 (M+Na+), 1208.1 (M+K+). 
 
3.33c Trans-4: 
5.00 mg, 4.27 μmol, 3.07% (3.84% on reacted fullerene) 
 
 
 
C85H28N4O4 (MW 1169.16) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.85 (td, J = 8.9, 1.8 Hz, 2H), 7.68 (d, J = 1.7 Hz, 1H), 7.64 (d, 
J = 1.6 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 4.85 (d, J = 9.0 Hz, 1H), 4.79 (d, J = 
8.6 Hz, 1H), 4.75 – 4.60 (m, 5H), 4.52 (ddd, J = 11.8, 6.1, 3.1 Hz, 1H), 4.44 (d, J = 9.2 Hz, 1H), 4.34 
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(s, 2H), 4.26 (d, J = 9.9 Hz, 1H), 4.21 (d, J = 16.6 Hz, 1H), 4.12 (d, J = 16.4 Hz, 1H), 3.99 (d, J = 9.1 
Hz, 1H), 3.95 (d, J = 8.7 Hz, 1H), 3.78 (d, J = 7.2 Hz, 1H), 3.67 (d, J = 9.2 Hz, 1H), 3.53 (ddd, J = 
12.9, 8.9, 4.2 Hz, 1H), 3.44 – 3.37 (m, 1H), 3.26 (ddd, J = 12.8, 6.1, 2.7 Hz, 1H), 3.06 (dt, J = 12.8, 
4.4 Hz, 1H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
ES-MS (THF / MeOH) m/z = 1170.2 (MH+), 1191.1 (M+Na+), 1208.1 (M+K+). 
 
3.33d Equatorial: 
7.60 mg, 6.50 μmol, 4.68% (5.86% on reacted fullerene) 
 
 
 
C85H28N4O4 (MW 1169.16) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.92 (dd, J = 8.4, 1.7 Hz, 1H), 7.89 (dd, J = 8.4, 1.7 Hz, 1H), 
7.65 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 1.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 
4.84 (m, 1H), 4.74 (d, J = 16.5 Hz, 1H), 4.69 (d, J = 16.4 Hz, 1H), 4.66 – 4.59 (m, 1H), 4.51 (m, 2H), 
4.42 (s, 2H), 4.25 (d, J = 9.0 Hz, 1H), 4.21 (d, J = 16.7 Hz, 1H), 4.17 – 4.07 (m, 4H), 4.04 (d, J = 9.4 
Hz, 1H), 4.00 (d, J = 9.3 Hz, 1H), 3.90 (d, J = 9.1 Hz, 1H), 3.81 (d, J = 9.1 Hz, 1H), 3.51 – 3.44 (m, 
1H), 3.41 (m, 1H), 3.26 (m, 1H), 3.06 (m, 1H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
IR (KBr) = 2921, 2783, 1718, 1610, 1488, 1458, 1343, 1279, 1205, 1170, 1122, 965, 772, 527. 
ES-MS (THF / MeOH) m/z = 1169.1 (MH+), 1192.1 (M+Na+), 1207.1 (M+K+). 
 
3.33e Trans-3: 
1st preparative TLC: 9.40 mg, 8.04 μmol, 5.78% (7.24% on reacted fullerene) 
2nd preparative TLC: 6.95 mg, 5.94 μmol, 4.28% (5.86% on reacted fullerene) 
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C85H28N4O4 (MW 1169.16) 
1H-NMR (500 MHz, CDCl3, 25°C): =7.80 (dd, J = 8.4, 1.9 Hz, 2H), 7.51 (d, J = 1.6 Hz, 2H), 6.97 (d, 
J = 8.4 Hz, 2H), 4.92 – 4.85 (m, 2H), 4.82 – 4.77 (m, 2H), 4.72 (d, J = 9.8 Hz, 2H), 4.60 (d, J = 16.5 
Hz, 2H), 4.42 (d, J = 9.8 Hz, 2H), 4.36 (d, J = 9.8 Hz, 2H), 4.18 (d, J = 10.0 Hz, 2H), 4.11 (s, 2H), 
4.06 – 3.94 (m, 2H), 3.98 (d, J = 16.7 Hz, 2H), 3.51 – 3.42 (m, 2H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
ES-MS (THF / MeOH) m/z = 1169.2 (MH+), 1192.1 (M+Na+), 1199.7 (MH++MeOH) 
 
3.33f Trans-2: 
2.24 mg, 1.91 μmol, 1.38% (1.72% on reacted fullerene) 
 
C85H28N4O4 (MW 1169.16) 
ES-MS (THF / MeOH) m/z = 1170.2 (MH+), 1191.1 (M+Na+), 1208.1 (M+K+). 
 
3.33g: 
1st preparative TLC: 9.18 mg, 7.85 μmol, 5.65% (7.07% on reacted fullerene) 
2nd preparative TLC: 6.38 mg, 5.46 μmol, 3.93% (4.92% on reacted fullerene) 
 
C85H28N4O4 (MW 1169.16) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.87 (dd, J = 8.4, 2.0 Hz, 0.2H), 7.77 (dd, J = 8.4, 1.9 Hz, 1H), 
7.69 (dd, J = 8.4, 1.9 Hz, 0.8H), 7.56 (d, J = 1.7 Hz, 1H), 7.51 (s, 0.2H), 7.45 (d, J = 1.7 Hz, 0.8H), 
6.99 (d, J = 8.4 Hz, 0.2H), 6.95 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 0.8H), 5.55 – 5.49 (m, 0.2H), 
5.40 – 5.33 (m, 0.8H), 5.07 (dd, J = 10.6, 2.4 Hz, 0.2H), 5.04 – 4.95 (m, 2H), 4.91 (dd, J = 10.3, 2.4 
Hz, 0.8H), 4.68 (d, J = 10.2 Hz, 1H), 4.66 – 4.56 (m, 4H), 4.51 (m, 2H), 4.41 – 4.37 (m, 1H), 4.35 
(d, J = 10.2 Hz, 1H), 4.26 (d, J = 10.3 Hz, 1H), 4.13 (s, 1H), 4.11 (s, 0.2H), 4.09 (s, 0.8H), 4.00 (d, J 
= 16.9 Hz, 1H), 3.97 (d, J = 16.9 Hz, 1H), 3.92 (m, 2H), 3.65 – 3.57 (m, 1.8H), 3.52 – 3.45 (m, 
0.2H). 
After the second chromatography the ratio 1:08:02 remain unchanged. 
1H-NMR at 40°C is perfectly superimposable. 
ES-MS (THF / MeOH) m/z = 1170.2 (MH+), 1191.1 (M+Na+), 1208.1 (M+K+). 
 
 
SYNTHESIS ALCOHOLS 3.34 – 3.39 
The synthesis of compounds from 3.34 to 3.39 was described in the previous work.[212] 
 
 
SYNTHESIS OF 3.40, 3.41 AND 3.42 (GENERAL PROCEDURE) 
 
To a solution of 3.34, 3.35 or 3.36 (7.46 mmol) and 602 μl of dry Pyridine (588 mg, 7.46 mmol) 
in 10 ml of dry DCM under Argon were added dropwise 345 μl of malonyl chloride (500 mg, 
3.54 mmol) at 0°C, the mixture was allow to warm to room temperature and was stirred 
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overnight. The solution was washed with 3 x 10 ml water, dried over anhydrous Na2SO4, 
evaporated and purified by flash chromatography with petroleum ether/EtOAc 75:25. 
 
3.40  
 
 
Sticky colorless oil, 1.27 g, 2.05 mmol, yield = 58% 
 
C29H50N2O12 (MW 618.71) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.28 (m, 4H), 3.89 and 3.80 (s, 4H), 3.55 (m, 4H), 3.38 (s, 
2H), 1.47 and 1.43 (s, 36H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.07, 166.24, 155.30, 81.79, 81.68, 80.75, 80.56, 64.27, 
64.08, 51.37, 50.74, 47.37, 41.44, 28.51, 28.40, 28.25. 
IR (NaCl) = 2977, 2934, 1743, 1702, 1457, 1394, 1367, 1249, 1228, 1029 779. 
ES-MS (MeOH) m/z = 641.3 (M+Na+). 
 
3.41  
 
 
Sticky colorless oil, 1.32 g, 2.05 mmol, yield = 58% 
 
C31H54N2O12 (MW 646.77) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.18 (m, 4H), 3.83 and 3.74 (s, 4H), 3.38 (s,2H), 3.35 (m, 
4H), 1.89 (m, 4H), 1.46 and 1.42 (s, 36H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.21, 166.62, 155.37, 81.69, 81.64, 80.39, 80.25, 63.40, 
50.90, 50.27, 45.73, 41.61, 28.53, 28.47, 28.27. 
IR (NaCl) = 2977, 2934, 1745, 1700, 1460, 1367, 1247, 1227, 1156, 1032. 
ES-MS (MeOH) m/z = 669.3 (M+Na+). 
 
3.42  
 
 
Sticky colorless oil, 1.33 g, 1.89 mmol, yield = 53% 
 
C35H62N2O12 (MW 702.87) 
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1H-NMR (200 MHz, CDCl3, 25°C): = 4.12 (m, 4H), 3.82 and 3.73 (s, 4H), 3.36 (s, 2H), 3.24 (m, 
4H), 1.67 (m, 4H), 1.46 and 1.43 (s, 36H), 1.34 (m, 4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.30, 166.70, 155.41, 81.49, 80.00, 65.61, 50.40, 49.80, 
48.39, 41.72, 28.58, 28.50, 28.42, 28.28, 23.27. 
IR (NaCl) = 2976, 2935, 1747, 1700, 1458, 1366, 1248, 1225, 1154. 
ES-MS (MeOH) m/z = 725.4 (M+Na+). 
 
SYNTHESIS OF 3.43, 3.44 AND 3.45 (GENERAL PROCEDURE) 
 
150 mg of fullerene (0.208 mmol), malonate 3.40, 3.41 or 3.42 (0.208 mmol) and iodine (0.229 
mmol) were dissolved in 100 ml of Tol and 69 μl of DBU (70 mg, 0.458 mmol) were slowly 
added. The solution was stirred at room temperature for 1 hour, then was washed with 50 ml 
of 0.1 M Na2S2O3, and dried over anhydrous Na2SO4. The mixture was separated by flash 
chromatography in gradient from Tol to Tol/EtOAc 90:10. The product was obtained as a brown 
powder after precipitation from DCM/MeOH. 
 
3.43 
 
 
123 mg, 92 µmol, yield = 44% 
 
C89H48N2O12 (MW 1337.34) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.64 (m, 4H), 3.95 and 3.86 (s, 4H), 3.72 (m, 4H), 1.55 and 
1.48 and 1.47 and 1.44 (s, 36H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.04, 163.37, 155.35, 155.25, 145.37, 145.29, 145.15, 
145.01, 144.97, 144.78, 143.96, 143.17, 143.12, 143.09, 142.28, 141.97, 141.08, 139.27, 139.10, 
138.85, 81.95, 81.85, 81.04, 80.78, 65.88, 65.72, 65.62, 51.60, 50.93, 47.57, 47.40, 28.60, 28.45, 
28.31. 
IR (NaCl) = 2975, 2918, 1850, 1744, 1703, 1455, 2392, 1367, 1265, 1230, 1170, 1142, 738, 527. 
ES-MS (MeOH) m/z = 1360.2 (M+Na+) 1375.2 (M+K+). 
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3.44 
 
 
127 mg, 93 µmol, yield = 45% 
 
C91H52N2O12 (MW 1365.39) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.56 (t, J = 6.2 Hz, 4H), 3.87 and 3.78 (s, 4H), 3.44 (m, 4H), 
2.10 (m, 4H), 1.55 and 1.51 and 1.47 and 1.43 (s, 36H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.18, 163.55, 155.62, 155.37, 145.36, 145.31, 144.98, 
144.78, 144.74, 143.96, 143.11, 143.08, 142.28, 141.99, 141.08, 139.04, 81.75, 81.69, 80.64, 
80.37, 65.50, 51.15, 50.54, 46.09, 45.93, 28.66, 28.47, 28.31, 27.90. 
IR (NaCl) = 2956, 2917, 2849, 1743, 1700, 1457, 1425, 1393, 1366, 1266, 1231, 1170, 737, 527. 
ES-MS (MeOH) m/z = 1388.2 (M+Na+) 1403.2 (M+K+). 
 
3.45 
 
 
127 mg, 89 µmol, yield = 43% 
 
C95H60N2O12 (MW 1421.50) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.48 (t, J = 6.3 Hz, 4H), 3.83 – 3.74 (s, 4H), 3.25 (m, 4H), 
1.87 (m, 4H), 1.54 (m, 8H), 1.47 – 1.43 (s, 36H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.07, 166.24, 155.30, 81.79, 81.68, 80.75, 80.56, 64.27, 
64.08, 51.37, 50.74, 47.37, 41.44, 28.51, 28.40, 28.25. 
IR (NaCl) = 2919, 2850, 1743, 1697, 1456, 1425, 1394, 1367, 1265, 1237, 1172, 1154, 738, 527. 
ES-MS (MeOH) m/z =1443.4 (M+Na+) 1459.3 (M+K+). 
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SYNTHESIS OF 3.46, 3.47 AND 3.48 (GENERAL DEPROTECTION PROCEDURE) 
 
50 mg of Bingel adduct 3.43, 3.44 or 3.45 was dissolved in 4 ml of DCM and 4 ml of TFA, the 
solution was stirred at room emperature for 6 hours. Then the solvents were evaporated and 
the product was triturated with Et2O. Product was obtained in 90-95%. The NMR spectra could 
not be recorded, being the product completely insoluble in any solvent (DMSO-d6, DMF-d7, Py-
d5). The compound were used directly in the next step. 
 
 
CYCLOADDITION WITH 3.47 AND 3.48: GENERAL PROCEDURE 
 
20 mg of 3.47 or 3.48 and 100 eq of paraformaldehyde were suspended in 20 ml of DMF, the 
mixture was heated at 130°C and the reaction was followed by TLC. Reaction time 30-45 min. 
 
 
SYNTHESIS OF 3.49 
 
67 mg of 3.46 (53.5 µmol) and 160 mg of paraformaldehyde (5.3 mmol) were suspended in 100 
ml of DMF, the mixture was heated at 130°C for 45 min. The solvent was evaporated and the 
crude was separated by chromatography in gradient up to Tol/EtOAc 80:20 and the main 
fraction was chromatographed again in Tol/EtOAc 90:10. The product was precipitated from 
DCM/MeOH. 
6.20 mg, 6.45 µmol of a brown powder were obtained, 12%. 
 
 
 
C71H16N2O4 (MW 960.90) 
1H-NMR (200 MHz, CDCl3, 25°C): = 5.42 (m, 2H), 4.45 (m, 2H), 4.44 (d, J = 9.2 Hz, 2H), 4.20 (d, J 
= 8.8 Hz, 2H), 4.04 (d, J = 8.7 Hz, 2H), 3.75 (d, J = 9.3 Hz, 2H), 3.02 (m, 4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 180.33, 164.45, 154.13, 148.86, 148.03, 147.66, 147.29, 
147.08, 146.87, 146.35, 145.94, 145.50, 145.29, 145.16, 144.55, 143.77, 143.59, 141.75, 140.35, 
139.91, 134.32, 134.20, 70.58, 67.62, 67.50, 61.87, 60.12, 53.86, 41.53. 
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UV: CHCl3 
 
 
 
SYNTHESIS OF 3.50-3.56 
 
Aminoacid 3.50 and fullerenes 3.51, 3.52, 3.55 and 3.56 were synthesized according to 
reported procedures.[231] 
 
SYNTHESIS OF 3.53-3.54 
 
Thread 3.53 and Rotaxane 3.54 were synthesized following the literature procedure as well. [216] 
 
CYCLOADDITION ON ROTAXANE (GENERAL PROCEDURE) 
 
5.00 mg of fullerenes 3.51 (Boc-protected), 3.53 (Thread) and 3.54 (Rotaxane) were dissolved in 
3.00 ml of the dry solvent, with 0.1 eq. of TFA. To the room temperature experiments were 
added 2 equivalents of N-(Methoxymethyl)-N-(trimethylsilylmethyl)benzylamine, while in the 
low temperature experiment, the solution was cooled at -20°C before adding the reactive. 
Room temperature reactions were stirred for 24h, low temperature reactions were stored in 
freezer at -20°C for two weeks and daily manually swirled. 
Reaction mixtures were diluted with 20 ml of CHCl3 and washed 3 x 20 ml of water, organic 
layer was dried over anhydrous Na2SO4, and evaporated. The crude was precipitated from 
CHCl3/Et2O. 
The mixture was redissolved in CHCl3 and injected in HPLC. 
 
HPLC for cycloadditions on Fullerene 3.51 
Column: Phenomenex, Cosmosil 5 μm PBB, 4.6 mm x 250 mm 
Eluent: CHCl3/Tol 60:40, 
Flow: 0.15 ml/min 
Run time: 70 min 
Chromatograms extracted @ 322 nm 
0
0,5
1
1,5
2
2,5
3
350 450 550 650 750
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HPLC for cycloaddition on Thread 3.53 and Rotaxane 3.54 
Column: Phenomenex, Cosmosil 5 μm PBB, 4.6 mm x 250 mm 
Eluent: CHCl3/Tol 60:40 
Flow: 0.2 ml/min 
Run time: 50 min 
Chromatograms extracted @ 322 nm 
 
 
SYNTHESIS OF 3.57 
 
In a screw cap vial 30 mg of fullerene 3.52 (0.0297 mmol) were dissolved in 3 ml of o-DCB, 1 ml 
of γ-butyrolactone, and 384 μl of a solution of 10 mg/ml DIEA in o-DCB (0.0297 mmol DIEA). 
The resulting solution was heated at 80°C overnight, and for additional 8 hours at 100°C. The 
product was purified by flash chromatography in Tol/EtOH 95:5 and precipitated from 
CHCl3/MeOH and washed with Et2O. 
19 mg (0.019 mmol) of a brown powder were obtained in 65% yield. 
 
C72H24N2O4 (MW 980.97) 
1H-NMR (200 MHz, CDCl3, 25°C): = 6.54 (br t, 1H, NH), 4.60 (s, 4H), 4.13 (br t, 2H), 3.89 – 3.33 
(m, 12H), 2.41 (br t, 2H), 1.89 (br m, 2H). 
The low solubility of this derivative did not allow to record 13C-NMR spectrum. 
IR (ATR): 3313, 2925, 2867, 1652, 1543, 1426, 1120, 1084, 767. 
ES-MS (MeOH) m/z = 981.1 (MH+), 1003.1 (M+Na+). 
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SYNTHESIS OF 3.58 
 
 
29 mg of fullerene 3.57 (0.0296 mmol) were suspended in 5 ml of dry DCM, with 764 μl of a 
solution of 10 mg/ml DIEA in o-DCB (0.0591 mmol DIEA) under Argon. 12 mg of p-nitrophenyl 
chloroformate (0.0591 mmol) were added. The reaction was followed by TLC (Tol/MeOH 9:1) 
and other 12 mg aliquots of p-nitrophenylchloroformate were added until all starting material 
was consumed. DCM was evaporated and the product was precipitated with Et2O, washed 
twice with MeOH and finally with Et2O. 
26 mg (0.019 mmol) of product were obtained as a brown powder in 77% yield. 
 
C79H27N3O8 (MW 1340.82) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.27 (d, J = 9.0 Hz, 2H), 7.38 (d, J = 8.9 Hz, 2H), 6.44 (br t, 
1H, NH), 4.55 (s, 4H), 4.34 (t, J = 6.1 Hz, 2H), 4.09 (br t, 2H), 3.92 – 3.70 (m, 4H), 3.63 (m, 2H), 
3.54 – 3.39 (m, 4H), 2.39 (t, J = 7.1 Hz, 2H), 2.22 – 2.03 (m, 2H). 
The low solubility of this derivative did not allow to record 13C-NMR spectrum. 
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SYNTHESIS OF 3.59 
 
12.00 mg of fullerene 3.58 (10.46 μmol) and 4.05 mg of DIEA (31.39 μmol) were dissolved in 2 
ml of dry DMF, under Argon. 6.06 mg of doxorubicin hydrochloride (10.46 μmol) were added to 
the solution and the resulting mixture was stirred overnight with protection from light. The 
reaction was dilued with 25 ml of DCM and washed with 2 x 25 ml of water, and 1 x 25 ml of 
BRINE, organic layer was dried over anhydrous Na2SO4, evaporated and chromatographed in 
gradient up to DCM/MeOH 90:10. Product was precipitated from DCM/MeOH, washed with 
MeOH with Et2O. 7.99 mg (5.15 μmol) of a brown-red powder were obtained in 49% yield 
 
C100H51N3O16 (MW 1550.49) 
1H-NMR (500 MHz, DMSO-d6, 25°C): = 14.06 (s, 1H, Ar-OH), 13.30 (s, 1H, Ar-OH), 7.97 – 7.87 
(m, 2H), 7.77 (t, J = 5.3 Hz, 1H, CONH), 7.67 (dd, J = 6.7, 2.9 Hz, 1H), 6.67 (d, J = 7.3 Hz, 1H, 
O(CO)NH), 5.38 (s, 1H, OH), 5.23 (s, 1H), 4.95 (t, J = 4.6 Hz, 1H), 4.83 (t, J = 6.0 Hz, 1H, OH), 4.65 
(d, J = 5.8 Hz, 1H, OH), 4.56 (d, J = 5.9 Hz, 2H), 4.48 (s, 4H), 4.04 (q, J = 6.4 Hz, 1H), 4.00 (s, 3H), 
3.93 (t, J = 5.3 Hz, 2H), 3.77 (t, J = 6.8 Hz, 2H), 3.73 – 3.69 (m, 2H), 3.66 – 3.61 (m, 2H), 3.56 (br 
m, 1H), 3.45 (m, 3H), 3.27 (t, J = 5.3 Hz, 2H), 3.20 – 3.15 (m, 2H), 3.04 (d, J = 18.2 Hz, 1H), 2.92 
(d, J = 18.2 Hz, 1H), 2.15 (br m, 2H), 2.06 (t, J = 7.5 Hz, 2H), 1.81 (m, 1H), 1.70 – 1.62 (m, 2H), 
1.43 (m, 1H), 1.11 (d, J = 6.4 Hz, 3H). 
The low solubility of this derivative did not allow to record 13C-NMR spectrum. 
IR (ATR): 3431, 2934, 1874, 1720, 1654, 1629, 1580, 1537, 1412, 1284, 1208, 1119, 1081, 1017, 
987, 766 
ES-MS (MeOH) m/z = 1550.6 (MH+), 1572.6 (M+Na+), 1588.6 (M+K+). 
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SYNTHESIS OF 3.60 
 
75 mg of fullerene 3.52 (0.074 mmol) were suspended in 3 ml of o-DCB, 2.4 ml of a solution of 
10 mg/ml DIEA in o-DCB (0.186 mmol DIEA) and 11 mg of succinic anhydride (0.112 mmol) were 
added. The resulting solution was stirred overnight, solvent was evaporated and the residue 
was sonicated and centrifuged in MeOH, HCl in MeOH (pH = 4), MeOH and 2 x Et2O. 
65 mg (0.065 mmol) of a brown powder were obtained in 88% yield. 
 
C72H22N2O5 (MW 994.96) 
1H-NMR (200 MHz, CDCl3, 25°C): = 6.77 (br t, 1H, NH), 4.64 (s, 4H), 4.10 (t, J = 5.4 Hz, 2H), 3.84 
(m, 2H), 3.76 (m, 2H), 3.63 – 3.41 (m, 6H), 2.67 (m, 2H), 2.59 (m, J = 7.6 Hz, 2H). 
Characterizations are in agreement with literature.[232] 
 
 
SYNTHESIS OF 3.61 
 
 
45 mg of fullerene 3.60 (0.0452 mmol), 25 mg of chlorotacrine-diaminobutane derivative (the 
compound was gently supplied by Dr. Federico, Univ. Trieste)(0.0823 mmol) and 9 mg of HOBt 
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(0.0678 mmol) were suspended in 10 ml of dry DCM and 5 ml of dry DMF under Argon, the 
mixture was cooled to 0°C and 13 mg of EDC•HCl (0.0678 mmol) were added. The reaction was 
allowed to warm to room temperature and was stirred overnight. The solvents were 
evaporated and the product was purified by chromatography in gradient up to CHCl3/MeOH 
90:10. The product was precipitated from CHCl3/Et2O, washed with MeOH and Et2O. 
39 mg (0.030 mmol) of a brown powder were obtained in 67% yield. 
 
C89H42ClN5O4 (MW 1280.77) 
1H-NMR (500 MHz, CDCl3, 25°C): = 7.87 (m, 2H), 7.28 (m, 1H), 6.38 (br t, 1H, CONH), 6.24 (br t, 
1H, CONH), 4.50 (s, 4H), 4.05 (t, J = 5.5 Hz, 2H), 3.98 (br t, 1H, ArNH), 3.82 (m, 2H), 3.73 (m, 2H), 
3.60 (t, J = 5.1 Hz, 2H), 3.45 (m, 4H), 3.37 (t, J = 5.5 Hz, 1H), 3.26 (dt, J = 6.5, 6.5 Hz, 2H), 3.02 (br 
t, 2H), 2.66 (br t, 2H), 2.54 (m, 2H), 2.48 (m, 2H), 1.91 (br t, 4H), 1.67 (m, 2H), 1.59 (m, 2H). 
13C-NMR (126 MHz, CDCl3, 25°C): = 172.39, 172.28, 155.09, 147.45, 146.38, 146.21, 146.14, 
145.78, 145.53, 145.43, 144.67, 143.25, 142.78, 142.32, 142.18, 142.01, 140.28, 136.30, 124.60, 
70.94, 70.72, 70.60, 70.57, 69.95, 68.69, 54.49, 53.76, 49.20, 39.99, 39.64, 39.24, 32.00, 31.89, 
24.90. 
IR (ATR): 2933, 2846, 1649, 1555, 1426, 1120, 1083. 
ES-MS (MeOH) m/z = 1281.4 (MH+). 
 
 
SYNTHESIS OF 3.62 
 
 
25.0 mg of fullerene 3.60 (0.0452 mmol), 11.3 mg of chlorotacrine-diaminoTEG derivative (the 
compound was gently supplied by Dr. Federico, Univ. Trieste)(0.0823 mmol) and 6.8 mg of 
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HOBt (0.0678 mmol) were suspended in 5 ml of dry DCM and 1 ml of dry DMF under Argon, the 
mixture was cooled to 0°C and 9.6 mg of EDC•HCl (0.0678 mmol) were added. The reaction was 
allowed to warm to room temperature and was stirred overnight. The solvents were 
evaporated and the product was purified by chromatography in gradient up to CHCl3/MeOH 
95:5. The product was precipitated from CHCl3/Et2O, washed with Et2O. 
12 mg (0.030 mmol) of a brown powder were obtained in 36% yield. 
 
C91H46ClN5O6 (MW 1340.82) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.93 (m, 2H), 7.29 (m, 1H), 6.47 (br t, 1H, CONH), 6.39 (br, 
1H, CONH), 4.83 (br t, 1H ArNH), 4.51 (s, 4H), 4.06 (t, J = 5.4 Hz, 2H), 3.82 (m, 2H), 3.75 (m, 2H), 
3.70 – 3.52 (m, 12H), 3.47 – 3.35 (m, 6H), 3.07 (br t, 2H), 2.71 (br t, 2H), 2.50 (m, 4H), 1.90 (br, 
4H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 172.22, 172.12, 155.10, 147.44, 146.37, 146.20, 146.16, 
145.79, 145.59, 145.53, 145.42, 144.67, 143.24, 142.78, 142.33, 142.19, 142.02, 140.28, 136.32, 
71.18, 71.02, 70.78, 70.67, 70.64, 70.47, 70.39, 70.12, 70.07, 68.75, 54.57, 48.65, 39.68, 39.49, 
38.40, 31.87, 29.96. 
IR (ATR): 2935, 2870, 1649, 1555, 1425, 1260, 1118, 766. 
ES-MS (MeOH) m/z = 1341.2 (MH+) 
 
 
SYNTHESIS OF 3.63 
 
 
To an ice-cooled solution of 1.000 g of Cyanuric Chloride (5.42 mmol) in 100 ml of THF was 
added dropwise, by means of a cannula, an ice-cooled solution of 1.346 g of mono-boc 
protected TEG diamine (5.42 mmol) and 2.102 g of DIEA (16.27 mmol) in 100 ml of THF. The 
mixture was stirred at 0°C for 30’. Then this solution was added dropwise, by means of a 
cannula, to an ice-cold solution of 4.018 g of TEG diamine (27.11 mmol) in 100 ml of THF. The 
resulting mixture was allow to warm to r.t. and was stirred for 45’, pH was adjusted to 5 with 
2N HCl and the solvent was evaporated. The residue was dissolved in 50 ml EtOAc and 
extracted with 75 ml of water. Aqueous phase was basified with K2CO3 until pH = 9 and 
extracted with EtOAc 4 x 75 ml. The organic phase was dried over anhydrous Na2SO4 and 
concentrated to ~100 ml. To this solution 1.403 g of Fmoc-OSu (5.42 mmol) were added at 0°C, 
followed by 913 μl of DIEA (677 mg, 5.42 mmol). The mixture was allow to warm to r.t. and 
stirred overnight, then was washed with 50 ml of water with some HCl (pH=4), and BRINE 25 
ml. Finally the product was purified by flash chromatography in gradient from DCM/EtOAc 
50:50 to pure EtOAc. 
2.142 g (2.93 mmol) of product were obtained with a 54% yield. 
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C35H48ClN7O8 (MW 730.25) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.76 (d, J = 7.3 Hz, 2H), 7.60 (d, J = 7.1 Hz, 2H), 7.36 (m, 
4H), 6.53 – 5.29 (m, 4H, 4xNH), 4.40 (d, J = 6.7 Hz, 2H), 4.23 (t, J = 6.5 Hz, 1H), 3.60 – 3.32 (br m, 
24H), 1.45 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 165.54 (2C) 165.19 (1C), 156.65 (C=O), 156.09(C=O), 144.00 
(2C), 141.24 (2C), 127.61 (2C), 127.01 (2C), 125.11 (2C), 119.91 (2C), 79.15 (1C), 70.40 (4C), 
70.24 (2C), 69.41 (2C), 66.63 (1C), 47.31 (1C), 40.98 (1C), 40.72 (2C), 40.42 (1C), 28.51 (3C). 
IR (NaCl) = 3318, 2932, 2871, 1708, 1578, 1250, 1105, 740. 
ES-MS (MeOH) m/z = 730.4 (MH+), 752.3 (M+Na+), 768.3 (M+K+), 630.3 (MH+ -Boc). 
 
 
SYNTHESIS OF 3.64 
 
 
To an ice-cooled solution of 200 mg of Cyanuric Chloride (1.048 mmol) in 20 ml of THF was 
added dropwise an ice-cooled solution of 269 mg of mono-boc protected TEG diamine (1.048 
mmol) and 566 μl of DIEA (420 mg, 3.253 mmol) in 20 ml of THF. The mixture was stirred at 0°C 
for 3 hours. To this solution was added dropwise an ice-cold solution of 114 mg of 2-(2-
aminoethoxy)ethanol (1.084 mmol) and 566 μl of DIEA (420 mg, 3.253 mmol) in 20 ml of THF. 
The resulting mixture was allow to warm to r.t. and was stirred overnight. The solvent was 
evaporated and the residue was dissolved in DCM and washed with BRINE, dried over 
anhydrous Na2SO4 and purified by flash chromatography with EtOAc. 360 mg (0.774 mmol) of a 
white waxy solid were obtained in 71% yield. 
 
C18H33ClN6O6 (MW 464.94) 
1H-NMR (200 MHz, CDCl3, 25°C): = 3.73 (br 2H), 3.62 (br 16H), 3.33 (br 2H), 1.43 (s 9H). 
Characterization are in agreement with literature.[233] 
 
 
SYNTHESIS OF 3.65 
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To an ice-cooled solution of 500 mg of Cyanuric Chloride (2.711 mmol) in 50 ml of THF was 
added dropwise an ice-cooled solution of 673 mg of mono-boc protected TEG diamine (2.711 
mmol) and 1.417 ml of DIEA (1.051 g, 8.134 mmol) in 50 ml of THF. The mixture was stirred at 
0°C for 3 hours. To this solution was added dropwise an ice-cold solution of 570 mg of 
diethanolamine (1.084 mmol) and 1.417 ml of DIEA (1.051 g, 8.134 mmol) in 50 ml of THF. The 
resulting mixture was allow to warm to r.t. and was stirred overnight. The solvent was 
evaporated and the residue was dissolved in DCM and washed with BRINE, dried over 
anhydrous Na2SO4 and purified by flash chromatography with DCM/EtOAc/MeOH 50:50:3. 660 
mg (1.420 mmol) of a sticky colorless oil were obtained in 52% yield. 
 
C18H33ClN6O6 (MW 464.94) 
1H-NMR (200 MHz, CDCl3, 25°C): = 3.86 (m, 4H), 3.78 (m, 4H), 3.59 (m, 10H), 3,31 (m, 2H), 
1.43 (s, 9H) 
Characterizations are in agreement with literature. [233] 
 
 
SYNTHESIS OF 3.66 
 
To an ice-cooled solution of 500 mg of Cyanuric Chloride (2.711 mmol) in 50 ml of THF was 
added dropwise an ice-cooled solution of 1.350 g of mono-boc protected TEG diamine (5.423 
mmol) and 2.833 ml of DIEA (2.102 g, 16.266 mmol) in 100 ml of THF. The mixture was allowed 
to warm to r.t. and was stirred overnight. The solvent was evaporated and the residue was 
dissolved in DCM and washed with BRINE, dried over anhydrous Na2SO4 and purified by flash 
chromatography with DCM / EtOAc / MeOH.100:100:1. 1.318 g (2.168 mmol) of a white solid 
were obtained in 80% yield. 
 
C25H46ClN7O8 (MW 608.13) 
1H-NMR (200 MHz, CDCl3, 25°C): = 3.63 (br s, 20H), 3.33 (br m, 4H), 1.45 (s 18H). 
Characterization are in agreement with literature. [233] 
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SYNTHESIS OF 3.67 
 
 
To an ice-cooled solution of 300 mg of Cyanuric Chloride (1.627 mmol) in 150 ml of THF, a 
solution of 428 mg of diethanolamine (4.067 mmol) and 992 μl of DIEA (736 mg, 5.694 mmol) in 
100 ml of THF was added dropwise during 40 minutes. When the addition was complete the 
mixture was allow to warm to r.t. and stirred overnight. 2N HCl was added until pH=4, then the 
solvent was evaporated and the residue was dissolved in 50 ml of BRINE, pH was adjusted again 
to 4 with NaHCO3 and product was extracted with 10 x 50 ml EtOAc, organic phase was dried 
over anhydrous Na2SO4 and evaporated. The residue was triturated with Et2O and filtered and 
washed with Et2O. 465 mg (1.445 mmol) of a white powder were obtained in 89% yield. 
 
C11H20ClN5O4 (MW 321.76) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 4.79-4.75 (br s, 4H, 4xOH), 3.58 (br s, 16H). 
13C-NMR (50 MHz, DMSO-d6, 25°C): = 168.81 (1C), 164.80 (2C), 59.48 (2C), 59.14 (2C), 51.34 
(2C), 50.84 (2C). 
IR (ATR) = 3403, 3353, 2952, 2911, 1580, 1509, 1482, 1461, 1439, 1411, 1306, 1233, 1039, 978, 
870, 793 
ES-MS (MeOH) m/z = 344.1 (100%), 346.1 (33%), 345.1 (10%) (M+Na+). 
  
134 
 
SYNTHESIS OF 3.68 
 
 
75 mg of fullerene 3.52 (0.074 mmol) and 109 mg of MCT 3.63 (0.149 mmol) were suspended in 
15 ml of o-DCB, the mixture was degassed by means of 2 vacuum/Argon cycles. 2.10 ml of a 
solution of DIEA in o-DCB 10 mg/ml (21 mg, 0.164 mmol) were added. The resulting solution 
was stirred under Argon at 80°C for 67 hours. The crude of reaction was directly loaded on a 
flash chromatography column and eluted with Tol to remove o-DCB, then with Tol/EtOH 95:5. 
Desired product and unreacted 3.63 were eluted together. The product was precipitated from 
DCM to acetone, washed with acetone and finally with Et2O affording 57 mg (0.035 mmol) of a 
brown powder in 48% yield. 
 
C103H65N9O10 (MW 1588.67) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.75 (d, J = 7.2 Hz, 2H), 7.59 (d, J = 7.2 Hz, 2H), 7.36 (m, 
4H), 5.76 (br, 4H, 4xNH), 4.50 (s, 4H), 4.37 (d, J = 7.0, Hz, 2H), 4.23 (br t, 1H), 4.03 (br d, 2H) 3.74 
– 3.16 (br m, 34H), 1.43 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 156.75 (C=O), 156.18 (C=O), 155.24 (4C), 147.40 (2C), 
146.32 (4C), 146.16 (8C), 145.80 (2C), 145.47 (4C), 145.39 (4C), 144.65 (4C), 144.14 (2C Fmoc), 
143.18 (2C), 142.72 (4C), 142.33 (4C), 142.10 (4C), 141.97 (4C), 141.42 (2C Fmoc), 140.21 (4C), 
136.32 (4C), 127.80 (2C), 127.21 (2C), 125.33 (2C), 120.10 (2C), 83.79 (2C), 79.39 (1C), 71.03 – 
68.62 (19C), 54.35 (2C), 47.79 (1C), 40.99 (5C), 28.69 (3C). 
IR (ATR) = 2868, 1707, 1566, 1512, 1448, 1341, 1166, 1106, 810, 736. 
ES-MS (MeOH) m/z = 1589.6 (MH+), 1614.6 (M+Na+). 
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SYNTHESIS OF 3.69 
 
 
150 mg of fullerene 3.52 (0.149 mmol) and 138 mg of MCT 3.64 (0.297 mmol) were suspended 
in 26 ml of o-DCB, the mixture was degassed by means of 2 vacuum/Argon cycles. 4.20 ml of a 
solution of DIEA in o-DCB 10 mg/ml (42 mg, 0.327 mmol) were added. The resulting solution 
was stirred under Argon at 80°C for 40h. The reaction mixture was directly loaded on a flash 
chromatography column and eluted with Tol to remove o-DCB, then with Tol/EtOH 95:5 and 
finally 93:7. The product was precipitated from DCM/Et2O, washed with acetone/Et2O and 
finally with Et2O affording 128 mg (0.097 mmol) of a brown powder in 65% yield. 
 
C86H50N8O8 (MW 1323.37) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.52 (s, 4H), 4.07 (t, J = 4.9 Hz, 2H), 3.92 – 3.45 (m, 26H), 
3.78 (m, 4H), 1.44 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 171.52, 165.80, 155.26 (4C), 147.43 (2C), 146.37 (4C), 
146.21 (4C), 146.19 (4C), 145.84 (2C), 145,.52 (4C), 145.42 (4C), 144.69 (4C), 143.21 (2C), 
142.74 (4C), 142.37 (4C), 142.21 (4C), 142.01 (4C), 140.27 (4C), 136.35 (4C), 79.41, 72.72, 71.07, 
70.70, 70.45, 68.72, 61.92, 54.45, 40.73, 28.74. 
IR (NaCl) = 3354, 2954, 2917, 2850, 1735, 1713, 1566, 1518, 1464, 1264, 1117, 737. 
ES-MS (MeOH) m/z = 1323.7 (MH+), 1345.6 (M+Na+). 
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SYNTHESIS OF 3.70 
 
 
100 mg of fullerene 3.52 (0.099 mmol) and 69 mg of MCT 3.65 (0.149 mmol) were suspended in 
17 ml of o-DCB, the mixture was degassed by means of 2 vacuum/Argon cycles. 2,70 ml of a 
solution of DIEA in o-DCB 10 mg/ml (27 mg, 0.208 mmol) were added. The resulting solution 
was stirred under Argon at 80°C for 72h. The reaction mixture was directly loaded on a flash 
chromatography column and eluted with Tol to remove o-DCB, then with Tol/EtOH 95:5 and 
finally 93:7. The product was precipitated from DCM/Et2O, washed with acetone/Et2O and 
finally with Et2O affording 67 mg (0.051 mmol) of a brown powder in 51% yield. 
 
C86H50N8O8 (MW 1323.37) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.52 (s, 4H), 4.07 (br, 2H), 3.97 – 3.48 (m, 26H), 3.37 (s, 
4H), 1.44 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 155.24 (4C), 147.41 (2C), 146.34 (4C), 146.18 (8C), 145.81 
(2C), 145,49 (4C), 145.40 (4C), 144.69 (4C), 143.18 (2C), 142.74 (4C), 142.37 (4C), 142.17 (4C), 
141.97 (4C), 140.23 (4C), 136.33 (4C), 79.42, 71.05, 70.73, 70.45, 70.04, 68.70, 66.07, 62.98, 
59.41, 54.40, 51.79, 41.03, 28.72 . 
IR (ATR): 3352, 2866, 1702, 1554, 1506, 1424, 1116. 
ES-MS (MeOH) m/z = 1323.7 (MH+), 1345.6 (M+Na+). 
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SYNTHESIS OF 3.71 
 
 
50 mg of fullerene 3.52 (0.0496 mmol) and 60 mg of MCT 3.66 (0.0991 mmol) were suspended 
in 8.6 ml of o-DCB, the mixture was degassed by means of 2 vacuum/Argon cycles. 1.40 ml of a 
solution of DIEA in o-DCB 10 mg/ml (14 mg, 0.1090 mmol) were added. The resulting solution 
was stirred under Argon at 80°C for 63 hours. The crude of reaction was directly loaded on a 
flash chromatography column and eluted with Tol to remove o-DCB, then with Tol/EtOH 95:5. 
The product was precipitated from DCM to Et2O, washed with Et2O and re-precipitated from 
DCM to pentane and washed with pentane. 42 mg (0.029 mmol) of a brown powder were 
obtained in 58% yield. 
 
C93H63N9O10 (MW 1466.55) 
1H-NMR (200 MHz, CDCl3, 25°C): = 4.52 (s, 4H), 4.07 (t, J = 5.1 Hz, 2H), 3.82 (m, 2H), 3.78 (m, 
2H), 3.60 (br m, 24H), 3.35 (m, 6H) 1.44 (s, 18H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 156.26, 155.26, 147.43 (2C), 146.36 (4C), 146.22 (4C), 
146.19 (4C), 145.83 (2C), 145.51 (4C), 145.41 (4C), 144.69 (4C), 143.21 (2C), 142.75 (4C), 142.36 
(4C), 142.20 (4C), 142.00 (4C), 140.26 (4C), 136.34 (4C), 79.41, 71.07, 70.72, 70.45, 70.23, 68.71, 
54.42, 40.68, 28.72. 
IR (NaCl) = 3351, 2924, 2867, 1709, 1568, 1519, 1455, 1364, 1250, 1104. 
ES-MS (MeOH) m/z = 1467.4 (MH+), 1488.5 (M+Na+), 1505.4 (M+K+). 
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SYNTHESIS OF 3.72 
 
 
50 mg of fullerene 3.52 (0.0496 mmol) and 32 mg of MCT 3.67 (0.0991 mmol) were suspended 
in 8.6 ml of o-DCB, the mixture was degassed by means of 2 vacuum/Argon cycles. 1.40 ml of a 
solution of DIEA in o-DCB 10 mg/ml (42 mg, 0.1090 mmol) were added. The resulting solution 
was stirred under Argon at 80°C. Other 3 aliquots of 32 mg of 3.67 in 1 ml of MeOH were added 
after 10, 34 and 58 hours. Reaction was stopped after 80 hours, MeOH was evaporated and the 
crude of reaction was directly loaded on a flash chromatography column and eluted with Tol to 
remove o-DCB, then with Tol/EtOH 95:5 and finally 85:15. The product was precipitated from 
DCM/MeOH to Et2O and washed with Et2O affording 23 mg (0.0194 mmol) of a brown powder 
in 39% yield. 
 
C79H37N7O6 (MW 1180.18) 
1H-NMR (500 MHz, DMSO-d6, 25°C): = 6.36 (br, 1H, NH), 4.71 (br, 2H, 2xOH), 4.63 (br, 2H, 
2xOH), 4.55 (s, 4H), 3.96 (br t, 2H), 3.74 (br t, 2H), 3.68 (br t, 2H), 3.50 (br m, 22H). 
The low solubility of this derivative did not allow to record 13C-NMR spectrum. 
IR (ATR) = 3347, 2933, 2870, 1535, 1501, 1422. 1360, 1044, 807, 774. 
ES-MS (MeOH) m/z = 1180.3 (MH+), 1202.3 (M+Na+), 1214.2 (M+Cl-), 1178.2 (M-1-). 
 
 
SYNTHESIS OF 3.73 
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85 mg of fullerene 3.69 (0.064 mmol) were suspended in 10 ml of dioxane/conc HCl 2:1, the 
mixture was stirred overnight at r.t. The solvent was evaporated and the residue was 
precipitated from MeOH/Et2O and washed twice with Et2O affording 76 mg (0.060 mmol) of a 
brown powder in 94% yield. 
 
C81H43ClN8O6 (MW 1259.71) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 8.36 (br, 1H, NH
+), 7.99 (br, 3H, NH3
+), 5.27 (br, 2H, NH) 
4.19 (br, 2H), 4.74 – 3.36 (m, 28H), 2.95 (m, 2H) 
13C-NMR: even if visibly soluble the compound seems to aggregate and the spectrum has a low 
resolution. 
IR (ATR): 3255, 2872, 1630, 1563, 1450, 1323, 1120, 769. 
ES-MS (MeOH) m/z = 1223.6 (MH+), 612.5 (MH2
2+). 
 
 
SYNTHESIS OF 3.74 
 
 
15.00 mg (11.3 µmol) of fullerene 3.69 were dissolved in 1.00 ml of DCM and 0.50 ml of 
iodomethane were added. The PYREX was sealed and heated for 5 hours at 60°C. The 
suspension was diluted with Et2O and centrifuged. The precipitate was washed with Et2O, Tol 
and Et2O. 12.69 mg (8.66 µmol) of a brown powder were obtained in 77% yield. 
 
C87H53IN8O8 (MW 1465.30) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 8.25 (br, 2H, NH) 6.78 (br, 1H, NH), 6.40 (br, 1H, NH), 
5.79 (s, 4H), 5.60 (br, 1H, NH) 4.53 (br, 2H), 4.30 (br, 2H), 4.19 (s, 3H), 3.80 (br, 2H), 3.68 (br, 
2H), 3.47 – 3.34 (br, 22H), 3.04 (m, 2H), 1.36 (s, 9H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
ES-MS (MeOH) m/z = 1337.4 (M+). 
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SYNTHESIS OF 3.75 
 
 
12.69 mg (8.66 µmol) of fullerene 3.74 were suspended in 3 ml of dioxane/conc HCl 2:1, the 
mixture was stirred overnight at r.t. The solvent was evaporated and the residue was 
precipitated from MeOH/Et2O and washed twice with Et2O affording 9.82 mg (6.49 µmol) of a 
brown powder in 75% yield. 
 
C82H49Cl4IN8O6 (MW 1511.03) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 7.96 (br, 3H, NH3
+), 5.86 (s, 4H), 4.58 (br, 2H), 4.31 (br, 
2H), 4.20 (s, 3H), 3.82 (br, 2H), 3.68 (br, 2H), 3.53 – 3.37 (br, 22H), 2.93 (m, 2H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
IR (ATR): 3339, 2873, 1611, 1573, 1430, 1347, 1119. 
ES-MS (MeOH) m/z = 1237.4 (M+), 619.3 (MH2+). By-product: 1251.4 [M(+CH3)
+], 626.3 
[M(+CH3)H
+]. 
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SYNTHESIS OF 3.76 
 
 
16.52 mg of 3.73 (11.8 µmol) were dissolved in 1.25 of anhydrous MeOH under Argon 
atmosphere and 1.25 ml of a solution of DIEA in o-DCB 10 mg/ml (12.5 mg, 94.3 µmol) were 
added. 6.88 mg of FITC (17.7 µmol) were added and the mixture was stirred at r.t. in the dark. 
Overnight a brown solid starts to precipitate. The stirring was continued for 5 days. MeOH was 
evaporated and Et2O was added to the residue to remove o-DCB, then the solid was washed 
with MeOH several times, until the solution was colorless and non-fluorescent, then was 
washed twice with Et2O. 15.71 mg (9.74 µmol) of an ochre-brown powder were obtained in 
82% yield. 
 
C102H53N9O11S (MW 1612.63) 
1H-NMR (500 MHz, DMSO-d6, 25°C): = 10.07 (br, 2H, NH+OH), 8.35 (br m, 1H), 7.99 (brm, 1H), 
7.69 (br m, 1H), 7.29 – 7.17 (m, 2H, NH), 6.67 (s, 2H), 6.57 (br m, 4H), 4.53 (s, 4H), 3.95 (br t, 
2H), 3.76 – 3.20 (br m, 30H). 
The low solubility of this derivative did not allow to record 13C-NMR spectrum. 
IR (ATR) = 2869, 1766, 1573, 1505, 1461, 1329, 1261, 1206, 1179, 1110, 851, 766. 
ES-MS (MeOH) m/z = 1613.6 (MH+), 1611.4 (M-1-). 
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SYNTHESIS OF 3.77 
 
 
20.0 mg of fullerene 3.73 (0.015 mmol) were dissolved in 2.5 ml of DCM and 2.5 ml of TFA were 
added. After 36 hours the solvents were evaporated and the residue was co-evaporated with 
MeOH/Et2O and MeOH/Tol. The residue was dissolved in 2 ml of anhydrous DMF under Argon 
atmosphere and 12 mg of DIEA (0.091 mmol) were added. The solution was cooled to 0°C and a 
solution of 10.5 Sulforhodamine B acid chloride in 2 ml of anhydrous DMF was added dropwise. 
The mixture was allowed to warm to r.t. and stirred overnight. The solvent was concentrated 
and the crude was precipitated with Et2O and washed with the same solvent. The product was 
purified by flash chromatography in gradient from chloroform to chloroform/MeOH 93:7. The 
product was further purified by preparative TLC (chloroform/MeOH 95:5) and finally 
precipitated from DCM/Hex and washed twice with Et2O. 
6.53 mg (3.6 µmol) of a purple powder were obtained in 24% yield. 
 
C108H70N10O12S2 (MW 1763.90) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.87 (br s, 1H), 8.04 (br s, 1H), 7.26 (br s, 1H), 7.19 (br d, 
2H), 6.82 (d, J = 8.2 Hz, 2H), 6.67 (s, 2H), 4.53 (s, 4H), 4.08 (br m, 2H), 3.84 – 3.10 (br m, 38H), 
1.30 (m, 12H). 
The small quantity of product did not allow to record 13C-NMR spectrum. 
IR (KBr) = 3436, 2920, 1591, 1416, 1337, 1274, 1245, 1181, 1075. 
ES-MS (MeOH) m/z = 1674.5 (MH+), 1662.4 (M-1-), 1797.3 (M+Cl-). 
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SYNTHESIS OF 3.78 
 
25.42 mg of fullerene 3.73 (0.0202 mmol) were dissolved in 1.3 ml of dry MeOH under Argon, 
1.3 ml of a solution of DIEA in o-DCB 10 mg/ml (13.04 mg, 0.1009 mmol) and 10.00 mg of 
compound 3.A (Figure 75, the compound was gently supplied by the group of Prof. Minarini, 
Univ. Bologna) (0.0168) were added. The mixture was stirred at room temperature overnight, 
MeOH was evaporated and the product was purified by flash chromatography with 
CHCl3/MeOH 90:10. The product was precipitated from DCM/Et2O, washed with Et2O and re-
precipitated as hydrochloride salt from DCM to DCM/Et2O saturated with HCl, washed with Tol 
and with Et2O. 20.54 mg (0.0122 mmol) of a brown powder were obtained in 60% yield. 
 
C102H61ClN12O10S (MW 1682.17) 
1H-NMR (free base, before HCl) (200 MHz, CDCl3, 25°C): = 8.72 (s, 4H), 4.52 (s, 4H), 4.33 (m, 
4H), 4.07 (t, J = 4.9 Hz 4H), 3.80 (m, 30H), 3.54 (m, 8H), 2.69 (t, J = 6.4 Hz, 1H), 2.35 (s, 6H). 
IR (ATR): 3229, 2944, 2869, 1703, 1664, 1628, 1558, 1454, 1337, 1248, 1114, 768. 
ES-MS (MeOH) m/z = 1646.4 (MH+), 1681.2 (M+Cl-). 
 
 
DEGRADATION OF FOLIC ACID TO PTEROIC ACID 
I 
 
500 mg of Folic Acid (1.13 mmol) were suspended in 6 ml of anhydrous THF under Argon 
atmosphere. 1.575 ml of trifluoroacetic anhydride (2379 mg, 11.33 mmol) were added 
dropwise at 0°C. The resulting orange solution was allowed to warm to r.t. and was stirred for 
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48 hours protected from light. The solution was evaporated and dissolved in 1 ml of THF, 
filtered over Celite and dropped into 8 ml of Et2O, the resulting yellow precipitate was washed 
with 5 ml Tol and then with 2 x 5 ml of Pentane. 639 mg (1.23 mmol) were obtained. The 
mixture was dissolved in 2 ml of THF and ~ 400 mg of crushed ice were added. The solution was 
stirred for 3 hours and was dropped in 8 ml of Et2O, the resulting yellow precipitate was 
washed with Et2O, DCM and Et2O. 416 mg (0.80 mmol) of impure material were obtained 
(71%). 
C21H16F3N7O6 (MW 519.39) 
The resulting mixture was directly used in the next step without purification. 
 
II 
 
409 mg of compound the mixture obtained from the first step (0.787 mmol) were dissolved in 8 
ml of DMSO, the solution was degassed with a vacuum/Argon cycle and 382 μl of hydrazine 
hydrate (394 mg, 7.875 mmol) were added drop by drop maintaining the temperature below 
25°C. After 8 hours the solution was filtered over Celite and MeOH was added, the resulting 
yellow precipitate was washed with 3 x 10 ml of MeOH and 3 x 10 ml of Et2O. 247 mg (0.76 
mmol) of product were obtained in 96% yield. 
 
C14H14N8O2 (MW 326.31) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 9.32 (br s, 1H OH), 8.63 (s, 1H), 7.58 (d, J = 8.4 Hz, 2H), 
7.04 (br s, 2H, NH2), 6.91 (t, J = 5.8 Hz, 1H NH), 6.60 (d, J = 8.4 Hz, 2H), 4.45 (d, J = 5.4 Hz, 2H). 
Characterizations are in agreement with literature.[221] 
 
III 
 
 
382 mg of IBX 45% (0.6131 mmol) were dissolved in 10 ml of DMSO and 10 ml of water and 100 
mg Pteroyl Hydrazide  were added in one portion. The resulting suspension was stirred for 1 h 
protected from light. Water was evaporated and the residue was poured in 50 ml of 
Acetone/Et2O 1:1, the yellow precipitate was washed with 10 ml MeOH, 2 x 10 ml of water, 10 
ml of MeOH, 2 x 10 ml of Et2O. 
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80 mg (0.26 mmol) of Pteroic Acid were obtained as a yellow powder in 84% yield. 
 
C14H12N6O3 (MW 312.28) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 11.43 (br s, 1H, OH), 8.65 (s, 1H), 7.66 (d, J = 8.0 Hz, 
2H), 7.17 (br t, 1H, NH), 6.89 (br t, 2H, NH2), 6.64 (d, J = 8.0 Hz, 2H), 4.48 (d, J = 5.2 Hz, 2H) 
Characterizations are in agreement with literature.[220] 
 
 
SYNTHESIS OF 3.79 
 
 
2.00 g of 4,4'-dimethyl-2,2'-bipyridine (10.85 mmol) and 1.44 g of SeO2 (13.03 mmol) were 
refluxed in 150 ml of dioxane for 24h. The mixture was filtered and the solvent was evaporated. 
The residue was dissolved in 100 ml EtOAc and washed once with aqueous Na2CO3 to remove 
the acid. Then the water soluble aldehyde-bisulfite adduct was extracted with 3 x 30 ml of 0.2 
M NaHSO3. Combined aqueous phase was washed once with 50 ml of EtOAc to remove any 
trace of starting material and then basified with Na2CO3 until pH = 10. The aldehyde was 
extracted with 3 x 80 ml of EtOAc, the organic layer was dried over anhydrous Na2SO4 and 
evaporated. 781 mg (3.94 mmol) of product were obtained as a white solid in 36% yield. 
 
C12H10N2O (MW 198.22) 
1H-NMR (200 MHz, Acetone-d6, 25°C): = 10.26 (s, 1H), 8.95 (d, J = 4.8 Hz, 1H), 8.89 (s, 1H), 
8.58 (d, J = 4.9 Hz, 1H), 8.34 (s, 1H), 7.84 (dd, J = 4.8, 1.3 Hz, 1H), 7.31 (d, J = 4.5 Hz, 1H), 2.47 (s, 
3H). 
Characterizations are in agreement with literature.[234] 
 
 
SYNTHESIS OF 3.80 
 
 
 
To a solution of 4.85 g of 2-(2-aminoethoxy)ethanol (46.1 mmol) in 75 ml of DCM were added 
dropwise at 0°C a solution of 2.27 ml of tert-butylbromoacetate (3.00 g, 15.4 mmol) in 50 ml of 
DCM. The mixture was allow to warm to r.t. and was stirred overnight. Then the solvents were 
concentrated to 50 ml and washed with water to remove the salt and the excess of amine. The 
combined organic layers were evaporated and the residue was dissolved in 50 ml of water with 
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some drops of MeOH and extracted with petroleum ether 5 x 100 ml to remove the bis-
alkylated product. Product was extracted with EtOAc 4 x 100 ml. 
2.74 g (12.5 mmol) of a colorless oil were obtained in 81% yield. 
 
C10H21NO4 (MW 219.28) 
1H-NMR (200 MHz, CDCl3, 25°C): = 3.74 (m, 2H), 3.58 (m, 4H), 3.33 (s, 2H), 2.81 (t, J = 5.2 Hz, 
2H), 1.17 (br m, 2H OH+NH), 1.47 (s, 9H). 
Characterizations are in agreement with literature.[235] 
 
 
SYNTHESIS OF 3.81 
 
 
 
2.14 g of compound 3.80 (9.76 mmol) were dissolved in 20 ml of DCM with 1.50 ml of TEA (1.09 
g, 10.7 mmol) and the 1.53 ml of benzylchloroformate (1.83 g, 10.7 mmol) were carefully added 
to the solution. The resulting mixture was stirred overnight, washed with water 20 ml and 
BRINE 20 ml. The organic phase was dried over anhydrous Na2SO4 and the solvent was removed 
by evaporation. 
3.06 g (8.66 mmol) of pure product were obtained as colorless oil in 89% yield. 
 
C18H27NO6 (MW 353.41) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.31 (br m, 5H), 5.16 and 5.11 (s, 2H), 4.00 and 3.95 (s, 2H), 
3.66 (m, 4H), 3.55 (m, 4H), 2.48 and 2.23 (t, 1H, OH), 1.46 and 1.38 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.26, 156.25, 136.54, 128.65, 128.55, 128.20, 128.11, 
128.04,127.95, 81.98, 72.56, 70.26, 70.14, 67.62, 61.86, 51.27, 51.19, 49.09, 48.36, 28.34, 
28.22. 
IR (NaCl) = 3454, 2929, 2871, 1743, 1707, 1458, 1409, 1367, 1225, 1157, 1137, 1061. 
ES-MS (MeOH) m/z = 376.0 (M+Na+). 
 
 
SYNTHESIS OF 3.82 
 
 
 
5.92 g of compound 3.81 (16.8 mmol) and 5 ml of iodomethane were dissolved in 10 ml of 
anhydrous THF under Argon atmosphere. 442 mg of NaH (18.4 mmol) were added in small 
portions at 0°C. The resulting suspension was allowed to warm to r.t. and left to stir overnight. 
The unreacted NaH was neutralized by careful addition of water at 0°C. The resulting mixture 
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was extracted with Et2O, and the organic phase was washed with BRINE and dried over 
anhydrous Na2SO4. The product was purified by flash chromatography with petroleum 
ether/EtOAc 70:30. 
3.78 g (10.3 mmol) of a colorless oil were obtained in 61% yield. 
(unreacted alcohol can be recovered from the column with petroleum ether/EtOAc 50:50) 
 
C19H29NO6 (MW 367.44) 
1H-NMR (200 MHz, CDCl3, 25°C): = 7.31 (br m, 5H), 5.15 and 5.11 (s, 2H), 4.02 and 3.98 (s, 2H), 
3.52 (m, 8H), 3.36 (s, 3H), 1.45 and 1.39 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.16, 156.22, 136.70, 128.63, 128.54, 128.15, 
128.05,127.91, 81.75, 81.65, 72.06, 70.68, 70.57, 70.43 67.63, 67.49 59.27, 51.07, 48.74, 48.04, 
28.35, 28.25. 
IR (NaCl) = 2955, 2923, 2871, 1475, 1708, 1458, 1367, 1223, 1137. 
ES-MS (MeOH) m/z = 390.0 (M+Na+). 
 
 
SYNTHESIS OF 3.83 
 
 
 
3.78 g of compound 3.82 (21.33 mmol) were dissolved in 10 ml of DCM and 10 ml of TFA were 
added. After 90 minutes the solvents were evaporated and the residue was dissolved in water 
and extracted with EtOAc, the organic phase was dried over anhydrous Na2SO4 and the solvent 
was evaporated. The residue was dissolved in 50 ml of MeOH, the solution was degassed by 
bubbling Argon for 10 minutes and Pd/C was added. The argon atmosphere was replaced with 
H2 by means of 2 vacuum/H2 cycles. The mixture was stirred overnight at r.t., then filtered over 
celite and the solvent was evaporated. The product was precipitated from a minimum amount 
of DCM by slowly adding Et2O/c.Hex 1:1 with sonication, then the mixture was cooled. 331 mg 
(1.87 mmol) of a white sticky solid were obtained in 9% yield. 
 
C7H15NO4 (MW 177.20) 
1H-NMR (200 MHz, CDCl3, 25°C): = 3.84 (br, 2H), 3.65 (br, 4H), 3.54 (br, 2H), 3.36 (s, 3H), 3.26 
(br, 2H). 
Characterizations are in agreement with literature.[236] 
 
 
SYNTHESIS OF 3.84 
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1.41 g of compound 3.82 (3.84 mmol) were dissolved in 50 ml of MeOH, argon was bubbled in 
the solution for 10 minutes, then 10% Pd/C was added. The argon atmosphere was substituted 
with H2 by means of two vacuum/H2 cycles. The mixture was stirred overnight, then was 
filtered over celite and the solvent was removed yielding 860 mg (3.69 mmol) of the product as 
a colorless oil in 96% yield. 
 
C11H23NO4 (MW 233.30) 
1H-NMR (200 MHz, CDCl3, 25°C): = 3.61 (m, 6H), 3.83 (s, 3H), 3.23 (s, 2H), 2.81 (t, J = 5.1 Hz, 
2H), 1.46 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 171.55, 81.27, 72.17, 71.08, 50.54, 59.28, 52.06, 49.00, 
28.40. 
Characterizations are in agreement with literature. [237] 
 
 
SYNTHESIS OF 3.85 
 
 
 
250 mg of fullerene (0.347 mmol), 62 mg of sarcosine (0.694 mmol) and 69 mg of bpy-aldehyde 
3.79 (0.347 mmol) were dissolved in 250 ml of Tol and the mixture heated at reflux. Additional 
62 mg of sarcosine were added after 30’ and after 60’. The reaction was refluxed 2h more, then 
was cooled and separated by flash chromatography. C60 was first eluted with Tol and the 
monoadduct with Tol/EtOAc 90:10. Finally the product was precipitated from CS2/Acetone and 
washed twice with MeOH. 134 mg (0.142 mmol) of a brown powder were obtained in 41% yield 
(82% on reacted C60). 
 
C74H15N3 (MW 945.93) 
1H-NMR (270 MHz, CDCl3, 25°C): = 8.77 (d, J = 5.0 Hz, 2H), 8.56 (d, J = 4.9 Hz, 1H), 8.27 (s, 1H), 
7.88 (br d, 1H), 7.15 (d, J = 3.9 Hz, 1H), 5.06 (s, 1H), 5.02 (d, J = 9.5 Hz, 1H), 4.31 (d, J = 9.5 Hz, 
1H), 2.83 (s, 3H), 2.43 (s, 3H) 
Characterizations are in agreement with literature.[234] 
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SYNTHESIS OF 3.86 
 
 
180 mg of fullerene (0.25 mmol), 154 mg of aminoacid 3.50 (0.50 mmol) and 100 mg of bpy-
aldehyde 3.79 (0.50 mmol) were dissolved in 150 ml of Tol. The mixture was refluxed for 2h30’. 
Product was separated by flash chromatography with Tol, then Tol/i-prOH 99:1. The product 
was precipitated from DCM/Et2O and washed with Et2O to give 116 mg (0.10 mmol) of a brown 
powder in 40% yield. 
 
C84H34N4O4 (MW 1163.19) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.76 (s, 1H), 8.75 (d, 1H), 8.54 (d, J = 5.0 Hz 1H), 8.26 (s, 
1H), 7.90 (br d, 1H), 7.14 (d, J = 5.2 Hz, 1H), 5.30 (s, 1H), 5.24 (d, J = 10.5 Hz 1H), 4.99 (br, 1H, 
NH), 4.36 (d, J = 9.9 Hz, 1H), 4.03 (m, 2H), 3.77 (m, 4H), 3.61 (t, J = 5.0 Hz, 2H), 3.42 (m, 1H), 
3.34 (m, 2H), 2.96 (m, 1H), 2.43 (s, 1H), 1.44 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 156.81, 156.21, 155.64, 153.97, 152.94, 149.71, 149.21, 
148.30, 147.76, 147.49, 146.44, 146.10, 145.84, 145.69, 145.52, 143.15, 142.85, 142.73, 142.17, 
140.39, 136.22, 125.11, 124.32, 122.33, 81.61, 75.80, 70.76, 70.64, 70.42, 69.57, 67.86, 52.45, 
28.71, 21.47. 
IR (ATR):  2868, 1713, 1506, 1457, 1363, 1247, 11171, 1121. 
ES-MS (MeOH) m/z = 1163.5 (MH+), 1185.3 (M+Na+). 
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SYNTHESIS OF 3.87 
 
 
500 mg of fullerene (0.694 mmol), 148 mg of aminoacid 3.83 (0.833 mmol) and 165 mg of bpy-
aldehyde 3.79 (0.833 mmol) were dissolved in 150 ml of Tol. The mixture was heated at reflux 
for 20 minutes, cooled and separated by flash chromatography. C60 was eluted with Tol. A 
second fraction containing the product and unreacted aldehyde was eluted with Tol/EtOH 98:2. 
This mixture was dissolved in 150 ml of chloroform and washed with 1N HCl 3 x 100 ml, once 
with BRINE and was dried over anhydrous Na2SO4. Finally the product was purified again by 
flash chromatography with Tol/EtOH 98:2 and precipitated from DCM/MeOH, washed with 
MeOH and finally with Et2O. 
178 mg (0.172 mmol) of a brown powder were obtained in 25% yield (50% on reacted C60). 
 
C78H23N3O2 (MW 1034.04) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.74 (br d, 2H), 8.54 (d, J = 4.8, Hz 1H), 8.25 (s, 1H), 7.91 
(br, 1H), 7.14 (d, J = 4.8 Hz, 1H), 5.30 (s, 1H), 5.23 (d, J = 8.1 Hz, 1H), 4.35 (d, J = 8.1 Hz, 1H), 4.07 
(m, 2H), 3.80 (m, 2H), 3.68 (m, 2H), 3.44 (s, 3H) 3.39 (m, 1H), 2.96 (m, 1H), 2.43 (s, 3H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 156.79, 156.28, 155.66, 154.04, 152.99, 152.51, 149.73, 
149.21, 148.28, 147.80, 147.45, 146.38, 146.10, 145.87, 145.69, 145.44, 144.87, 144.58, 143.30, 
142.85, 142.73, 142.28, 140.36, 139.66, 137.34, 136.64, 135.78, 126.58, 125.09, 124.35, 122.32, 
81.62, 75.81, 72.29, 70.82, 70.48, 69.61, 67.87, 59.43, 52.47, 21.47. 
IR (ATR) = 2867, 2808, 1593, 1566, 1460, 1430, 1108, 827. 
ES-MS (MeOH) m/z = 1034.3 (MH+). 
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SYNTHESIS OF 3.88 
 
 
50 mg of fullerene 3.52 (0.056 mmol), 13 mg of bpy-acid (0.061 mmol) and 9 mg of DMAP 
(0.070 mmol) were dissolved in 2.5 ml of anhydrous DCM and 2.5 ml of anhydrous Py under 
Argon atmosphere. The mixture was cooled at 0°C and 14 mg of EDC-HCl (0.070 mmol) were 
added, the mixture was allowed to warm to r.t. and after 2 hours the solvents were 
evaporated. The residue was dissolved in 20 ml of chloroform and washed with BRINE 2 x 20 
ml. The product was purified by flash chromatography in DCM/EtOH 95:5 and precipitated from 
DCM/MeOH, washed with MeOH and finally with Et2O. 
37 mg (0.034 mmol) of a brown powder were obtained in 61% yield. 
 
C80H26N5O3 (MW 1091.09) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.79 (d, J = 5.2 Hz, 1H), 8.74 (s, 1H), 8.60 (d, J = 4.6 Hz, 1H), 
8.27 (s, 1H), 8.79 (dd, J = 4.7, 1.5 Hz, 1H), 7.32 (br t, 1H, NH), 7.17 (d, J = 4.4 Hz, 1H), 4.38 (s, 
4H), 4.07 (t, J = 5.5 Hz, 2H), 3.86 – 3.76 (m, 8H), 3.30 (t, J = 5.5 Hz, 2H), 2.43 (s, 3H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 165.83, 155.01, 146.36, 146.19, 146.10, 145.51, 142.76, 
142.30, 142.01, 136.28, 125.44, 122.48, 122.09, 117.94, 70.93, 70.83, 70.65, 69.95, 68.66, 
54.49, 40.43, 21.54. 
IR (ATR): 2866, 1667,1650, 1539, 1456, 1427, 1106, 770. 
ES-MS (MeOH) m/z = 1091.4 (MH+), 1113.3 (M+Na+). 
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SYNTHESIS OF 3.89 
 
500 mg of fullerene (0.694 mmol), 324 mg of aminoester 3.84 (1.389 mmol) and 104 mg of 
paraformaldehyde (3.472 mmol) were dissolved in 125 ml of Tol. The mixture was heated to 
reflux for 20 minutes, cooled and separated by flash chromatography. C60 was first eluted with 
Tol and the monoadduct with Tol/EtOAc 95:5. Finally the product was precipitated from 
DCM/MeOH and washed with MeOH. 
261 mg (0.27 mmol) of a brown powder were obtained in 39% yield (65% on reacted C60). 
 
C72H23NO4 (MW 965.96) 
1H-NMR (200 MHz, CDCl3, 25°C): = 5.16 (d, J = Hz, 1H), 5.07 (s, 1H), 4.46 (d, J = Hz, 1H), 4.06 
(m, 2H), 3.84 (m, 2H), 3.67 (m, 2H), 3.58 (m, 1H), 3.44 (s, 3H), 3.35 (m, 1H), 1.50 (s, 9H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.25, 155.25, 155.17, 154.34, 151.58, 148.87, 147.58, 
147.47, 146.79, 146.46, 146.25, 146.07, 145.94, 145.85, 145.77, 145.46, 144.74, 143.29, 142.86, 
142.44, 142.30, 142.20, 142.02,140.46, 139.93, 139.48, 137.93, 136.19, 83.18, 77.42, 73.00, 
72.31, 70.76, 70.44, 70.09, 66.29, 59.38, 51.71, 28.63. 
IR (NaCl) = 2955, 2921, 2868, 1741, 1461, 1428, 1365, 1247, 1148. 
 
 
SYNTHESIS OF 3.90 
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223 mg of 3.89 (0.23 mmol) were dissolved in 5 ml of DCM, 5 ml of TFA were added and the 
mixture was stirred at r.t. overnight. The solvents were evaporated and the residue was 
triturated with MeOH and then with Et2O. 
203 mg (0.22 mmol) of a brown powder were obtained in 97% yield. 
 
C68H15NO4 (MW 909.85) 
1H-NMR (200 MHz, d-Py-d5, 25°C): = 5.58 (s, 1H), 5.48 (d, J = 9.6 Hz, 1H), 4.62 (d, J = 9.6 Hz, 
1H), 4.29 (m, 1H), 4.20 (m, 1H), 3.99 (m, 1H), 3.89 (m, 2H), 3.70 (m, 2H), 3.62 (m, 1H), 3.37 (s, 
3H). 
The low solubility of this derivative did not allow to record 13C-NMR spectrum. 
IR (KBr): 3435, 2919, 1730, 1634, 1429, 1184, 1108, 526. 
ES-MS (MeOH) m/z = 908.1 (M-1-). 
 
 
SYNTHESIS OF 3.91 
 
 
80 mg of fullerene 3.89 (0.083 mmol) were dissolved in 3 ml of DCM and 3 ml of TFA were 
added. The solution was stirred at r.t. for 36h, the solvents were evaporated and the residue 
was directly used in the coupling reaction. 28 mg of HOBt-H2O (0.207 mmol) was added to the 
flask and the powder was dried under vacuum for 1h. Then 4 ml of anhydrous DCM were added 
under Argon atmosphere and 40 mg of EDC-HCl (0.207 mmol) were added at 0°C. After 15 
minutes mono-boc protected TEG diamine was added in 2 ml of anhydrous DCM and the 
resulting solution was allowed to warm to r.t. and stirred overnight. The product was directly 
purified by flash chromatography with Tol/EtOH 95:5. The compound was precipitated from 
DCM/Hex and washed with Hex yielding 91 mg (0.080 mmol) of a brown powder in 96% yield. 
 
C79H37N3O7 (MW 1140.15) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.03 (br t, 1H, NH), 5.14 (d, J = 9.6 Hz, 1H), 5.00 (br t, 1H, 
NH), 4.85 (s, 1H), 4.26 (d, J = 9.7 Hz, 1H), 4.02 (br t, 2H), 3.85 – 3.28 (m, 20H), 3.05 (m, 1H). 
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13C-NMR (50 MHz, CDCl3, 25°C): = 168.96, 156.06, 155.56, 153.37, 151.86, 147.50, 147.47, 
147.04, 146.49, 146.47, 146.44 146.32, 146.25, 146.23, 146.18, 146.09, 145.83, 145.76, 145.57, 
145.48, 145.31, 145.29, 144.77, 144.75 144.61, 144.54, 143.31, 143.19, 142.83, 142.80, 142.76, 
142.46, 142.31, 142.26, 142.25, 142.20, 142.11, 141.95, 141.88, 140.37, 139.55, 137.01, 136.41, 
135.72, 79.49, 73.06, 72.23, 70.91, 70.54, 69.85, 69.51, 67.41, 59.31, 53.77, 40.64, 39.16, 28.71. 
ES-MS (MeOH) m/z = 1162.3 (MH+), 1138.1 (M-1-). 
 
 
SYNTHESIS OF 3.92 
 
 
114 mg of fullerene 3.91 (0.100 mmol) were dissolved in 5 ml of DCM, 2.5 ml of TFA were 
added and the solution was stirred at r.t. for 4h. The solvents were evaporated and the product 
was precipitated from MeOH/Et2O and washed with Et2O affording 108 mg (0.094 mmol) of a 
brown powder in 94% yield. 
 
C76H30F3N3O7 (MW 1154.06) 
1H-NMR (200 MHz, DMSO-d6, 25°C): = 8.63 (br t, 1H, NH), 7.71 (br t, 3H, NH3
+), 5.20 (d, J = 
25.0 Hz, 1H), 4.94 (s, 1H), 4.38 (d, J = 23.5 Hz, 1H), 3.96 (m, 2H), 3.71 – 2.93 (m, 21H). 
IR (ATR):  2874, 1686, 1200, 1180, 1129, 799, 721. 
ES-MS (MeOH) m/z = 1040.2 (MH+). 
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SYNTHESIS OF 3.93 
 
 
22 mg of bpy-acid (0.104 mmol) and 21 mg of HOBt-H2O (0.156) were dried under vacuum for 
30 minutes, then 6 ml of anhydrous DCM were added under Argon atmosphere. 30 mg of EDC-
HCl (0.156) were added to the suspension at 0°C. After 20 minutes the mixture turns in a clear 
solution, 60 mg of fullerene 3.92 (0.052 mmol) were added, followed by 3 drops of anhydrous 
DIEA (~20 mg, 0.156 mmol). The resulting solution was allowed to warm at r.t. and was stirred 
overnight. The mixture was purified by flash chromatography with DCM/EtOH 95:5 and the 
product was precipitated to DCM to acetone/MeOH 1:1, the sticky precipitate was triturated 
and sonicated with Et2O affording 44 mg (0.036 mmol) of the product as a brown powder in 
68% yield. 
 
C86H37N5O6 (MW 1236.24) 
1H-NMR (200 MHz, CDCl3, 25°C): = 8.78 (d, J = 13.0 Hz 1H), 8.65 (s, 1H), 8.54 (d, J = 13.0 Hz 
1H), 8.26 (s, 1H), 8.02 (br t, 1H, NH), 7.76 (d, J = 9.0 Hz, 1H), 7.17 (br m, 2H, CH+NH), 5.09 (d, J = 
24.5 Hz, 1H), 4.80 (s, 1H), 4.21 (d, J = 24.5 Hz, 1H), 3.97 (m, 2H), 3.82 – 3.29 (m, 20H), 2.99 (m, 
1H), 2.45 (s, 3H). 
13C-NMR (50 MHz, CDCl3, 25°C): = 169.05, 165.86, 153.31, 150.16, 149.16, 148.54, 146.45, 
146.23, 145.63, 145.48, 145.46, 142.83, 142.75, 142.19, 142.09, 140.37, 135.69, 125.39, 122.42, 
121.95, 117.93, 80.53, 73.06, 72.22, 70.90, 70.60, 70.23, 70.01, 60.87, 69.51, 67.42, 59.29, 
53.77, 40.32, 39.12, 21.53. 
IR (ATR): 3325, 2874, 1664, 1535, 1459, 1106. 
ES-MS (MeOH) m/z = 1236.4 (MH+), 1258.5 (M+Na+), 1274.4 (M+K+). 
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SYNTHESIS OF 3.94 
 
 
250 mg of fullerene (0.347 mmol), 213 mg of aminoacid 3.50 (0.694 mmol) and 63 mg of 4,5-
diazafluoren-9-one (0.347 mmol) were dissolved in 100 ml of o-DCB. The mixture was degassed 
by means of 3 freeze-pump-thaw cycles and refluxed for 2h under Argon atmosphere. The 
product was separated by flash chromatography in gradient from Tol to Tol/EtOH 97:3. Product 
was precipitated from DCM/MeOH and washed with MeOH to give 99 mg (0.086 mmol) of a 
brown powder in 25% yield. 
 
C83H30N4O4 (MW 1147.15) 
1H-NMR (500 MHz, CDCl3, 25°C): = 8.82 (dd, J = 4.9, 1.4 Hz, 2H), 8.56 (dd, J = 7.8, 1.3 Hz, 2H), 
7.45 (dd, J = 7.8, 4.9 Hz, 2H), 5.30 (s, 2H), 4.91 (br t, 1H, NH), 3.76 (t, J = 5.7 Hz, 2H), 3.65 (s, 4H), 
3.55 (t, J = 5.2 Hz, 2H), 3.30 (br t, 2H), 2.71 (t, J = 5.7 Hz, 2H), 1.42 (s, 9H). 
13C-NMR (68 MHz, CDCl3, 25°C): = 159.28, 156.17, 155.70, 153.52, 152.03, 147.71, 147.68, 
146.65, 146.44, 146.37, 146.34, 146.03, 145.76, 145.69, 145.67, 145.61, 145.57, 145.54, 144.85, 
144.68, 143.45, 143.03, 142.89, 142.47, 142.39, 142.35, 142.28, 141.94, 141.75, 140.72, 140.44, 
140.04, 136.36, 136.30, 135.73, 123.55, 82.87, 79.47, 76.43, 70.94, 70.56, 70.51, 70.46, 69.39, 
65.09, 47.90, 28.48. 
IR (ATR): 2871, 1708, 1401, 1249, 1169, 1115, 777, 574. 
ES-MS (MeOH) m/z = 1147.2 (MH+), 1170.2 (M+Na+), 1185.1 (M+K+). 
 
SYNTHESIS OF 3.95 
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200 mg of fullerene (0.278 mmol), 247 mg of sarcosine (2.778 mmol) and 51 mg of 4,5-
diazafluoren-9-one (0.278 mmol) were dissolved in 50 ml of o-DCB. The mixture was degassed 
by means of 3 vacuum / Argon cycles and refluxed for 4h30’ under Argon atmosphere. Product 
was separated by flash chromatography in gradient from Tol to Tol/EtOH 99.1. Product was 
precipitated from CS2/Acetone and washed twice with MeOH to give 90 mg (0.097 mmol) of a 
brown powder in 35% yield. 
C73H11N3 (MW 929.89) 
1H NMR (270 MHz, CDCl3/CS2, 25°C):  = 8.80 (dd, J = 4.8, 1.4 Hz, 2H), 8.51 (dd, J = 7.8, 1.4 Hz, 
2H), 7.43 (dd, J = 7.8, 4.9 Hz, 2H), 5.13 (s, 2H), 2.37 (d, J = 17.6 Hz, 3H). 
13C-NMR (68 MHz, CDCl3, 25°C):  = 159.29, 155.25, 153.31, 151.80, 147.50, 146.49, 146.25, 
146.20, 146.17, 145.82, 145.64, 145.53, 145.50, 145.46, 145.38, 144.64, 144.53, 143.96, 143.29, 
142.75, 142.27, 142.23, 142.19, 142.10, 141.83, 141.60, 140.58, 139.94, 139.57, 136.23, 135.30, 
123.19, 82.25, 69.00, 66.55, 34.39. 
IR (ATR): 3006, 1511, 1401, 1275, 1261, 749. 
ES-MS (MeOH) m/z = 952.1 (M+Na+) 
 
 
SYTHESIS OF 3.96-3.100 (GENERAL PROCEDURE) 
 
7.00 mg of RuCl2(dmso)2(PTA)2 (the compound was gently supplied by the group of prof. 
Alessio, Univ. Trieste)(0.0109 mmol) and 1 equivalent of fullerene-bpy ligand were dissolved in 
2 ml of dry o-DCB in screw-cap vial, Argon was bubbled in the mixture for 5 minutes and the vial 
was sealed. The mixture was heated at 80°C for 18-24h, in the dark. The products were purified 
by chromatography on silica (alumina for 3.99 and 3.100) in gradient from CHCl3 to CHCl3/EtOH 
80:20. 
The complexes were precipitated from CHCl3/Acetone and washed once with Acetone. 
 
 
3.96 
 
 
5.17 mg, 3.61 µmol, yield: 33% 
Diasteromeric ratio = 50:50 
 
C86H39Cl2N9P2Ru (MW 1432.21) 
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1H-NMR (500 MHz, CDCl3, 25°C): = 9.69 (m, 2H), 8.63 (d, J = 5.9 Hz, 1H), 8.58 (s, 1H), 8.55 (d, J 
= 5.7 Hz, 1H), 8.22 (s, 1H), 8.07 (s, 1H), 7.90 (s, 1H), 7.86 (br, 1H), 7.49 (br, 1H), 7.42 (d, J = 5.7 
Hz, 1H), 7.39 (d, J = 5.4 Hz, 1H), 5.06 (m, 2H), 4.67 – 4.56 (m, 9H), 4.56 – 4.46 (m, 3H), 4.38 (d, J 
= 9.8 Hz, 1H), 4.35 (d, J = 9.7 Hz, 1H), 4.25 (m, 4H), 4.02 (d, J = 13.0 Hz, 3H), 3.98 (d, J = 13.3 Hz, 
3H), 3.49 (d, J = 14.9 Hz, 3H), 3.36 (m, 3H), 2.88 (s, 3H), 2.86 (s, 3H), 2.64 (s, 3H), 2.56 (s, 3H). 
IR (KBr) = 2922, 1673, 1417, 1282, 1241, 1197, 1123, 1016, 974, 948, 815, 721, 582, 527. 
ES-MS (MeOH) m/z = 1396.1 (M-Cl)+. 
 
 
3.97 
 
 
5.38 mg, 3.26 µmol, yield: 30% 
Diasteromeric ratio = 50:50 
 
C96H58Cl2N10O4P2Ru (MW 1649.48) 
1H-NMR (500 MHz, CDCl3, 25°C): = 9.61 (s, 2H), 8.71 (br m, 1H), 8.62 (br m, 1H), 8.57 (br m, 
1H), 8.28 (s, 1H), 8.09 (s, 1H), 8.00 (br m, 1H), 7.93 (s, 1H), 7.57 (br m, 1H), 7.42 (m, 2H), 5.40 – 
5.24 (m, 2H), 5.07 – 4.95 (br t, 1H, NH), 4.85 – 4.53 (m, 10H), 4.42 (m, 1H), 4.29 (m, 3H), 4.06 
(m, 4H), 3.79 (m, 4H), 3.62 (m, 2H), 3.53 (d, J = 14.3 Hz, 3H), 3.47 – 3.28 (m, 6H), 3.02 (s, 1H), 
2.63 (s, 3H), 2.58 (s, 3H), 1.44 (s, 9H) 
IR (KBr) = 2922, 1682, 1423, 1281, 1241, 1173, 1123, 1016, 974, 948, 726, 571, 527. 
ES-MS (MeOH) m/z = 1613.3 (M-Cl)+. 
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3.98 
 
 
4.50 mg, 3.14 µmol, yield: 29% 
Diasteromeric ratio = 50:50 
 
C90H47Cl2N9O2P2Ru (MW 1432.21) 
1H-NMR (500 MHz, CDCl3, 25°C): = 9.68 (m, 2H), 8.72 (br m, 1H), 8.61 (d, J = 6.0 Hz, 1H), 8.52 
(d, J = 5.9 Hz, 1H), 8.25 (s, 1H), 8.10 (s, 1H), 7.91 (br m, 2H), 7.48 (d, J = 5.6 Hz, 1H), 7.41 (d, J = 
5.9 Hz, 1H), 7.39 (d, J = 6.0 Hz, 1H), 5.36 (s, 1H), 5.35 (s, 1H), 5.29 (m, 1H), 4.60 (m, 9H), 4.52 (m, 
3H), 4.44 (m, 1H) 4.25 (m, 3H), 4.06 (m, 1H), 4.02 (d, J = 13.0 Hz, 3H), 3.97 (d, J = 13.1 Hz, 3H), 
3.86 – 3.78 (m, 2H), 3.71 (m, 2H), 3.54 and 3.43  and 3.31 (m, 11H), 3.02 (m, 3H), 2.63 (s, 3H), 
2.56 (s, 3H). 
IR (KBr) = 2920, 1679, 1419, 1281, 1241, 1196, 1094, 1015, 973, 947, 725, 582, 527. 
ES-MS (MeOH) m/z = 1484.2 (M-Cl)+. 
 
 
3.99 
 
 
8.52 mg, 5.22 µmol, yield: 48% 
 
C95H54Cl2N10P2Ru (MW 1633.43) 
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1H-NMR (500 MHz, CDCl3, 25°C): = 9.23 (d, J = 5.4 Hz, 1H), 8.56 (d, J = 7.8 Hz, 1H), 8.39 (d, J = 
7.7 Hz, 1H), 8.33 (d, J = 5.5 Hz, 1H), 7.70 (dd, J = 7.3, 5.9 Hz, 1H), 7.38 (dd, J = 7.7, 5.6 Hz, 1H), 
5.32 (m, 2H), 4.94 (s, 1H, NH), 4.70 (s, 6H), 4.62 – 4.42 (m, 6H), 4.26 (d, J = 13.2 Hz, 3H), 3.99 (d, 
J = 13.0 Hz, 3H), 3.70 (m, 2H), 3.64 (m, 7H), 3.54 (m, 5H), 3.30 (m, Hz, 2H), 2.84 (m, 2H), 1.45 
and 1.43 (s, 9H). 
IR (KBr) = 2924, 1703, 1631, 1413, 1281, 1241, 1095, 1015, 974, 947, 584, 527. 
ES-MS (MeOH) m/z = 1597.3 (M-Cl)+. 
 
 
3.100 
 
 
 
5.50 mg, 3.88 µmol, yield: 36% 
Diasteromeric ratio = A:B = 77:23 
 
C85H35Cl2N9P2Ru (MW 1416.17) 
1H-NMR (500 MHz, CDCl3, 25°C): = 9.24 (d, J = 5.1 Hz, 1H), 8.54 (d, J = 7.7 Hz, 1H), 8.37 – 8.31 
(m, 2H), 7.71 (dd, J = 7.2, 5.9 Hz, 1H), 7.39 (dd, J = 7.7, 5.6 Hz, 1H), 5.18 – 5.05 (m, 2H), 4.65 (s, 
6H), 4.55 (m, 6H), 4.47 (m, 3H, B) 4.26 (d, J = 13.1 Hz, 3H), 3.99 (d, J = 13.0 Hz, 3H, A), 3.81 (d, J 
= 15.3 Hz, 3H, B), 3.73 (d, J = 15.5 Hz, 3H, B), 3.64 (d, J = 15.1 Hz, 3H, A), 3.54 (d, J = 15.2 Hz, 3H, 
A), 2.52 (s, 3H, A), 2.50 (s, 3H, B). 
13C-NMR (126 MHz, CDCl3, 25°C):  = 155.26, 152.29, 152.08, 147.75, 146.56, 146.52, 146.46, 
146.40, 146.29, 146.27, 145.76, 145.73, 145.66, 145.63, 145.59, 145.56, 145.53, 145.51, 145.48, 
145.47, 145.42, 144.89, 144.87, 144.44, 144.38, 144.30, 144.10, 143.70, 143.51, 143.10, 142.92, 
142.42, 142.39, 142.36, 142.32, 142.31, 142.29, 142.16, 142.15, 141.80, 141.78, 141.66, 140.89, 
140.17, 139.95, 139.48, 136.66, 136.04, 134.44, 126.08, 125.89, 89.29, 76.48, 73.68, 73.63, 
73.23, 73.18, 69.41, 67.07, 55.10, 54.97, 53.84, 53.72, 35.39. 
IR (KBr) = 2921, 1633, 1412, 1280, 1240, 1014, 972, 946, 803, 732, 572, 526. 
ES-MS (MeOH) m/z = 1380.0 (M-Cl)+. 
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